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The most common mechanism of resistance in clinically significant bacteria to |3-
lactam antibiotics is the production of Class A (3-lactamase enzymes that hydrolyse
the P-lactam bond of this family of antibiotics. Extended-spectrum P-Iactamases
(ESBLs) are produced and expressed by Enterobacteriaceae. They are derived from
blajEM-b b/tfTEM-2 and b/asHv-i genes. ESBLs are capable of inactivating second and
third generation cephalosporins. They have been found mainly in Klebsiella
pneumoniae and Escherichia coli, while more recently in other species of
Enterobacteriaceae and Gram-negative bacteria.
In this study, one hundred-and-one unique patient isolates ofK. pneumoniae (69) and
E.coli (32) from different patients, flagged as ESBL-positive by the Vitek system
(GNS 526 card) were collected. These strains were isolated from a variety of clinical
specimens submitted to the clinical bacteriology laboratories of the Royal Infirmary
of Edinburgh (RIE). Of the 101 strains tested, 15 E.coli were subsequently found to
be ESBL-negative by E-test ESBL strips. On re-testing with Vitek using the (GNS
532 card which had superseded the GNS 526 card), 14 of these were found to be
ESBL-negative despite originally flagging as ESBL-positive. The remaining 87
ESBL-producing strains were also tested with E-test ESBL strips and additionally
subjected to the double disc diffusion (DDD) method for the detection of ESBLs. Of
these, one was falsely negative for ESBL-production by E-test ESBL strips, and 7
were false negative by the double disc diffusion method. The 87 isolates were tested
for susceptibility to a wide range of
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antibiotics by both Vitek microdilution technique (NCCLS) and disc diffusion
method (NCCLS).
In addition, MICs of the isolates were obtained by agar dilution to aminoglycosides
(gentamicin and tobramycin) and the quinolone, ciprofloxacin, and by E-test strips
to cefotaxime and ceftazidime.
To study the epidemiology ofESBL producing strains ofK. pneumoniae and E.coli,
all isolates were examined by Pulsed-field gel-electrophoresis (PFGE) analysis using
the Xba 1 restriction enzyme. K. pneumoniae demonstrated seven distinct clusters,
each containing isolates with similar coefficients, which were identified among 62
isolates. A high level of genetic heterogeneity was found among six other isolates,
and one isolate was non-typeable by PFGE. PFGE demonstrated that 5 of the 18
E.coli were genetically related, 2 isolates belonged to one group, 8 isolates were
genetically distinct and 3 were non-typeable. The presence of blajEM and blasnv
were detected by dot-blot hybridisation and polymerase chain reaction (PCR) for all
87 isolates. P-lactamase and genetic material from strains demonstrating presumption
ESBL production were subjected to further study by a combination of Iso-electric
focusing (IEF) and PCR-restriction fragment length polymorphisms (PCR-RFLP)




The epidemiology of ciprofloxacin-resistance and its relationship to ESBL producing
K pneumoniae was studied for 32 (46.6%) isolates that were found to be resistant to
ciprofloxacin.
To investigate the epidemiological relationship between the ciprofloxacin
resistant/ESBL-positive strains, PFGE analysis indicated that the clinical isolates
belonged to 4 distinct genotypes (A,B,C and D). PCR was used to amplify the gyrA
and parC genes from genomic DNA of the ciprofloxacin-resistant isolates. The
amplified product was sent for analysis by automated DNA sequencing and the
resulting DNA sequence compared with gyrA and parC genes of K. pneumoniae.
The sequencing results demonstrated that alteration of the gyrA subunit DNA gyrase
at amino acid 83 and/or amino acid 87 was shown to play a central role in conferring
high-level quinolone resistance in K. pneumoniae possessing ESBLs.
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The discovery of antibiotics was one of the greatest advances in the history of
medicine, saving more lives than any other clinical armamentarium, increasing
average life expectancy by years.
In 1969 an historic statement was made at that time by US Surgeon General
testifying to the congress "...it is the time to close the book on infectious diseases"*.
This statement was made at an optimistic time when more than 25,000 antibiotic
products had been developed and antibiotic resistance was not a major public health
issue.
Heavy use of antibiotics in clinical treatment began with the introduction of
penicillins in the 1940s and over the next sixty years numerous classes of antibiotics
have been introduced (see figure 1.1). However, the widespread use of these
antibiotics in medicine and animal husbandry has compromised their success and
provided strong selective pressure for the emergence and persistence of bacterial
resistance to these antibiotics. Pharmaceutical companies have tried to overcome this
dilemma by modification of existing antibiotics and the introduction of newly
developed novel drugs into clinical use. However, the genetic versatility of bacteria
has enabled them to respond by modifying existing resistance mechanisms or by
acquiring resistance genes from other bacteria.

























Clavulanic acid, Cefotaxime, Ceftazidime, Cefuroxime, piperacillin
& Amoxycillin.
1980
Netilmicin, Ciprofloxacin, Imipenem, Aztreonam, Norfloxacin,
Ciclaclilin & Cefpodoxime.
1990
Teicoplanin, Cefpime, Meropenem, Tazobactam, Cefmetazole,
Azithromycin, Flurithromycin, Moxifloxacin, Cefmetazole &
Gatifloxacin.
2000 Dalfopristin, quinapristin (Synercid), Linezolid & Gemifloxacin




In the 1890s Paul Ehrlich (Ehrlich, 1913) predicted that chemical compounds could
be found or synthesized that would specifically inhibit or kill parasitic micro¬
organisms without damage to the host. Such synthetic compounds have been found.
By contrast, penicillin is an antibiotic, a naturally occurring compound synthesized
by one organism but capable in low concentration of inhibiting or destroying another
(selective toxicity) (Ehrlich, 1913).
The general term antimicrobial agent includes antibiotics and synthetic compounds
such as the sulfonamides and trimethoprim. Bacteria are able to develop resistance to
antimicrobials, and it is only by a combination of judicious use and ongoing
intensive research that antimicrobial chemotherapy continues to be effective in most
cases and to be one of the hallmarks of modern medical practice. Nowadays, many
different classes of antibiotics are used individually or in combination in clinical
treatment regimens but the most commonly used and frequently prescribed group of
antimicrobials are the p-lactams. p-lactams comprise a wide selection namely;
penicillins, cephalosporins, carbapenems in addition to other related compounds.
4
Chapter 1 Introduction
1.3 What is an antibiotic ?
Webster's New World Dictionary of the American language defines an antibiotic as
"
any of certain chemical substances produced by various microorganisms, especially
bacteria, fungi and actinomycetes, and having the capacity, in dilute solutions, to
inhibit the growth of or to destroy bacteria and other microorganisms" . This
definition leaves us in the somewhat awkward position of having to use more
cumbersome terms to allow the inclusion of drugs that inhibit the growth or destroy
bacteria and other microorganisms but are not produced by microorganisms. Such
compounds include the sulfonamides and trimethoprim; man-made modifications of
microbial products, such as the semi-synthetic penicillins; and alkylation of
aminoglycosides such as amikacin and netilmicin.
Lietman, in 1986, thought it would be more appropriate to redefine an antibiotic as
"any of certain chemical substances produced by various microorganisms or by
humans and having the capacity, in dilute solutions, to inhibit the growth of or to
destroy bacteria and other microorganisms" (Lietman, 1986).
The essence of an antibiotic is its selective toxicity. Selective toxicity refers to the
capacity of an antibiotic to adversely affect essential bacterial processes without
adversely affecting the host's cells. Paul Ehrlich, is credited with the term "magic
bullet" used to describe selective toxicity " a chemical that was selectively toxic to
invading microbes but innocuous to humans" (Lietman, 1986).
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1.4 The birth of penicillin
The discovery of penicillin ranks as one of the most important in the history of
medicine (Fleming, 1929). It was the first, and remains the most important, of the
antibiotics. Pneumonia, puerperal fever, bacterial meningitis and staphylococcal
septicaemia remain common diseases, however, the development of penicillin
revolutionized their treatment.
Penicillin was discovered by Alexander Fleming in 1928 (Hare, 1970). At the end of
July in 1928, Fleming left his laboratory, unaware that he was due to make an
historic discovery when he returned in September of the same year. One of the dishes
that he had inoculated previously and left on the bench, caught his eye. He observed
that a contaminating mould was causing apparent lysis of colonies of Staphylococcus
aureus he had previously inoculated onto the plate. The colonies took on a "ghost"
like appearance, indicating, that the mould was causing the bacteria to lyse. The
mould was subsequently identified as Penicillium notatum (Fleming, 1929).
Fleming was later to receive worldwide acclaim for the discovery and is still
generally regarded as the man who gave penicillin to the world. However, while
Fleming undoubtedly discovered penicillin, and was first to try and use it to cure
infections, his attempts to achieve the all important purification were largely
unsuccessful. Nor did he achieve the first cures with penicillin, an accolade which
fell to one of his former students, Cecil G. Paine, who did his work independently of
Fleming at the Royal Infirmary in Sheffield during 1929-1930 (Hare, 1970;
Wainwright, 1990).
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The miraculous therapeutic powers of penicillin were to remain unrecognized,
however, until around 1940, when it was purified by a team of Oxford University
scientists led by Howard Florey (Wainwright, 1990). The development of penicillin
then moved to the USA, where scientists were to be remarkably successful at
producing large quantities of cheap penicillin just in time to treat Allied soldiers,
from D-day onwards.
The discovery and subsequent development of penicillin is one of the most
remarkable stories to emerge from the history of medical and scientific research, its
appearance encouraged scientists to search for new antimicrobial agents which then
entered the physician's armoury. The chemical structure of penicillins is shown in
figure 1.2
1.5 p-lactam antibiotics
[1-lactam antibiotics are among the most widely used drugs in clinical practice around
the world. This group of antibiotics consists of penicillin, cephalosporins,
monobactams and carbapenems. This family can be divided into bi-cyclic penicillins
(penams, penams carbapenems, oxapenams), cephalosporins (cephems,
cephamycins, oxacephems, carbacephems) and the monocyclic monobactams (see
figure 1.3). The possession of an intact P-lactam ring is essential to their
antibacterial activity. Differences in side chains of the basic molecules influence
pharmacological properties and antibacterial spectra by determining permeability
into the bacterial cell, affinity for enzymes involved in cell wall synthesis, and





B-lactam ring Thiazolidine ring
6-aminopenicillanic acid
Chemical structure of penicillins
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P-lactam antibiotics are usually bactericidal to the growing susceptible bacteria
(Neu, 1986).
1.5.1 Mode of action of P-Iactam antibiotics
[1-lactams inhibit synthesis of the cell wall, a structurally unique feature found in
Gram-negative and Gram-positive bacteria but which is absent from mammalian
cells. The cell wall which provides bacteria with a physical barrier against substances
that may damage the cell. The major component of the cell wall, which plays a vital
role in providing rigidity and strength to this structure, is the polymer peptidoglycan.
P-lactams act by interfering with the biosynthesis of peptidoglycan, specifically
targeting the enzymes involved in the final stages of its assembly (Greenwood,
1995).
Bacteria may have existed more than 3.5 billion years ago (Holland, 1997;
Manchester et al., 1995). A primary structural feature of bacteria is the cell wall
whose function is to provide support for the maintenance of bacterial morphology




Skeletons of B-Iactam antibiotics.




1.5.2 The structure of the bacterial cell wall
The cell wall of Gram-negative bacteria differs in structure from that of Gram-
positive bacteria. Each possess peptidoglycan, but the wall of Gram-positive bacteria
is a thicker, less complex structure consisting of a network of cross-linked
peptidoglycan interspersed with teichoic acid and teichuronic acid polymers,
amounts of which vary between species (Neidhardt et al., 1990a). Gram-negative
bacteria have a much thinner peptidoglycan layer, which is covered by a lipid bi-
layer outer membrane. This consists of lipopolysaccharide and protein and prevents
many hydrophilic and some hydrophobic molecules from penetrating the cell.
Nutrients required by the cell are able to gain entry through this barrier via protein
channels called porins located within the outer membrane (Neidhardt et al., 1990a).
These channels are also utilized by the hydrophilic p-lactam antibiotics to gain
access to their target enzymes located within the periplasmic space (Nikaido, 1993).
The differential activity of P-lactams is due to their ability to cross the membrane
and move through the porin channels, which in turn is determined by their size as
well as physicochemical structure (Livermore, 1987).
In general, peptidoglycan is made of linear chains of alternating pi-4 linked N-acetyl
glucosamine and N-acetlylmuramic acid residues that are crossed-linked via
oligopeptide bridges attached to the muramic acid residues (Neidhardt et al., 1990b).
Convention consist of the synthesis of pentapeptide precursors in the cytoplasm that
are transported across the cell membrane, after which they are added to the existing
peptidoglycan chain. There are a number of enzymes involved in the final cross-
linking process (Barnikel et al., 1983). Transpeptidases catalyse the formation of a
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peptide bond between the carboxyl of the penultimate D-alanine of one pentapeptide,
and the amino group of the middle amino acid of another pentapeptide. The loss of
the second pentapeptide's terminal D-alanine, which is catalysed by
carboxypeptidases, provide the energy required for this reaction (Barnikel et al.,
1983).
1.5.3 Penicillin-binding-proteins (PBPs)
The targets of P-lactam antibiotics are proteins with transpeptidase, caboxypeptidase,
and transglycosylase activity (Georgopapadoakou, 1993; Ghuysen, 1991; Ghuysen,
1997; Jamin el al., 1995). They are also known as penicillin-binding proteins (PBPs)
since they are able to bind penicillin efficiently (Massova and Mobashery, 1998).
PBPs la, lb, 2 and 3 of Gram-negative bacteria have essential functions in the
peptidoglycan synthesis (Ghuysen, 1991). They are numbered in descending order
according to their molecular weight. In addition, their numbers vary between species
(Ghuysen, 1994; Ghuysen, 1997). The N-terminal domain of PBP la and PBP lb
display transglycosylase activity (Ghuysen, 1997). (1-lactams exert their effect by
their action as substrate analogues for the PBPs. The amide group (0=C-N) of the P~
lactam ring is similar in confirmation to the carboxyl terminal of the D-alanyl-D-
alanine. PBPs thus effectively recognise the antibiotic as they would their normal
substrate, allowing it to interfere with the cell wall formation by commandeering the
active-site cavity (Tipper and Strominger, 1965). PBPs share a common feature, in
which the C-terminal transpeptidase domain with a conserved active-site serine
residue is acylated by the P-lactam resulting in the formation of a stable covalent
ester and inactivation of the enzyme (Ghuysen, 1988).
12
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Such interaction depends on the enzyme that is involved. PBPs 1, 2 and 3 are
transpeptidase penicillin-binding proteins to which most P-lactams bind
(Georgapapadoakou, 1993; Massova and Mobashery, 1998).
1.6 Antibiotic resistance in bacteria
1.6.1 The origin of bacterial resistance
Antibiotic resistance was observed soon after the advent of antimicrobial
chemotherapy in clinical practice. The first P-lactamase was identified even before
the wide spread use ofpenicillin (Abraham and Chain, 1940).
1.6.2 Antibiotics and their producers
Many theories abound to explain the function of antibiotics in producer
microorganisms. The most plausible theory suggests a functional role in the survival
of producing organisms, thus offering a competitive advantage to the cell (Brian,
1957). It has even been suggested that antibiotics act as bacterial pheromones in
promoting the transfer of plasmids between different bacteria (Mazodier and Davies,
1991). What is clearly established is that antibiotics are secondary metabolites that
are produced after the logarithmic growth phase of the organism, and that enzymes
involved in antibiotic biosynthesis are repressed during active growth. Demain, in
1974 stated another theory, namely that they have a regulatory role during the
transition from vegetative cell to spore in sporulation organisms (Demain, 1974).
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1.6.3 Mechanisms of resistance to p-lactams
Many antibiotics in use today were discovered in soil microorganisms. It is hardly
surprising, therefore, that bacteria have developed the remarkable ability to acquire
resistance to them. There is evidence suggesting that one source of resistance genes
found in clinical isolates are soil micro-organisms which produce many of the
antibiotics in use today (Thompson and Gary, 1983). There are other potential
sources, for instance, the modification of genes encoding essential metabolic
enzymes, also known as 'housekeeping' genes (Rather et al., 1993).
(1-lactam antibiotics exert their antimicrobial effect by interfering with bacterial cell
wall biosynthesis. This is accomplished by the drugs attaching covalently to their
targets, PBPs. The PBPs are diverse enzymes involved in cell wall synthesis, and are
anchored in the cytoplasmic membrane of the bacterium (Georgopapadoakou, 1993;
Pitout et al., 1997). The site at which B-lactam drugs bind to PBPs is located on the
portion of the PBP that extends into the periplasmic space of Gram-negative bacteria
(Pitout et al., 1997). Covalent binding to PBPs interferes with the synthesis of cell
wall and ultimately leads to cell death. To reach target PBPs, (3-lactam antibiotics
must penetrate through the outer membrane of Gram-negative bacteria porins,
because the hydrophilic nature of these drugs precludes passage through the
hydrophobic proteins of the outer membrane (Pitout et al., 1997). (See figure 1.4). In
Gram-positive bacteria the outer-membrane is absent and the P-lactam molecule can








In Gram-negative bacteria, (3-lactam antibiotics must enter
through porins in the outer membrane, traverse the periplasmic
space, and attach to their target penicillin-binding proteins (PBPs)
located on the outer aspect of the cytoplasmic membrane
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Resistance to (3-lactam antibiotics may occur at any of the steps involved in the
action of the antibiotic. There are essentially 3 main mechanisms described, by
which bacteria evade the action of p-lactam antibiotics:
1- Alteration in outer membrane permeability (in Gram -ve bacteria).
2- Alteration in target enzymes PBPs (in both Gram -ve and Gram +ve bacteria).
3- Enzymatic degradation of the drug (production of p-lactamases in both Gram -ve
and Gram +ve bacteria).
1.6.3.1 Alteration in outer membrane permeability
In Gram-negative bacteria, the presence of porin channels in their outer membrane
facilitates the trans-membrane diffusion of hydrophilic molecules, including P-
lactams (Nikaido, 1989; Yoshimura and Nikaido, 1985). However, mutations
resulting in the loss of a specific porin can result in an increase in resistance to P-
lactams. This is evident with Pseudomonas aeruginosa, a pathogen renowned for its
intrinsic resistance to a wide range of antibiotics (Pitout et al., 1997; Yoshimura and
Nikaido, 1985).
Increased resistance to P-lactams has also been associated with a decrease in the
number of porins produced by some bacteria (see figure 1.5),(Yamazaki et al., 1989).
Loss of porin expression in clinical isolates of Klebsiella pneumoniae due to
insertion of insertion sequences (ISs) within the porin gene is a mechanism that has
been described in isolates obtained from patients under going antibiotic treatment








Alteration in porin proteins that impede drug (P-lactam
antibiotic) penetration into the bacterial cell
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It is usually insufficient for reduced permeability alone to prevent antibiotic
resistance, and subsequently, it generally occurs in conjunction with a second
mechanism to produce this effect (Nikaido, 1981). In the case of P-lactams, this
additional mechanism is usually the production of P-lactamases (Hancock and Bell,
1988).
1.6.3.2 Alteration in target enzymes (PBPs)
Alteration in the binding characteristics of PBPs for P-lactam compounds may result
in the development of resistance (Malouin and Bryan, 1986). (See figure 1.6).
Alteration in target enzymes is more common in Gram-positive bacteria, and in
certain fastidious Gram-negatives (Livermore and Wood, 1990). Clinical resistance
to P-lactams in Gram-negative bacteria is not commonly associated with alteration in
PBPs (Spratt, 1988). It is generally not regarded as a primary resistance mechanism
in other Gram-negative bacteria that have more efficient mechanisms at their
disposal. It is likely that in bacteria in which this resistance mechanisms occurs, the
development of p-lactam resistance is as a result of multiple amino acid
substitutions, each resulting in a relatively small decrease in affinity of the PBP for
the p-lactam, and this may potentially alter the stability of the enzyme. Re-stabilising
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1.6.3.3 Enzymatic inactivation of substrate
Enzymatic inactivation by the production of p-lactamase (see figure 1.7) is by far the
most widespread as well as the most common mechanism of resistance to p-lactam
antibiotics. P-lactamase enzymes cleave the amide bond of the P-lactam ring thus
rendering inactive a vast number of these antibiotics (Dever and Dermody, 1991). p-
lactamases are produced by both Gram-negative and Gram-positive bacteria, and
their impact on antimicrobial efficacy has been immense.
1.7 The origin and evolution of p-lactamases
It has been conceded that P-lactamases might have evolved from penicillin-sensitive
D-anayl-D-alanine-cleaving peptidases (DD-peptidase/PBPs), that are involved in
the synthesis of peptidoglycan, and are the target for p-lactam antibiotics. Kelly et al
(Kelly et al, 1986), collated the DD-peptidase from Streptomyces R61 with the P-
lactamase from Bacillus licheniformis 749/C. In spite of the fact that the two strains
belonged to different species and lacked close homology in their primary structure,
the three dimensional structure of the two enzymes were similar, implying a close
relationship between the two. The theory that p-lactamases have evolved from PBPs
hypothesis is now generally accepted as a result of sequence-based analysis, and
structural and enzymatic information. We now know that p-lactamases and PBPs
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Kelly hypothesised that P-lactamases probably evolved in soil bacteria, like
Streptomyces spp. Significant progress has been made by Huletsky (Huletsky el al.,
1990), in explaining how the class A (3-lactamases evolved (see 1.7.1 and 1.8.1).
They constructed a phylogenetic tree, that split the (3-lactamases into Gram-negative
and Gram-positive subgroups and demonstrated that P-lactamases from Gram-
positive bacteria probably evolved earlier in evolution than those of the Gram-
negative bacteria. Kirby, (Kirby, 1992) following on from the work of Huletsky,
examined the protein sequences of 18 Class A P-lactamases and 2 Class C P-
lactamases and constructed a phylogenetic tree employing the DD-peptidase of
Streptomyces R61 as an out group. Kirby's work suggested that all the Class A and
C P-lactamases were evolved from an actinomycete P-lactamase, that had previously
evolved from the DD-peptidase gene.
1.7.1 Structure and mechanisms of the action of (3-lactamases
P-lactamases are represented by two broad categories, based on the structure of their
active-site. The first category comprises those with a serine amino acid at this site,
and can be further subdivided into molecular classes designated A, C and D on the
basis of sequence similarity (Ambler, 1980; Bush et al., 1995). The second category
comprises the small but rapidly growing group of class B P-lactamases, or metallo-
enzymes, so called because they utilise 1 or 2 zinc ions to disrupt the P-lactam ring




1.7.2 Structure of the serine ^-lactamases
P-lactamase and DD-peptidase similarity is not restricted to 'mechanistic' properties.
X-ray studies have highlighted striking structural analogies between the
Streptomyces R61 (S. R61) DD-peptidase and several class A and class C p-
lactamases (Kelly et al., 1986; Matagne et al., 1998). These enzymes are all medium-
sized monomeric proteins, that consist of two structural domains (an all-a and an
a/p domain) with the active site located in a groove between the two domains.
Compared with the class A p-lactamases, both class C enzymes as well as X.R61
PBP have additional loops and secondary structure on the surface of the all-a
domain, at a distance from the active site. However, the active serine is located at the
N-terminus of the first hydrophobic helix of the all- a domain (a-2 helix) (Matagne
et al., 1998).
In the immediate vicinity of the active-site serine residue of the DD-peptidase and P-
lactamase, several conserved elements have been identified, which appear to be
directly or indirectly involved in the substrate recognition and catalytic processes.
Careful comparisons of the primary and tertiary structures have allowed
identification of the same structural and functional elements in all active-site serine
penicillin-recognizing enzymes (Joris et al., 1991; Sanschagrin et al., 1995).
The first element contains the active serine and, one helix-turn downstream, a lysine
residue whose side-chain also points into the active site. The proximity of the serine
and lysine side-chains, which are hydrogen-bonded, suggested the likely involvement
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of the lysine side-chain amino group in the catalytic process (Herzberg and Moult,
1987; Strynadka et al., 1992). The second element is located on a short loop in the
all-a domain, where it forms one side of the catalytic cavity. It consists of Tyr-Xaa-
Asn (P-lactamase of class C and D, some PBPs) or Ser-Xaa-Asn (P-lactamase of
class A, most PBPs) sequences (Matagne et al., 1998). The third element is called the
KTG triad and is located on the innermost strand of the a-sheet (a/p domain) that
forms the opposite wall of the catalytic cavity. It is generally a Lys-Thr-Gly
sequence, but Lys is replaced by His or Arg in a few exceptional cases and Thr by
Ser in several class A P-lactamases (Matagne et al., 1998).
A fourth element containing a negatively charged residue has been tentatively
identified in all enzymes, but it seems to play a catalytic role only in the Class A p -
lactamase, found on a 16-19 residue loop [Arg161-Asn170 in TEM-1 (Jelsch et al.,
1993)] usually referred to as Q-loop. In most cases, this loop contains the Glu166-
Xaa-Glu-Leu-Asn170 sequence where the two residues Glutamic acid-166 and
Aspartic acid-170 seem essential in positioning the conserved water molecule very
close to the active serine (Lamottebrasseur et al., 1991).
1.7.3 Serine ester mechanism of Class A, C and D p-lactamases
The majority of p-lactamases harbour a serine at the active site that forms a non-
covalent complex with the P-lactam compound. (See figure 1.8). The carbonyl
group of the P-lactam ring is attacked by a free hydroxyl on the side chain of the
serine residue (Ser-70 in class A and D, Ser-64 in class C) at the active-site of the
Chapter 1 Introduction
Figure 1.8



































Action of serine p-lactamase
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enzyme to yield a covalent acyl ester (Livermore, 1993). Apart from the crucial role
of the serine active site in the process of P-lactam acylation, additional residues are
known to play an important role in the formation of the acyl-enzyme intermediate,
and in the regeneration of the free enzyme (Massova and Mobashery, 1998). In
TEM-1 the hydroxyl group of Ser-68 binds to the P-lactam molecule. However, Arg-
244, Ser/Thr-235 and Ser-130 also contribute to the existence of multiple hydrogen
bonding interactions with the substrate carboxylate (Imtiaz et al., 1993; Zafaralla et
al., 1992).
1.8 Classification of |3-Iactamases
In 1968, Sawai discriminated penicillinases from cephalosporinases based on their
response to antisera (Sawai et al., 1968). As more information on enzyme function
became available and with the discovery of new p-lactamases, other classification
schemes have evolved (Bush, 1989a; Bush, 1989b; Bush, 1989c). Ambler was the
first to propose a molecular classification scheme (Ambler, 1980), which is still the
most widely used scheme.
1.8.1 The Ambler classification scheme
Richard Ambler originally identified two classes of enzyme, class A and class B,
based on their molecular structure (Ambler, 1980). There are now four molecular
classes to which P-lactamases are assigned based on the similarity of their amino
acid sequences (Huovinen and Jacoby, 1991; Ouellet et al., 1987).
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1.8.1.1 Class A P-lactamases
All the class A enzymes have a molecular mass of -30 KDa, share considerable
homology and have a serine moiety at their active site. Class A includes TEM-1 and
SHV-1, which are two of the most prevalent P-lactamases found in
Enterobacteriaceae (Wiedemann et al., 1989). Ambler concluded that their similarity
was so great that they must have diverged from a single ancestral gene.
In 1991, Ambler introduced a standard numbering scheme for class A P-lactamases,
by aligning 20 class A proteins and attaching numbers to the alignment (Ambler et
al., 1991). In this scheme the active site serine residue has been given the number
Ambler 70. Many p-lactamases that belong to this class are encoded by genes on
plasmids or transposones, and can be produced by both Gram-negative as well as
Gram-positive bacteria (Bush et al., 1995).
1.8.1.2 Class B p-lactamases
Class B comprise the metallo-P-lactamases, that require a bivalent metal ion, usually
zinc for their activity, and P-lactamases II from Bacillus cereus 5/B/6. Class B
enzymes show no similarity in sequence to class A enzymes. Sanders (Sanders,
1989), suggested that a new class E, could be created for the LI P-lactamase found in
Stenotrophomonas maltophilia (Saino et al., 1982).
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1.8.1.3 Class C p-lactamases
This class was first recognised by Jaurin and Grundstrom in 1981 (Jaurin and
Grundstrom, 1981). Confirmation of this group was also shown by Knott-Hunziker et
al (Knott-Hunziker et al., 1982). Succeeding experiments with DNA probes
indicated that the genes encoding this class of enzyme are widely spread through the
chromosomes of Gram-negative bacteria (Bergstrom et al., 1982). These
chromosomal cephalsoporinases also function with a serine residue at the active site,
but are very different in structure to those of the class A enzymes (Sanders, 1989). In
contrast to class A enzymes, class C enzymes are generally not inhibited by
clavulanic acid.
1.8.1.4 Class D p-lactamases
This class was proposed by Huovinen et al. (Huovinen et al., 1988), who after
having deduced the amino acid sequence of the PSE-2 (3-lactamase, found that it
shared extensive homology with the OXA-2 p-lactamase (Dale et al., 1985). None of
these enzymes share structural similarities with TEM or AmpC P-lactamases, and
were therefore placed in a new class designated class D (Dale et al., 1985).
1.8.2 The Bush classification scheme of p-lactamases
The most recent scheme of Bush attempts to correlate both the phenotypic and the
molecular properties of known P-lactamases (Bush et al., 1995). This classification
system catalogues a large number of P-lactamases in detail on the basis of their
functional characteristics. It retrains from using the location of the gene encoding the
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P-lactamases as a primary classification factor, reflecting the ability of a large
number of these genes to move between chromosome and plasmid.
There are four main functional groups within this classification scheme of P-
lactamases.
1.8.2.1 Bush classification scheme: Group 1
The chromosomal cephalosporinases of this group, often referred to as AmpC-type p-
lactamases, are intrinsically resistant to P-lactamase inhibitors and are ubiquitous in
most enterobacteria. The amount and the mode of expression of these enzymes vary
between genera (Sanders and Sanders, 1988). Some of the genes encoding the P-
lactamases have migrated onto plasmids in clinical isolates of K. pneumoniae and E.
coli (Sanders and Sanders, 1992).
1.8.2.2 Bush classification scheme: Group 2
P-lactamases of this group belong to Ambler molecular classes A or D. They are
generally inhibited by active-site directed inhibitors such as clavulanic acid. The P-
lactamases of this group hydrolyse a diverse range of substrates, which is
acknowledged by the definition of subgroups for these enzymes. Extended spectrum
P-lactamases that are derived from the TEM and SHV enzymes constitute subgroup
2b- and subgroup 2be. Those that have a reduced affinity for P-lactamase inhibitors
comprise the 2br group. The main criterion for group 2d is the preferential hydrolysis
of cloxacillin or oxacillin (hydrolysis rate of greater than 50% than that for
benzylpenicillin) (Bush et al., 1995). P-lactamases that hydrolyse carbenicillin at a
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rate of greater than 60% compared with that for benzylpenicillin have been allocated
to group-2c. Group 2f comprise the active-site serine carbapenemases. Many of the
genes that encode these (3-lactamases are found on plasmids.
1.8.2.3 Bush classification scheme: Group 3
This group comprises metallo-p-lactamases that are not inhibited by the classical p-
lactamase inhibitors with the exception of EDTA, a metal chelator and p-
chloromercuribenzonate (p-CMB), an amino acid modifier.
1.8.2.4 Bush classification scheme: Group 4
This group contains penicillinases that are not inhibited by the suicide inactivator,
clavulanic acid. The LCR-1 p-lactamase from P. aeruginosa was originally a
member of group 4 (Bush, 1989c); however, sequence data have subsequently
revealed its homology with Class D OXA enzymes (Couture et al., 1992), with the
result that it has been relocated to group 2d (Bush et al., 1995).
In general, Bush and colleagues have endeavoured to produce "workable, and a
potentially useful compilation of P-lactamase characteristics". However, as they
concede, "No functional classification will ever be completely satisfactory" (Bush et
al., 1995). As more sequence data are produced and revealed about P-lactamases,
and enzyme variants emerge with altered substrate and inhibitor profiles as a result of
point mutations of their genes, it is likely that the composition of the classification
group described here will alter accordingly.
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1.9 The development ofmodern cephalosporins
In 1945, a bacteriologist, Giuseppi Brotzu, studied the microbial flora of seawater
near a sewage out-fall in Sardinia, and came across a strain of Cephalosporium
acremonium, which secreted a substance with activity against a number of Gram-
positive as well as Gram-negative bacteria. Due to lack of facilities and expertise, he
passed a culture to Florey's team in Oxford for further analysis. Their studies
revealed a number of antibiotic substances. However, it was not until the mould was
grown on a much larger scale that these were identified. The first was named
cephalosporin P because it demonstrated activity against certain Gram-positive
bacteria (Burton and Abraham, 1951).
Sufficient amounts of cephalosporin P could not be obtained for clinical trials.
However, another antibiotic substance, initially designated cephalosporin N, was
discovered from the extraction procedure used to obtain cephalosporin P. This was
active against Gram-negative bacteria and penicillin-sensitive staphylococci, and was
undoubtedly the same substance that Brotzu had originally found. It was discovered
that this antibiotic was inactivated by the penicillinase from Bacillus cereus (Newton
and Abraham, 1954) and was subsequently re-named penicillin N. As a result of the
difficulties in successfully isolating penicillin N, this compound was never produced
in quantity by the pharmaceutical industry. A small amount of another substance was
found during an attempt to establish the molecular structure of penicillin N by
chromatography. This was named cephalosporin C, the first and original member of
the class of antibiotics known as cephalosporins (Newton and Abraham, 1955).
Unlike penicillin N, cephalosporin C was relatively acid-stable and demonstrated a
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high resistance to inactivation by B. cereus and staphylococcal penicillinases.
Although it was used in the treatment of urinary tract infection in children (Fleming,
1963), cephalosporin C did not play a major role in the treatment of infections caused
by penicillinase-producing staphylococci, as by this time the semi-synthetic
penicillins were very much in the therapeutic spotlight.
The modification of the side chains of the 7-aminocephalosporanic acid (7-ACA)
nucleus (see figure 1.9) generated new cephalosporins that were active against
bacteria which had shown resistance to the older cephalosporins. As these later
cephalosporins, in turn, succumbed to novel p-lactamases, compounds with a still
wider spectrum of activity and high stability against ^-lactamase degradation were
sought (Du Bois et al., 1995). The most recent cephalosporins possess broad spectra
of activity against Gram-negative bacteria, including some P. aeruginosa strains. At
the time of their introduction, these cephalosporins were considered to be an example
of the ultimate ability to overcome antimicrobial resistance, especially that mediated
by the ubiquitous TEM-1. Amongst these cephalosporins, e.g. cefotaxime,
ceftazidime and ceftriaxone, the increase in activity against Gram-negative bacteria
is ascribed to a modification of the side-chain attached to the 7-carbon of the 7-ACA
nucleus, to one containing a 2-aminothiazole group. More than that, these three
cephalosporins also contain an osubstituted oxyimino group on the 7-P-acyl side-
chain. This group of cephalosporins can be epitomised by ceftazidime, with a
carboxylic alkoxyimino group, which shows slow outer membrane penetration but





methoxyimino side-group, which exhibits faster penetration but has little anti-
pseudomonas activity (Du Bois et al., 1995).
1.9.1 Classification of the cephalosporins
The most widely accepted classification of cephalosporins splits them into 7 groups,
which belong to four generations (see figure 1.9). Group 1 and 2 (the "early
compounds") often referred to as the first generation cephalosporins. Second
generation cephalosporins have only group 3 compounds that are resistant to (3-
lactamases. Groups 4, 5 and 6, have compounds resistant to P-lactamases and
generally exhibit enhanced antibacterial activity (Wise, 1997). These are known as
third generation cephalosporins. The fourth generation of cephalosporins consist only
of group 7 (Wise, 1997). In general, the groups listed below differentiate these
compounds based on the route of administration, their degree of antimicrobial
activity and their stability to bacterial p-lactamases (Wise, 1997).
1.9.1.1 Group 1 cephalosporins
The parental compounds of this group were developed in response to a need for a
more effective antibiotic against staphylococci. They have moderate antimicrobial
activity and relative stability to staphylococcal P-lactamases. However, they are
hydrolysed by many enzymes produced by the Enterobacteriaceae. The first
compounds to be developed in this group were cephalothin and cephaloridine.
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1.9.1.2 Group 2 cephalosporins
The compounds within this group are administered orally and demonstrate moderate
resistance to some of the enterobacterial P-lactamases. The first of these compounds
to be developed was cephalexin, which has a methyl-group at C3. This was followed
by cefaclor, which has chlorine in place of the methyl-group, and cephradine, which
has the phenyl group of cephalexin replaced by a acyclohexadiene group.
1.9.1.3 Group 3 cephalosporins
All compounds that belong to this group are parenteral and include the related group,
the cephamycins, which share the common feature of a methoxy group attached to
the 7-a position of the p-lactam ring conferring stability to the structure. This group
displays moderate antimicrobial activity and includes activity against the anaerobe
Bacteroides fragilis.
1.9.1.4 Group 4 cephalosporins
This group includes parenteral compounds with potent antimicrobial activity and
resistance to a wide range of p-lactamases. They are characterised by the presence of
an N-acyl side-chain containing a 2-aminothiazole group.
1.9.1.5 Group 5 cephalosporins
The compounds of this group originate from an attempt to improve the intrinsic
activity of the previous oral cephalosporins. Although they have improved activity
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against many of the enterobacteria, their spectrum against the Gram-positive bacteria
is not as good.
1.9.1.6 Group 6 cephalosporins
These are parenteral compounds that are characterised by their activity against P.
aeruginosa and resistance to a wide range of P-lactamases.
1.9.1.7 Group 7 cephalosporins
Group 7 includes the parental compounds cefepime and cefpirome. The major
properties of this group are similar to those of group 4 agents (Wise, 1997). They
should probably be reserved for use in patients with severe infection caused by
bacteria with plasmid as well as chromosomally mediated p-lactamases. However,
they have potent activity against enterobacteria, enhanced activity against





Classification of the cephalosporins
Group 1- Parenteral
cephalothin, cephaloridine, cephazolin, cephapirin, ceftezole, ceforanide,
eefonicid, cefazedone, cephacetrile
Group 2- Oral
cephalexin, cephradine, cephaclor, cephaloglycin, loracarbef, cefadroxil,
cefatrizine, cefroxadine, cefporzil
Croup 3- Parenteral, improved p-lactamase
stability
cefuroxime, cefotiam, cefonicid, cephamandole, cefoxitin, cefotetan,
cefrnetazole, cefbuperazone, cephamycins
Group 4- Parenteral, improved intrinsic
activity and P-lactamase stability
cefotaxime, ceftizoxime, ceftriaxone, cefodizime, cefmenoxime, latamoxef
Group 5- Oral, improved p-lactamase
stability
cefdinir, celprozil, eefetamet, ceftibuten, eefixime, cefteram, cefpodoxime
Group 6- Parenteral
ceftazidime, cefsulodin, cefoperazone, cefpimazole, cefpiramide
Group 7- Parenteral, enhanced P-lactamase
stability, potent activity against enterobacteria
cefipime, cefpirome
Adapted from Wise, 1997
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1.10 The history of extended-spectrum p-lactamases
The earliest clinical strain known to possess an extended spectrum P-lactamase
(ESBL) was isolated in England in 1982 (Du Bois et al., 1995). The strain was
identified as Klebsiella oxytoca and was responsible for an out break of infection in a
neonatal unit in Liverpool. The initial antibiotic profile indicated that the infection
was originally due to a strain that was gentamicin-resistant but ceftazidime-sensitive
and which produced TEM-1 P-lactamase. Ceftazidime was used in treatment to
control it, but subsequent isolates ofK. oxytoca from the unit showed that the strain
had become ceftazidime-resistant. The ceftazidime resistance gene was transferable
and carried on a 141-kb plasmid (Payne et al., 1990). Subsequent detailed
biochemical analysis showed that the ceftazidime resistance was mediated by a new
p-lactamase, which was able to slowly hydrolyse ceftazidime (Payne et al., 1990). In
spite of the fact that the earliest transferable ESBL to be identified has now been
shown to have originated in England, it is on the mainland of Europe where most of
these derivative enzymes have been found and where they were first reported
(Jacoby and Medeiros, 1991; Payne and Amyes, 1991; Philippon et al., 1989a). In
1983, three strains ofK. pneumoniae and one Serratia marcescens isolated in (West)
Germany were demonstrated to confer transferable resistance to cefotaxime (Knothe
et al., 1983). The plasmid-encoded P-lactamase was a modification of the ubiquitous
SHV-1 enzyme and was designed SHV-2 (Knothe et al., 1983). The nucleotide
sequence of the SHV-2 gene showed a single nucleotide (point mutation) difference
from the SHV-1 gene, changing the amino acid at position 238 from glycine to serine
(Huletsky et al., 1990). This observation spawned a succession of reports of
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transferable, plasmid-encoded resistance to cephalosporins. So far, almost all the
broad-spectrum B-lactamase enzymes described have been found to be modifications
ofeither TEM or SHV B-lactamases (Du Bois et al, 1995).
1.10.1 Spread of genes conferring resistance to (3-lactam antibiotic
Throughout the 1960s and 1970s there was a relentless rise in reports of resistance to
P-lactams as a consequence of the selection of bacteria that produce P-lactamase.
This increase in the level of resistance was due, at least in part to the spread of self-
transmissible plasmids that encode multiple resistance phenotypes. Furthermore, the
first prokaryotic transposon carried a bla-\\M gene (Hedegs and Jacob, 1974).
Transposons that encode extended-spectrum P-lactamases have also been described
(Heritage et al., 1992). The occurrence of the bla-gene on mobile genetic elements
undermines attempts to classify these elements by genetic location as transposons
may jump between plasmids and the bacterial chromosome.
1.10.2 Nomenclature of p-lactamases
There has been considerable confusion over the nomenclature of p-lactamases. There
is no rational basis for the naming of these enzymes.
The name 'TEM' is a contraction of Temoniera, the name of the patient from whom
the first ampicillin-resistant E.coli was isolated. In contrast, 'SHV' is a contraction of
'sulphydryl variable' a description of the biochemical properties of this P-lactamase.
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Furthermore, ^-lactamases may be given one name when first identified, only to
have this name changed after subsequent studies have allowed a more complete
characterisation of the properties (Heritage et al., 1999). CTX-1 was so called
because it conferred resistance to cefotaxime. Nucleotide sequence analysis showed
that this enzyme had arisen by the accumulation of a point mutation in the gene
encoding TEM P-lactamase. Consequently, CTX-1 is now named TEM-3. Similarly,
SHV-1 has also been called PIT-2, as it was first described by Pitton in 1972 (Pitton,
1972).
1.10.3 Classification of extended-spectrum (3-lactamases
The classification of fl-lactamases has always proved problematic. Several schemes
have been proposed for the classification of this large family of enzymes. The first
proposal was to divide p-lactamases into the penicillinases that hydrolyse penicillin,
and cephalosporinases that attacked cephalosporins. The biochemical activity and
substrate profiles of different enzymes formed the basis of other early classification
schemes (Jack and Richmond, 1970). Later, the location of the genetic determinants,
whether plasmid mediated or chromosomal, became incorporated into classification
schemes. Data from isoelectric focusing studies and enzyme kinetics were also
considered important and these formed the basis of subsequent classification (Du
Bios et al., 1995). These schemes all had major anomalies but, following rapid
developments in molecular biology, sequence homology studies were able to resolve
difficulties with previous classification schemes (Richmond et al., 1971). It is current
practice to classify p-lactamases by their nucleotide sequence and for most enzymes
this works well; however, all the extended-spectrum p-lactamases described fall into
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class A and D (Ambler, 1980), which encompasses enzymes whose genes share as
little as 35% identity but retain the same overall shape. Nevertheless, the lack of
direct correlation between sequence and enzyme function is epitomised with the
prototype enzymes. Enzymatically, it is impossible to distinguish between TEM-1
and SHV-1 (Du Bios et al., 1995). In contrast, the gene for TEM-5 has only three
nucleotide changes from TEM-1 (i.e. >99.5% homology) (Sougakoff et al., 1989),
but these enzymes are easily distinguished on the basis of their substrate specificity.
Biochemical properties of the TEM-5 (3-lactamase and the resistance profiles that it
confers are of immense clinical importance. An alternative categorisation scheme
(Payne and Amyes, 1991), based on the biochemical properties and resistance
profiles that enzymes confer, shows that the mutation produce three major changes in
function. Group 1 ESBLs confer decreased susceptibility to ceftazidime and possess
an amino acid substitution that increases the ability of the enzyme to hydrolyse
ceftazidime faster than cefotaxime. Groups 2 and 3 enzymes are able to confer higher
levels of resistance to both ceftazidime and/or cefotaxime. However, group 2
enzymes hydrolyse ceftazidime to a greater extent than cefotaxime, whereas enzymes
in group 3 hydrolyse cefotaxime better than ceftazidime. An additional group has
also been suggested, (Du Bios et al., 1995) namley Group 0 (zero), which
accommodates the in vitro ability to hydrolyse cefotaxime more efficiently than
ceftazidime. However, the ability of cefotaxime to rapidly penetrate the outer
membrane ensures that this hydrolysis is insufficient to overcome the drug's
antibacterial activity (Du Bios et al., 1995).
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1.10.4 Relation between structure and function of ^-lactamases
The minimum inhibitory concentration (MIC) is the universally recognised indicator
of bacterial sensitivity to antibiotics, and is defined as the lowest concentration of the
agent that is required to inhibit bacterial multiplication. These values can be used to
compare the in vitro manifestations of each mutation with the biochemical properties
of the enzyme and the resistance profile that it confers, allowing a structure-function
relationship to be deduced and an evolutionary scheme to be proposed (Amyes et al.,
1992). The susceptibility profile will to some extent, be dependent on the encoding
plasmid and the promoter controlling the P-lactamase gene. However, the important
comparison of the relative MICs of cefotaxime and ceftazidime is less dependent on
these factors as both MICs will be influenced by them (Du Bios et al., 1995).
1.10.5 Types of ESBLs
Most ESBLs are derivatives form TEM or SHV enzymes (Bush et al., 1995). There
are now more than 100 TEM-type P-lactamases and more than 35 SHV- type
enzymes (for amino acid sequences for TEM and SHV extended spectrum P-
lactamases, see http://www.lahey.org/studies/web.htm). With both of these groups of
enzymes, a few point mutations at selected loci within the gene give rise to the
extended-spectrum phenotype. TEM- and SHV- type ESBLs are most often found in
E.coli and K pneumoniae; however, they have also been found in Proteus spp.,




As it has been mentioned previously (section 1.10), the first extended-spectrum SHV
enzyme was described in 1983 in clinical isolates of K. pneumoniae, K. ozaenae and
Serratia marcescens (Knothe el al., 1983). Because of its similarity to SHV-1 the
new enzyme was named SHV-2 (Kliebe et al., 1985). A single amino acid
substitution, in which glycine at position 238 in SHV-1 is replaced by serine in SHV-
2 alters the spectrum of activity of the SHV-1 p-lactamase to encompass extended-
spectrum cephalosporins (Brathelemy et al., 1988).
In 1988, Jarlier et al (Jarlier et al., 1988) described SHV-3, a P-lactamase isolated
from K. pneumoniae. This was isolated from a patient in an intensive therapy unit in
a French hospital where SHV-2 had also been reported. Both SHV-2 and SHV-3
have a spectrum of activity that includes extended-spectrum cephalosporins and they
share a substrate and inhibitor profile. At the nucleotide sequence level, a point
mutation causes the substitution of leucine at amino acid position 205 in SHV-3 for
the arginine that is found at this position. Both SHV-1 and SHV-2 also have a serine
residue at amino acid position 238. It is thus probable that SHV-3 evolved from
SHV-2 by a point mutation.
The isoelectric point (pi) of both SHV-1 and SHV-2 is 7.6 whereas that of SHV-3 is
pi 7.0. Soon after the first description of SHV-3, yet another member of this family
was described (Bure et al., 1988). The SHV-4 P-lactamase is another enzyme with
extended-spectrum cephalosporinase activity. It was first described in a strain of K.
pneumoniae in 1987 and like SHV-3, it was first seen in a French hospital. The strain
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of K. pneumoniae that harboured SHV-4 disseminated rapidly and by 1990 had been
found in 14 hospitals throughout France (Arlet et al., 1994). The pi of SHV-4 is 7.8.
Analysis of amino acid sequence data shows that SHV-4 evolved by a point mutation
in the gene that codes for SHV-3. In the case of SHV-4 the amino acid substitution
occurs at position 240, where as lysine replaces the glutamic acid found in this
position in the other members of the SHV family.
The fifth member of the SHV family was first observed in Chile (Gutmann et al.,
1989). This was the first variant not to have been first observed in Europe. SHV-5
was again first described from K. pneumoniae and has a pi of 8.2. As with SHV-4,
the amino acid found at position 240 in SHV-5 is lysine. It is possible, however, to
say from which ancestral gene the SHV-5 determinant evolved, it is most likely to
have evolved by a point mutation from SHV-2.
In 1991, the SHV-6 P-lactamase was discovered (Arlet et al., 1991). This is an
unusual enzyme in that its spectrum of activity is different from the other ESBLs in
this family. SHV-6 is able to hydrolyse ceftazidime but it has no activity against
other extended-spectrum cephalosporins such as cefotaxime. It is also inactive
against monobactams such as aztreonam, which distinguishes it from other extended
spectrum SHV enzymes. SHV-6 was first found in France where it was produced by
a strain ofK. pneumoniae isolated from a patient on a paediatric oncology ward. It is
probable that SHV-6 arose by a point mutation from SHV-1 since these two enzymes
differ only at amino acid position 179 where the aspartic acid found in SHV-1 has
been replaced with alanine in SHV-6 (Arlet et al., 1997). In 1993 a new ESBL SHV
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type SHV-7 was described in E.coli was isolated in the USA (Bradford et al., 1995).
E.coli provided the background for the emergence of SHV-8 (Rasheed el al., 1997).
This was also first observed in the USA. The SHV-9 ( Prinarakis el al., 1996) P-
lactamase appears to have evolved from SHV-5. This enzyme was found to be
produced by E.coli, K. pneumoniae and S. marcescens isolated from a Greek hospital
in 1995 ( Prinarakis et al., 1996). The latest additions to the SHV family were both
first described from Switzerland and are found in a number of species in the
Enterobacteriae (Niiesch et al., 1997). SHV-11 is a variant of either SHV-1 or SHV-
3 and does not possess extended-spectrum cephalosporinase activity and the other
SHV is SHV-12, which is an ESBL. The current evolutionary picture is shown in
figure 1.11. Table 1.1 summarizes the first report of each of the SHV p-lactamases
(Heritage et al., 1999).
1.10.5.2 TEM-derived enzymes
TEM-1 is the most commonly encountered p-lactamase in Gram-negative bacteria.
Up to 90% of ampicillin resistance in E.coli is as a result of the production of TEM-1
(Livermore, 1995). This enzyme is also responsible for the acquired penicillin or
ampicillin resistance that is seen in Gram-negative bacteria such as Nesseria
gonorrhoeae and Haemophilus influenzae (Livermore, 1995). TEM-1 is able to
hydrolyse penicillin and early cephalosporins. TEM-2, the first derivative of TEM-1
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Amino acid substitution in SHV ESBL derivatives. The amino acid numbering is
according to the scheme of Ambler et al (Ambler el al., 1991). Substitution found in
SHV-type ESBL derivatives are shown under amino-acids of SHV-1. SHV-type

























































TEM-1/2 p-lactamases were detected among resistant Gram-negative organisms in
the 1960s shortly after the introduction of ampicillin to the clinical armamentarium
(Datta and Knotomichalou, 1965).
The mutational relationship is well known and defined amongst this group of
enzymes (Bradford, 2001). However, they are much more complicated than those in
SHV enzymes. It can be assumed that the mutation between TEM-1 and TEM-2,
namely, the change from glutamine to lysine at position 39 occurred before later
enzymes emerged. As shown in (figure 1.12), the amino acid substitution that occur
within the TEM enzyme occur at a limited number of positions. Therefore, two
clearly separate TEM-derived enzyme groups exist in the TEM-derived enzymes;
these are TEM-1 derived and TEM-2 derived.
The analysis of a three-dimensional structure of TEM-1 P-lactamase (Jelsch et al.,
1992, 1993) places the sites of amino acid variation adjacent to the proposed position
of the respective cephalosporin 7-substitutions when the P-lactam molecule is bound
at the active site. The amino acid mutation alters the shape of the active-site, directly
or indirectly, to reduce hindrance of p-lactamase-cephalosporin binding. In some
cases, changes may promote binding through additional charge-charge interaction
with drug moieties. The first alteration from TEM-1 leading to the enzymes TEM-5









































































































































































Amino acid substitution in TEM ESBL derivatives. The amino acid numbering is
according to the scheme of Ambler et al (Ambler et al., 1991). Substitution found
in TEM-type ESBL derivatives are shown under amino acids of TEM-1. TEM-type
variants may contain more than one amino acid substitution. Only amino acid




The resultant p-lactamase, TEM-12, has a limited capability to hydrolyze both
ceftazidime and cefotaxime and is classified as group 1 (Du Bios et al., 1995). The
production of this enzyme decreases ceftazidime susceptibility, but hardly affects
sensitivity to cefotaxime. The first emergence ofESBL TEM enzymes in the UK was
in response to ceftazidime treatment (Payne et al., 1990). The same substitution can
take place with the TEM-2 (f-lactamase to give TEM-7, which has the same
properties as TEM-12. The increased capability to hydrolyze 7-oxyimino
cephalosporins does not arise from the acquisition of serine at position 164 but rather
from the loss of arginine. The loss of this amino acid breaks two salt bridges, with
asparagine-179 and glutamic acid-171, which maintains the Q-loop (Jelsch et al.,
1992; Jelsch et al., 1993). Substitution of arginine-164 by histidine in TEM-2 also
gives an enzyme "TEM-11" with the same properties.
Interestingly, although substitution of arginine at position 164 is common in the
TEM enzymes, this substitution has not been found amongst the SHV group. We
suspect that the usually short a-7 helix of the TEM-1 enzyme (Jelsch et al., 1992),
compared with other Class A P-lactamases, may explain the lack of substitution at
this point among SHV enzymes.
The development of TEM-9 can be accomplished by two distinct routes. The TEM-
17 mutation, substituting glutamic acid with lysine at position 104 leads to TEM-12.
Synergy results from the combination of the lysine-104 and serine-164 substitution
(TEM-26), increasing the MIC of ceftazidime out of proportion to the contribution of
each separate mutation. In contrast the MIC of cefotaxime conferred by TEM-26 is
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the same as that conferred by TEM-17. The TEM-26 to TEM-9 transition (threonine-
265 to methionine) increases the MIC of cefotaxime to a greater extent than the MIC
of ceftazidime. Mutation of TEM-12 at position 240 to change the amino acid from
glutamic acid to lysine creates TEM-10, which has greatly increased resistance to
ceftazidime. Further substitution of threonine for alanine at position-237 (TEM-5)
considerably increases resistance to cefotaxime but not to ceftazidime.
In the years since that first report, over 90 additional TEM derivatives have been
described (for amino acid sequence for TEM and SHV extended spectrum (3-
lactamases see http://www,lahev.org/studies/temtable.htm). Some of these P-
lactamases are inhibitor-resistant P-lactamases (IRT), but the majority of the new
derivatives are ESBLs.
This variety represents a unique example of protein evolution in "real time"
(Petrosino et al., 1998). Such diversification was probably a consequence of an
equivalent diversification of elective challenge resulting from the introduction of
multiple P-lactam antibiotic molecules designed to resist hydrolysis by TEM-1, in
particular broad-spectrum cephalosporins such as cefotaxime and ceftazidime as well
as P-lactam inhibitors (Negri et al., 2000).
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1.10.6 The evolution ofAmpC genes
The evolution of TEM and SHV enzymes has not been the only challenge to the use
of cephalosporins and p-lactam/p-lactamase inhibitor combinations in the last
decade. The migration of Ambler class C chromosomal p-lactamases on to plasmids
and their subsequent dissemination into clinically relevant species has produced
isolates resistant to virtually all cephalosporins and P-lactamase inhibitors (Horii et
al., 1993; Leiza et al., 1994). Increasing resistance to P-lactams means that in some
cases, particularly intensive care units, we are reliant on the carbapenems as the only
remaining effective p-lactam agents. However, as the use of these compounds
increases so will the selective pressure for resistance to develop. Alternatively it may
be that the biggest challenge to the carbapenems comes from the rapid dissemination
of mobile resistance genes into clinically relevant species. The dissemination of the
IMP-1 gene throughout Japan in P. aeruginosa, and its detection in K. pneumoniae,




One of the most exciting advances in antimicrobial chemotherapy was the discovery
and development of the quinolone group (see figure 1.13). The quinolones drugs are
synthetic compounds which do not resemble any compounds found in living
organisms. The first quinolone to be synthesized was nalidixic acid which was
introduced into clinical use in 1962 (Lesher et al., 1962). Since then, there has been
a small, but significant, increase in the number of resistant clinical isolates of species
previously susceptible to these agents (King et al., 2000).
In the 1970s, several other antimicrobial agents that were chemically related to
nalidixic acid, such as oxolinic acid and cinoxacin, were introduced. However, the
most significant discovery in the development of quinolone antibacterial agents came
when it was discovered that the insertion of a fluorine at position 6 in the basic
nucleus enhanced and broadened the antimicrobial activity. (See figure 1.14). These
newer quinolones, such as ciprofloxacin, moxifloxacin, clinafloxacin, gatifloxacin,
and gemifloxacin exhibited antimicrobial activity approximately a thousand times
that ofnalidixic acid (Wolfson and Hooper, 1985).
1.11.1 Binding of quinolones to DNA
Since quinolone resistance mutation occurred in the gyrA gene, it was believed that
quinolone drug bound directly to the A subunit of DNA gyrase (Gellet et al., 1977;

























gyrB suggested that the quinolone binding site might encompass both subunit A and
B (Yamagishi et al., 1986). Binding studies undertaken by Shen and Pernet suggested
that quinolones bound to DNA but not to gyrase (Shen and Pernet, 1985). In 1988
Toranletti and Pedeini, observed that the binding of quinolones to DNA causes the
DNA to unwind to a small extent (Tornaletti and Pedrini, 1988). It has been
suggested that quinolones bind preferentially and cooperatively to single-stranded
DNA (Shen et al., 1989a) and this led to the idea that they interact with a single
stranded pocket of DNA formed during the strand passage reaction catalyzed by
gyrase. This hypothesis was modified slightly by Shen et al (Shen et al., 1989b,
1989c), who later proposed a cooperative drug DNA binding model for the binding
quinolones to the gyrase-DNA complex.
Quinolones are thought to interact with the bases of DNA through hydrogen bonds
that occur between the 3-carboxy and 4-oxo groups, which almost all quinolones
possess. At least four quinolone molecules are believed to bind per DNA binding site
and ring stacking and hydrophobic interactions contribute to this co-operativity.
Gyrase interactions with the C7 group position of the drug was postulated by Shen et
al (Shen et al., 1989c) while Maxwell later pointed out that the C7 group is rather
variable (Maxwell, 1992). (See figure 1.13). A new angle has been added to this drug
binding hypothesis with the discovery that mutation in gyrA where tyrosine-122 is
replaced with either phenylalanine or serine (which can not cleave DNA) still can
bind quinolone drugs (Critchlow and Maxwell, 1996).
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1.11.2 Mechanisms of quinolone resistance
Quinolone resistance has been mapped to a mutation within a specific region DNA
gyrase termed the quinolone resistance determining region (QRDR) (Wiedemann and
Heisig, 1994). Initial studies on the development of quinolone resistance
demonstrated that there are two basic strategies that bacteria could adopt to
circumvent the action of quinolones. First, alteration of DNA gyrase, which is the
target site of quinolones, and secondly, mutation that lead to reduced access of
quinolone to DNA gyrase, that could occur by either efflux systems found in both
Gram-negative and Gram-positive bacteria, or could occur by alteration in the outer
membrane of Gram-negative bacteria (Thomson, 1999). Alteration in the structure
of DNA gyrase has been commonly identified in resistant clinical isolates (Ball,
1994; Maxwell, 1997; Tillotson et al., 1997). DNA gyrase is composed of two
subunits, A and B, and most changes have been found in the QRDR region of the A
subunit. (Tillotson et al., 1997). This region is highly conserved within bacterial
species and alteration within it has been documented in different variety of species
e.g. E.coli, Salmonella spp., Acinetobacter spp., in addition to others (Brown et al.,
1996; Deguchi et al., 1995; Vila et al., 1995; Yoshida et al., 1988). Nowadays,
quinolone usage accounts for 11% of all antibiotic prescriptions (Thomson, 1999)
and thus, it is not surprising to note that the first instance of plasmid-mediated
fluoroquinolone resistance in a clinical isolate of K. pneumoniae has been identified
(Martinez et al., 1998), although plasmid-mediated transferable resistance to
quinolones in clinical isolates is not yet thought to be a major clinical concern
(Tillotson et al., 1997).
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However, a recent report documented that a multi-resistance plasmid (conferring
resistance to ceftazidime, cefotaxime, gentamicin, streptomycin, tobramycin,
trimethoprim and chloramphenicol) also conferred reduced susceptibility to
quinolones (Martinez et al., 1998).
1.12 Klebsiella spp A nosocomial pathogen
Klebsiella spp. are Gram-negative non-sporing, non-motile bacilli, which tend to be
short and thick, e.g. 1-2 x 0.8pm. Virtually all freshly isolated strains form a well
defined polysaccharide capsule.
Klebsiella is well known to most clinicians as a cause of community-acquired
bacterial pneumonia, occurring particularly in chronic alcoholics (Carpenter, 1990)
and showing characteristic radiographic abnormalities on chest X-rays due to severe
pyogenic infection with a high fatality rate if untreated. The vast majority of
Klebsiella infections, however, are associated with hospitalization. As an
opportunistic pathogen, K pneumoniae primarily attacks immuno-compromised
individuals who are hospitalized and suffering from severe underlying diseases such
as diabetes mellitus or chronic pulmonary obstruction. Nosocomial Klebsiella
infections are caused mainly by K pneumoniae, medically the most important
species of the genus. To a much lesser degree K oxytoca has been isolated from
human clinical specimens. It is estimated that Klebsiella spp. cause up to 7 % of all
nosocomial bacterial infection in the United States and in Europe. No great
geographical variations in frequency have been noted (Podschun and Ullmann,
1998). In the United States, Klebsiella spp. account for 3 to 7% of all nosocomial
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bacterial infection, placing them among the eight most important infectious
pathogens in hospitals (Podschun and Ullmann, 1998; Schaberg et al., 1991). Data
collected from the United Kingdom (Bergogne-Neberezin, 1995) and from Germany
(Podschun and Ullmann, 1998) show remarkable similarities to those reported by the
centers for Disease Control and Prevention, Atlanta, USA.
The urinary tract is the most common site of infection. Klebsiella account for 6 to
17% of all nosocomial urinary tract infections (UTI) and shows an even higher
incidence in specific groups of patients at risk, e.g., patients with neuropathic bladder
or with diabetes mellitus (Lye et al., 1992). As a cause of nosocomial Gram-
negative infection, K. pneumoniae is second only to E. coli (Duggan et al., 1985;
Pittet and Wenzel, 1993; Yinnon et al., 1996), (see table 1.2).
In paediatric wards, nosocomial Klebsiella infections are especially troublesome-
particularly in premature infants and intensive care units. Klebsiella spp. are often
the pathogen involved in neonatal sepsis, in both early manifestation and late
manifestation infections (Gotoff, 1992).
As a result of the extensive spread of antibiotic-resistant strains, particularly ESBL-




Ranking ofKlebsiella compared to all other bacterial infection
Infection % of infections caused by K. pneumoniae Rank
UTI 6-17 5-7
Pneumonia 7-14 2-4
I Septicaemia 4-15 3-8
Wound infections 2-4 6-11
Nosocomial infection in ICU 4-17 4-9
| Neonatal septicaemia 3-20!
2-8




K. pneumoniae is ubiquitous in nature. It probably has two common habitats, the
environment, where they are found in surface water, sewage, soil, plants (Brown and
Seider, 1973), and the mucosal surfaces of mammals such as humans, horses, or
swine, which they colonize. In this respect, the genus Klebsiella is similar to
Enterobacter and Citrobacter but unlike Shigella spp or E.coli, which are common in
humans but not in the environment (Brown and Seider, 1973). In humans K.
pneumoniae is present as a saprophyte in the nasopharynx and in the intestinal tract.
The carrier rate differs considerably from study to study. The detection rate in stool
samples ranges from 5 to 38%, while rates in the nasopharynx range from 1 to 6%
(Davis and Matsen, 1974). Gram-negative bacteria do not find good growth
conditions on the human skin, unlike Gram-positive bacteria. K. pneumoniae are
rarely found there and are regarded simply as transient members of skin flora (Kloos
and Musselwhite, 1975). These carrier rates change dramatically in the hospital
environment, where colonization rates increase in direct proportion to the length of
stay. Even hospital personal have elevated rates of Klebsiella carriage (Podschum
and Ullmann, 1998). Reported carrier rates in samples from hospitalised patients are
77% in the stool, 19% in the pharynx, and 42% on the hands of patients (Davis and
Matsen, 1974). The high rate of nosocomial K. pneumoniae colonisation appears to
be associated with the use of antibiotics rather than with factors connected with
delivery of care in hospitals (Podschum and Ullmann, 1998). Previous antibiotic
therapy is significantly associated with acquisition of Klebsiella by the patient. In
one study 2 weeks after admission to the hospital, a two-to fourfold increase in the
colonization rates with Klebsiella was observed; this increase occurred primarily in
Chapter 1 Introduction
patients receiving antibiotics, especially in patients receiving broad-spectrum or
multiple antibiotics. In the hospital setting, the local antibiotic policy is a major
determinant of the colonization pattern. The significance of increased colonization
was illustrated by the observation that the nosocomial infection rate with K.
pneumoniae in patients carrying hospital-acquired intestinal Klebsiella was four
times higher than that seen in non carriers (Podschum and Ullmann, 1998).
Furthermore, widespread use of antimicrobial therapy has often been held
responsible for the occurrence of multiply- resistant K. pneumoniae strains in
hospitals (Tullus et al., 1988). These undesired effects may be reversed by strict
control of antibiotic use, demands for strategies to avoid the overuse of antibiotics in
prophylaxis and empirical therapy.
1.12.2 The incidence of ESBL- producing Klebsiella pneumoniae
The incidence of ESBL-producing K. pneumoniae isolated in the United States has
been reported to be 5% of the K. pneumoniae strains tested in the National
Nosocomial Infection Study system (NNISS) (Jacoby, 1996). In Europe, the
frequency of such strains seems to be even higher. Fourteen to 16% of K.
pneumoniae clinical isolates have been found to harbour ESBLs in France and
England (Sirot, 1995). In particular regions, or hospitals, the incidence rate can reach
25 to 40% (Burwen et al., 1994). However, the percentage of ceftazidime-resistant
strains may be much higher, because the conventional disc diffusion criteria used in





The genus Escherichia was formerly subdivided into a number of species by
differences in sugar fermentation reactions, but nowadays only one species, E.coli, is
recognized (Pattison et al., 1995) although it is subdivided into serotypes and
biotypes. E.coli are Gram-negative bacilli most stains (-80%) are motile, though
motility is often feeble on primary isolation, and most strains (-80%) are fimbriate.
E.coli is the most common nosocomial Gram-negative bacterium followed by K.
pneumoniae (Podschum and Ullmann, 1998). The intestinal commensal strains of
E. coli commonly cause opportunistic infection in other parts of the body where there
is some abnormality or impairment of defences. They are a common cause of urinary
tract infection (cystitis, pyelititis and pyelonephritis) and are commonly present in
appendix abscesses, peritonitis, cholecystitis, septic wounds and bedsores. These
microorganisms are able to infect the lower respiratory passages or cause
bacteriaemia and endotoxic shock.
1.13.1 The incidence of ESBL-producing E.coli
Ampicillin resistance among these members of the Enterobacteriaceae is due
primarily to the production of Bush group2 p-lactamase (Bush et al., 1995; Sanders
and Sanders, 1992). For E.coli, this is usually due to the presence of TEM-1 P-
lactamase. E.coli strains expressing a high level of ESBL enzyme will also be
resistant to expanded-spectrum cephalosporins and aztreonam. Prevalence of
resistance to ampicillin and older cephalosporins is on the increase in these species
due primarily to the dissemination of plasmids encoding TEM-1 or SHV-1 P-
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lactamases (Pitout et al., 1997). In many geographic locations, resistance to
ampicillin among clinical isolates of E.coli exceeds 50% (Bush et al., 1995). After
the introduction of expanded-spectrum cephalosporins, strains of E.coli that were
resistant to these drugs and aztreonam began appearing in certain areas in Europe
(Thomson et al., 1996). Subsequent studies showed that this resistance was due to
the presence of new forms of TEM-1, TEM-2, and SHV-1 enzymes, which were
capable of hydrolyzing the expanded-spectrum cephalosporins. These ESBLs have
been recovered from isolates of K. pneumoniae and E.coli worldwide. ESBLs have
also been recovered from other species of Enterobacteriaceae, although they are
much less common (Pitout et al., 1997).
1.14 The aim of this study
1. To determine susceptibility of ESBL producing K. pneumoniae and E.coli
isolated from Edinburgh to various antimicrobial agents.
2. To detect the presence of extended-spectrum (3-lactamases (ESBLs) by use of
various methods.
3. To characterize the relationship between the ESBL-producing K. pneumoniae
and E.coli by genotypic (PCR, DNA-hybridization and PFGE) and phenotypic
(OMPs, antibiogram and IEF) methods.
4. To explore the relationship between the production of extended-spectrum 0-
lactamases (ESBLs) and resistance to ciprofloxacin in K. pneumoniae isolates.
5. To identify and characterize ESBLs in K. pneumoniae strains isolated from Chile.
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1.15 Significance of this study
The results of this study provide information on the presence of ESBLs in K.
pneumoniae and E.coli isolated from patients samples from Edinburgh and the
surrounding districts. It enriches our knowledge of the mechanisms of resistance to
third generation cephalosporins and ciprofloxacin in addition to other antimicrobial
agents. In addition, the study provides useful epidemiological and surveillance
information on the susceptibility of these particularly organisms at a local level. This
will hopefully provide clinicians with future guidance for empirical therapy for such
strains.
The study also demonstrates the identification and characterization of a novel SHV





Chapter 2 Materials and Methods
2.1 Bacterial Isolates
A total of 87 putative ESBL-producing clinical bacterial isolates were collected from
patients in the Edinburgh Royal Infirmary (ERI) and surrounding district between
May 1999 to March 2000. The isolates were from various clinical samples and
comprised 69 K. pneumoniae and 18 E. coli. All were single isolates from individual
patients. They were chosen on the basis of their putative resistance to any of the
second or third generation cephalosporins, as determined using the Vitek system.
Table (2.1) lists the isolates and their clinical sources. The 87 isolates were speciated
by both the automated Vitek system and by the API 20E system.
2.2 Storage of strains
Bacterial strains were inoculated onto MacConkey agar plates and incubated at 37°C
overnight to check their purity. All strains were stored at -70°C in cryovials (Alpha
Laboratories, East Leigh, Hampshire) until required. Working stock was stored on
nutrient agar slopes at room temperature.
2.3 Culture media
Unless otherwise stated, all growth media and components were sterilised by
autoclaving fori 5 minutes at 121 °C.
2.3.1 Solid media
Nutrient agar, Iso-Sensitest (1ST) agar, MacConkey agar, and Mueller-Hinton agar
were all obtained from Oxoid (Basingstoke, UK). They were prepared according to
the manufacturer's instructions and sterilised as described above. The agar was
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Table 2.1











AD313 F 1911 K. pneumoniae Urine 28.6.1999 W22
AD314 F 1930 K. pneumoniae Swab 20.7.1999 W22
AD315 M 1941 K. pneumoniae Respiratory | 23.8.1999 W15
AD316 F 1904 K. pneumoniae Urine 15.11.1999 W15
AD317 F 1913 K. pneumoniae Urine 16.8.1999 GP
AD318 M 1960 K. pneumoniae Respiratory 21.9.1999 W15
AD319 F 1903 K. pneumoniae Urine 26.7.1999 W15
AD320 F 1924 K. pneumoniae Swab 23.8.1999 W15
AD321 M 1960 K. pneumoniae Respiratory 23.9.1999 W17
AD322 M 1941 K. pneumoniae Swab 24.8.1999 W15
AD323 M 1926 K. pneumoniae Urine 8.10.1999 W15
AD324 M 1933 K. pneumoniae Respiratory 22.7.1999 W15
AD325 F 1909 K. pneumoniae Swab 12.11.1999 W37
AD326 F 1920 K. pneumoniae Urine 8.10.1999 W15
AD327 M 1918 K. pneumoniae Urine 11.10.1999 W15
AD328 F 1927 K. pneumoniae Urine 13.11.1999 W47
AD329 F 1939 K. pneumoniae Urine 13.11.1999 W38
AD330 F 1939 K. pneumoniae Urine 18.11.1999 W22
AD331 F 1921 K. pneumoniae Respiratory 24.11.1999 W33
AD332 M 1930 E. coli Urine 29.11.1999 GP
AD333 M 1935 K. pneumoniae Swab 10.1.2000 W5
AD334 F 1938 K. pneumoniae Respiratory 10.1.2000 W14
AD335 F 1936 K. pneumoniae Urine 16.12.1999 W14
AD336 M 1937 E. coli Urine 16.4.2000 GP
AD337 F 1915 K. pneumoniae Urine 21.2.2000 W14
AD338 F 1979 K. pneumoniae Urine 2.6.1999 W15
AD339 M 1920 K. pneumoniae Urine 3.3.2000 W37
AD340 M 1911 K. pneumoniae Urine 16.2.2000 W5
AD341 F 1933 K. pneumoniae Urine 28.2.2000 Wll
AD342 M 1911 K. pneumoniae Urine 6.2.2000 W5
AD343 M 1932 K. pneumoniae Urine 29.2.2000 W22
AD344 M 1932 K. pneumoniae Urine 22.2.2000 W22
AD345 F 1917 K. pneumoniae Urine 27.2.2000 W33
AD346 M 1939 K. pneumoniae Urine 16.2.2000 W15
AD348 F 1915 K. pneumoniae Urine 11.3.2000 W15
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Table 2.1 (cont.)
AD349 F 1956 E. coli Urine 16.3.2000 GP
AD350 F 1962 K. pneumoniae Urine 28.3.2000 W5
AD351 F 1983 K. pneumoniae Respiratory 27.3.2000 W15
AD352 M 1920 K. pneumoniae Urine 24.3.2000 GP
AD353 M 1935 K. pneumoniae Urine 28.3.2000 W5
AD354 M 1923 K. pneumoniae Urine 31.3.2000 W13
AD355 M 1942 K. pneumoniae Urine 11.4.2000 W15
AD356 M 1935 K. pneumoniae Urine 20.6.2000 W43
AD357 F 1932 E. coli Urine 10.4.2000 GP-2
AD358 M 1963 K. pneumoniae Respiratory | 14.4.2000 W15
AD359 M 1916 K. pneumoniae Respiratory 21.4.2000 GP
AD360 F 1961 E.coli Urine 19.4.2000 GP-1
AD362 F 1952 K. pneumoniae Respiratory 18.4.2000 W15
AD363 F 1918 K. pneumoniae Respiratory 27.7.2000 W15
AD364 F 1918 K. pneumoniae Urine 26.7.2000 W15
AD365 F 1949 K. pneumoniae Respiratory 27.7.2000 Wll
AD366 M 1920 K. pneumoniae Urine 28.7.2000 W33
AD367 F 1928 K. pneumoniae Swab 4.7.2000 W8
AD368 F 1911 K. pneumoniae Urine 26.4.2000 GP
AD369 F 1959 E.coli Urine 25.4.2000 GP-1
AD370 M 1961 K. pneumoniae Urine 7.4.2000 GP
AD371 F 1920 E.coli Urine 7.4.2000 GP
AD374 M 1924 K. pneumoniae Blood 19.6.2000 W15
AD375 F 1928 K. pneumoniae Urine 25.6.2000 W33
AD377 F 1946 K. pneumoniae Respiratory 3.7.2000 W15
AD378 M 1928 K. pneumoniae Respiratory 13.7.2000 W15
AD380 M 1943 K. pneumoniae Respiratory 17.7.2000 W15
AD382 F 1935 K. pneumoniae Respiratory 28.6.2000 W15
AD384 M 1924 K. pneumoniae Swab 3.7.2000 W15
AD385 F 1957 E.coli Urine 28.6.2000 GP
AD386 M 1947 E.coli Urine 1.7.2000 GP
AD387 F 1957 E.coli Urine 12.7.2000 GP-1
AD388 F 1908 E.coli Urine 28.6.2000 GP
AD389 F 1930 K. pneumoniae Swab 19.6.2000 W15
AD391 F 1928 K. pneumoniae Urine 27.6.2000 W3
AD392 M 1926 K. pneumoniae Urine 3.7.2000 W29
AD393 F 1954 E.coli Urine 28.6.2000 GP-1
AD395 F 1926 K. pneumoniae Swab 17.6.2000 W5
AD399 F 1938 E.coli Urine 19.6.2000 GP
AD400 F 1952 E. coli Swab 8.6.2000 GP
AD401 F 1920 K. pneumoniae Urine 9.6.2000 W37
AD402 M 1938 K. pneumoniae Urine 22.5.2000 W8
AD403 F 1962 E. coli Urine 3.5.2000 GP
69
Chapter 2 Materials and Methods
Table 2.1 (cont.)
AD404 F 1946 K. pneumoniae Urine 29.3.2000 I W15
AD405 F 1922 E.coli Urine 8.5.2000 GP-2
AD407 F 1930 K. pneumoniae Urine 7.4.2000 W25
AD408 M 1955 K. pneumoniae Urine 29.5.2000 W42
| AD409 M 1960 || K. pneumoniae Urine 29.3.2000 W42
j AD410 M 1920 || K. pneumoniae Urine 16.6.2000 W32
| AD411 F 1926 1 K pneumoniae Urine 14.6.2000 W32
AD412 M 1915 || E.coli Urine 9.6.2000 GP
AD413 F 1964 | E.coli Urine 18.6.2000 GP-1















GP-1: Eastfield medical center.
GP-2: West Linton health center.
GP: Other isolates were from single GPs.
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allowed to cool to 50°C before being poured into sterile petri dishes (Sterilin Ltd,
Stone, Staffordshire) and allowed to set. The plates were then stored at 4°C.
2.3.2 Liquid media
Nutrient broth and brain heart infusion broth (BHIB), were obtained from Oxoid and
Luria Bertani (LB) was obtained from GIBCO (BRL, Life Technologies, UK). Cells
were dissolved in distilled water and sterilised as described before.
2.4 Chemical reagents
All chemical reagents used were supplied by Sigma chemicals (Dorset, UK) unless
otherwise stated.
2.5 Antimicrobial susceptibility testing
2.5.1 Antimicrobial discs
All antimicrobial discs and their concentration for disc diffusion susceptibility testing
method are listed in table 2.5.1. Antimicrobial discs were supplied by Becton
Dickinson (Cockeysville, USA).
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Table 2.5.1 Antimicrobial agents discs and concentrations
No Antimicrobial Concentration
1 Ampicillin 30 pg
2 Augmentin 10 pg
3 Cephalexin 30 pg
4 Cephalothin 2.5 pg
5 Cefotaxime 50 pg
6 Ceftazidime 10 pg
7 Tazobactam 10 pg
8 Meropenem lOftg
9 Ciprofloxacin 1 Pg
10 Gentamicin 10 pg
11 Tobramycin 10 pg
12 Amikacin 30 pg
13 Chloramphenicol 30 pg
14 Trimethoprim 30 pg
15 Nitrofurantoin 30 pg
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2.5.1.1 Disc-diffusion method
Isolates were diluted in normal saline to a turbidity equivalent to 0.5 MaeFarland
standard 10"8colony-forming units per ml (cfu/ml). The diluted culture was used to
flood seed Mueller-Hinton agar plates. Excess fluid was removed and the plates
allowed to dry. Antibiotic discs were then applied and plates were incubated at 35°C
for 18-24 hours in air. Control strains used were E.coli NCTC 10418 and E.coli (3-
lactamase NCTC 11560. Results were reported as sensitive, resistant or intermediate
by comparing the diameter of the zone of inhibition around the antibiotic discs with
published values provided by the National Committee for Clinical Laboratory
standards (NCCLS).
2.5.2 Antimicrobial powders
The following antimicrobial agents were used for MIC determinations by agar
dilution. Gentamicin and tobramycin were purchased from David Bull Laboratories,
(Warwick, UK). Ciprofloxacin from Bayer (England). All compounds were
dissolved in sterile distilled water as recommended.
2.5.2.1 Minimum inhibitory concentration
Minimum inhibitory concentrations (MICs) were determined according to the
guidelines of the Working Party on Antibiotic Sensitivity Testing of the British
Society for Antimicrobial Chemotherapy (1991). Bacterial strains were grown
overnight at 37°C in 1ST broth and diluted in 0.9% saline to give 107 cfu/ml. A
denley multipoint inoculator (Denley, Surrey) was used to inoculate 1 pi of the
diluted suspension onto agar plates containing serially diluted antibiotics to give a
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final inoculum of 104 cfu/spot. Recommended NCTC strains were included as
controls (Working Party on Antibiotic Sensitivity Testing, 1991).
2.5.2.2 Vitek system
The Vitek system (bio-Merieux) was used for identification or/and susceptibility
testing. Each identification card (GNI+) contains 30 biochemical tests, which require
no addition of reagents. It is able to identify more than 300 species. The Vitek system
is able to test a wide range of antimicrobial agents. Interpretation of susceptibility
results are pre- programmed into the system, the breakpoint values being based on
NCCLS guidelines.
2.5.2.3 Epsilon test (E-test)
The E-test (AB Biodisk, Cambridge, UK) employs a more stringent and convenient
method of determining susceptibility of bacterial isolates. It comprises a plastic strip
embedded with an antibiotic gradient. An overnight broth culture was used to flood-
seed Mueller Hinton agar plates. The plastic strips were placed on the surface of the
agar plates and the antibiotic is released into the agar, to yield " pear-shaped" zones
of inhibition. The plates were incubated overnight at 37°C in air and MIC of the
antibiotic is indicated by the point at which the zone of inhibition intersects with the
strip.
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2.6 Methods for ESBL detection
2.6.1 Vitek system
The Vitek system is able to detect ESBL production by an automated version of the
synergy test, which is based on detection of the inhibitory effect of clavulanic acid on
ESBL in the presence of either cefotaxime or ceftazidime. The test is interpreted by
measuring the difference in bacterial growth with or without inhibitor.
2.6.2 E-test ESBL strips
E-test ESBL strips (AB Biodisk, Cambridge) employ a more stringent method of
detecting the presence of ESBLs. The strip is comprised of a plastic double ended
strip with two shorter antibiotic and antibiotic/inhibitor gradients aligned in opposing
directions from the center. Two strips are currently available containing either
cefotaxime and cefotaxime/clavulanic acid, or ceftazidime and
ceftazidime/clavulanic acid. These strips yield both the MIC of the cephalosporins
and the MIC ratio of the antibiotic relative to the antibiotic/inhibitor combination,
which indicates the presence or absence of an ESBL. Interpretation of the results was
as recommended by the manufacturer. A positive reaction is indicated by the ratio of
the antibiotic and antibiotic/inhibitor. A value of > 8mg/l indicates ESBL activity,
and a value of< 8mg/l indicates no ESBL activity.
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2.6.3 Double disc diffusion (DDD) test
Antimicrobial double discs (cefotaxime 30 pg, cefotaxime 30 gig + clavulanic acid
10 pg, ceftazidime 30 pg, ceftazidime 30 pg + clavulanic acid 10 fig and
cefpodoxime 10 jag, cepodoxime 1 pg + clavulanic acid 10 pg) were supplied by
Oxoid Ltd.
The DDD test was performed according to NCCLS guidelines. A broth culture was
adjusted to a 0.5 MacFarland and swabbed onto an Mueller-Hinton agar plate. The
combination and corresponding cephalosporin discs were placed on the agar plates
using a disc dispenser (Oxoid). The plates were incubated at 35°C for 18-24hours
before the zone size was recorded. A positive result (the production of an ESBL) was
indicated by a zone size difference of > 5mm between the combination disc and the
corresponding standard antibiotic disc. Interpretation of the results was as for
manufacturer's instructions.
2.7 Plasmid DNA preparation
Cells from 1.5 ml of an overnight incubation at 37°C LB culture were harvested by
centrifugation at 13000 rpm (MSE microcentrifuge) for 1 minute and re-suspended in
lOOpl of solution 1 (5mM sucrose, lOmM EDTA and 25mM Tris-pH 8.0) and re-
suspended by vortexing. Two hundred pi of solution 2 (0.2N NaOH and 1% (w/v)
SDS) was added and mixed by inversion till the cells were lysed. The tubes were
allowed to stand for 3 minutes, before solution 3 (3M sodium acetate, pH 4.8) was
added and mixed by inversion. The tubes were incubated on ice for at least 30
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minutes, after which, the tubes were centrifuged for 5 minutes at 13000 rpm, the
supernatant was transferred to a new microfiige tube, 1000 pi of 95% ethanol was
added and the tubes were centrifuged for 15 minutes at 13000 rpm. After
centrifugation, the supernatant was discarded and the white pellet washed with 500pl
of 80% ethanol for 5 minutes. The DNA was air dried and re-suspended in 200pl of
sterile TE buffer and stored at -20°C until required.
2.8 DNA- Labelling
The DNA fragment probe was labelled by DIG-dUTP (alkali-labile) in the
polymerase chain reaction by the PGR DIG probe synthesis kit (Roche diagnostic
GmbH, Germany).
2.8.1 DNA-DNA Hybridisation (Dot-Blot)
Hybond™-N+ nylon membrane (Amersham pharmacia Biotech UK Limited) was
spotted with 2.5 pi ofprepared DNA from the 87 strains. The membrane was dried in
air and the DNA was fixed onto the membrane by baking the membrane at 80°C for
2 hours (Bio-Rad Gel dryer model 583). The membrane then was incubated in pre-
hybridisation solution (50% formamide, deionized, 5XSSC, 0.1%(w/v) N-
lauroylsarcosine, 0.02%(w/v) SDS, and 2% of blocking reagent (1/5 volume of
blocking solution, 1OXconcentration) for 2 hours at 68°C. After pre-hybridisation a
denatured labelled probe was added to 5 ml of pre-hybridisation fluid and the
membrane was incubated overnight at 68°C in a hybridization incubator (Techne
Hybridiser HB-ID, Techne Ltd, Cambridge). Following hybridisation, the membrane
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was washed twice with 250 ml ofwash solution 1 (2x SSC, 0.1%(w/v) SDS) at room
temperature with gentle agitation (MK V Orbital Shaker, LH Engineering) for 10
minutes with each. This was followed by another wash with wash solution 2 (0.1%x
SSC, 0.1% (w/v) SDS) twice at 68°C for 15 minutes each.
2.8.2 Detection
After hybridisation and stringency washes, the nylon membrane was washed for 5
minutes in wash buffer (0.1M Maleic acid + 0.3(v/v) TweenK 20) and incubated for
30 minutes in 100 ml lx blocking solution (by diluting the stock solution 1:10 in
maleic acid) with gentle agitation. The nylon membrane was then incubated for 30
minutes in 20 ml of diluted antibody-conjugate solution (diluted anti-DIG-AP
conjugate (vial3) to 75mu/ml (vial2)) with gentle agitation. The unbound antibody-
conjugate solution was removed by washing twice for 15 minutes each in 100 ml of
washing buffer (0.1M Maleic acid + 0.3(v/v) Tween® 20). The nylon membrane was
equilibrated for 2-5 minutes in 20 ml of detection buffer ( 0.1M Tris-HCL, 0.1M
NaoH, pH 9.5). Finally the membrane was treated with 1:100 diluted CSPD
(Boehringer Mannheim, Germany) detection buffer and exposed to X-ray film
(Polaroid black/white) for 20 minutes at room temperature.
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2.9 Isolation of chromosomal DNA
Genomic DNA was extracted for PCR by using a Puregene DNA isolation kit
(Gentra system kit, USA) according to the manufacturer's instructions.
2.10 Polymerase chain reaction (PCR) primer design
Primers were either designed with primer 3 software
(http://www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi), or the sequence was
taken from previously published work. All primers were synthesized by the Oswell
DNA service (Southampton University, Southampton, UK). Primers used for each
PCR experiment are shown in table 2.10.1
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Table 2.10.1
Oligonucleotide primers used for PCR amplification
Primer pair Sequence ( 5' to 3') Reference
SHV
SHV
CGC CGG GTT ATT CTT ATT TGT CGC





CTG GGA AAC GGA ACT GAA TG





ATG AGT ATT CAA CAT TTC CG





TGC GAG AGA AAT TAC ACC




CTG AAT GCC AGC GCC AAA TT
TGC GGT GGA ATA TCG GTC GC
Primer design
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2.10.1 PCR reaction mixture
Each PCR reaction was performed in a total volume of 100 pi (table 2.10.2) prepared
in a 0.5 polypropylene microcentrifuge tube (Alpha Laboratories, UK) with
Cyclogene thermocycycler (Techne, Cambridge, UK) with a heated lid, thereby
negating the need for the use of a sterile oil overlay. Each reaction mixture was
subjected to 30 cycles, with each three steps: denaturation, annealing and extension.
Different cycling protocols were used to amplify the different blasuw, blaTEm genes
parC and gyrA gene.
Table 2.10.2
PCR reaction components





10 10 mM/ 50 mM
MgCb 25 mM 8 2.5 mM
dNTPs** 2 mM 10 0.2 mM
Primer 1 10 pmol/ pi 1 10 pmol
Primer2 10 pmol/ pi 1 10 pmol
MilliQ
water
make volume up to
100 pi
Taq DNA 5 U/pl 5 pi of 1:10
dilution
2.5 U
* Supplied by Promega UK; **2 mM 4dNTPs stock- 2 mM of each dNTP (
Boehringer Mannheim, Sussex) in TE buffer pH 7.5. Stored at -20°C in 0.5 ml
aliquots
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2.10.2 PCR cycles
The cycling parameters for the different genes are shown in table 2.10.3. To validate
the PCR reaction, negative as well as positive controls were incorporated and used.
2.10.3 PCR product size
All expected PCR product sizes are detailed and listed in table 2.10.4
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Table 2.10.3
PCR heating cycle protocol for different PCR reactions
TEM-1 Protocol
Segment Temperature Time Cycles
1 95°C 5 minutes 1
2-a 94°C 30 seconds
|
2-b 55°C 1 minute U 30
2-c 70°C 1 minute >)
3 75°C 10 minutes 1
SHV - Protocol
Segment Temperature Time Cycles
1 95°C 5 minutes 1
2-a 94°C 1 minute 3
2-b 56°C 1 minute ^ 30
2-c 70°C 1 minute -J
3 72°C 10 minutes 1
gyrA Protocol
Segment Temperature Time Cycles
1 95°C 5 minutes 1
2-a 94°C 1 minute 3
2-b 54°C 1 minute >- 30
2-c 70°C 1 minute J
3 72°C 7 minutes 1
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Table 2.10.3 (cont.)
parC Protocol
Segment Temperature Time Cycles
1 95°C 5 minutes 1
2-a 94°C 1 minute 1
2-b 55.5°C 1 minute y 30
2-c 70°C 1 minute J
3 72°C 7 minutes 1
SHV-1 Protocol
Segment Temperature Time Cycles
1 95°C 5 minutes 1
2-a 94°C 1 minute -
2-b 57°C 1 minute *" 32
2-c 70°C 1 minute -J
3 72°C 10 minutes 1
Table 2.10.4
Expected product sizes for PCR
PCR Reaction Expected product size
bla shv primers 1017 bp
bla shv-1 primers 383 bp
bla tem-i primers 858 bp
DNA gyrA primers 626 bp
DNAparC primers 346 bp
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2.10.4 Analysis of PCR products
PCR products were separated at neutral pH vales in 1% w/v agarose (GIBCO BRL,
Life Technologies, UK) gels in TAE buffer (40 mM Tris-acetate pH 7.6, 1 mM
EDTA). Under these conditions, double stranded DNA is negatively charged hence
loaded near the cathode and migrates towards the anode with the application of an
electric field (Aaji and Borst, 1972). Gel electrophoresis was carried out in a mini-
subcell GT (Bio Rad, UK) under the constant voltage of 100V (Powerpac 300, Bio
Rad, UK) for 40 minutes, depending on the migration of the bands. For larger gels
subcell GT (Biorad, UK) gel tanks were used. A DNA ladder (Generuler™, MBI,
Fermentas) was run alongside the PCR products verification of the sample's
molecular size. Each DNA sample was mixed with 2pl of loading buffer (30%w/v
glycerol, 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol) before loading the
wells.
2.10.5 Staining and visualization of DNA
The electrophoresed fragments were visualized after electrophoresis by staining for
one hour in a 50 pg/ml ethidium bromide solution. If necessary, de-staining was
carried out with gentle agitation in distilled water to remove excess ethidium
bromide and reduce background fluorescence. DNA was viewed by placing the gels
on a UV transilluminator (UV products, Cambridge, UK) and photographed.
2.10.6 Purification of DNA
PCR products were purified by using the Qiaquik PCR purification kit (Qiagen,
Germany) according to the manufacturer's instructions. The final volume for elution
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of the purified products was reduced to 30pl to concentrate the DNA. The
concentration of the DNA from the PCR product was approximated by comparing
the intensity of the bands after electrophoresis of A. DNA digested with HindlU
(Sigma, UK) known to contain 0.5pg per micro liter.
2.10.7 Automated DNA sequencing
The PCR primers had been used as sequencing primers at a concentration of 3.2 Pico
mol (10~12) per reaction. The DNA was purified as described before prior to
sequencing to ensure that the required concentration of 30 to 90 ng was achieved.
The DNA sequence was determined by the chain termination method developed by
Sanger (1977). Individual fragments of PCR were set up in the ready reaction format
for fluorescence based on dideoxy cycle sequencing (PE Applied System, UK). All
sequences were determined in the Department of Hematology, Royal Infirmary of
Edinburgh, Scotland. Sequences were then analysed by the BLAST online search
engine ( http://www.ncbi.nih.gov/cgi-bin/BLAST ) with the susceptible strains
sequence in the database.
2.11 Isoelectric focusing
For any protein there is a characteristic pH, called the isoelectric point (pi), at which
the protein has no net charge and therefore will not move in an electrical field. In
isoelectric focusing (IEF), proteins are electrophoresed in a narrow tube of
polyacrylamide gel in which a pH gradient is established by a mixture of special
buffers. Each protein moves to its pi point in the gradient.
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2.11.1 Purification of P-lactamase
Each of the 87 isolates was streaked onto a Mueller-Hinton agar slopes and incubated
overnight at 37°C. The cell growth was washed off the surface of the Mueller-Hinton
agar slope with 2.0 ml of 50mM sodium phosphate buffer, pH 7.0 then, transferred to
a fresh sterile bottle and cooled in an ice cold container. Bacterial cells were cooled
with ice and disrupted by sonication (MSE Soniprep 150. MSE instruments,
Crawley, Sussex) with two 15 second pulses of 6-8 pm of amplitude separated by a
15 second cooling period. The lysate was then cleared of cell debris by centrifiigation
at 4°C in an MSE microcentrifuge at 13000 rpm for 10 minutes. The cell free
supernatant was stored at -20°C until required.
2.11.2 Assessment of [3-Iactamase activity in the enzyme preparation
The reaction time for a 30 pi volume of the P-lactamase preparation to change the
colour of 100 pi of nitrocephin solution (50mg/ml) from yellow to red was taken as
an indication of the P-lactamase activity of the enzyme preparation.
2.11.3 Analytical isoelectric focusing
p-lactamases were identified by analytical IEF as described by Matthew et al.,
(1975). The P-lactamase preparation was focused on thin layer polyacrylamide gels
containing broad range (pH 3.5-10) or a mixture of broad range (pH 3.5-10) and
narrow range (pH 6-8) carrier ampholytes (1:1). Thin layers of polyacrylamide gel,
200mm x 150mm x 1mm were prepared by the polymerisation of the gel solution
described in table 2.11.3, catalysed by riboflavin in the presence ofUV light between
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two glass plates 1mm apart. To promote adhesion of the polyacrylamide gel to one of
the 2 glass plates, it was necessary to coat one glass with binding solution. The
remaining glass plate was siliconised, to prevent adhesion.
Preparation of binding solution was performed by dissolving 0.5% (w/v) gelatine
(ca.225.bloom from calf skin, Aldrich Chemical co. Ltd., Gillingham, Dorset) and
distilled water. Glass plates (210mm x 160mm) were submersed in the coating
solution for 10 minutes, before removal from the solution and drying in the incubator
at 55°C for 20 minutes prior to use.
Samples of P-lactamase preparation were loaded close to the anode on the gel surface
(volume in pi equivalent to spot test time). For all gels, P-lactamases with known pis
were focused alongside novel P-lactamase enzymes.
2.11.4 Running conditions
The running condition of the analytical IEF gels was at constant power of 1 watt
overnight at 4°C (power setting: voltage = 500V, current = 20mA, power = 1.0W).
2.11.5 Visualisation of ^-lactamases after electrophoresis
The focused p-lactamase bands were visualised by overlaying the polyacrylamide gel
with sheets of filter paper (Whatman® No.l, Whatman International Ltd, Maidstone)
soaked in ImM nitrocephin. pis of unknown or novel enzymes were estimated from
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the focused bands of enzymes of known pi. Stained gels were photographed with a
Polaroid camera using a Tiffen green filter.
2.11.6 Pre-cast IEF gel
Pre-cast IEF gels (Ampholine® PAGplate, Pharmacia Biotech, Uppsala, Sweden) are
polyacrylamide gel cast on plastic support films. The dimensions of the gel (110 mm
x 245 mm x 1mm) allow the screening of large number of samples. The Pharmacia
Ampholine PAG plate (pH range 3.5 to 9.5) was placed on a LKB 2217 Ultraphor
Electophoresing apparatus (Pharmacia Biotech) according to the manufacturer's
instructions, and run at temperature of4°C overnight. Strips of filter paper are coated
with 1M of H3PO4 and 1M of NaOH. These strips are then placed on the anode and
cathode respectively. The running conditions and staining methods are described in
the analytical isoelectric focusing section.
2.12 Restriction fragment length polymorphism (RFLP)
PCR-restriction fragment length polymerase (PCR-RFLP) is known as a fast and
easy genetic approach used to distinguish between the sensitive and resistant gyrA
and parC by the loss of single nucleotide.
2.12.1 Restriction of products from blasnv PCR
SHV- specific PCR products were used directly in an NheI restriction endonuclease
assay (Promega, Ltd). The full-length PCR product which was refractory to
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restriction by Nhel doesn't represent SHV-1, while, the cleavage product would
represent SHV-2 and/or SHV-5. The IEF values and the sequence of the cleavage
SHV could confirm its type. SHV PCR product was restricted with Nhel (lOu/pl),
5pl of restriction buffer (10 mM Tris-HCl, pH7.5, 60 mM NaCl, 7mM MgCk), 1 pi
of bovine serum albumin (BSA) (O.lmg/L), 4pl of sterile MilliQ water and 40 pi of
amplified PCR product. Digestion was carried out for a maximum four hours at
37°C. Fragments were resolved by agarose gel electrophoresis using 2% agarose in
lxTAE buffer, then stained with ethidium bromide, and visualized with a UV light.
2.12.2 Restriction of products from A/«tem PCR
The endonuclease digestion of TEM-specific PCR product was performed directly
using lOpl of PCR products without purification, according to the recommendation
of the restriction endonuclease suppliers Msel (New England, Biolabs, England) and
Sau3 AI (promega, Ltd). Using the following amounts 5pl of restriction buffer (10
mM Tris-HCl, pH7.5, 60 mM NaCl, 7mM MgCh), 1 pi of BSA (O.lmg/L), 4pl of
sterile MilliQ water. Restriction patterns of PCR products were analysed by agarose
gel electrophoresis using 2% agarose in lxTAE buffer, then stained with ethidium
bromide, and visualized with a UV light.
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Table 2.11.3
Composition of analytical IEF gels
Ingredient Stock Solution Volume (ml) Final concentration
Sterile distilled water 25 -
40% (w/v) ampholines 2.0 2% (w/v)
100 g acrylamide pluse 2.7 g methylene




5% (v/v) TEMED* 0.2 0.005% (v/v)
Riboflavin (20 mg/L) 4.0 2 mg/L
* Tetramethyl-ethylenediamine
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2.12.3 Restriction of products from topoisomcrasc PCR
RFLP was used to screen for the gyrA specific PCR product as used directly in an
Hinfl restriction endonuclease (Promega, Ltd). Conferring quinolone resistance, for
example resulting in the substitution of amino-acid 83 threonine in the quinolone
resistant determining region (QRDR) of gyrA region results in the loss of the Hinfl
G/ANTC restriction site. Hinfl was therefore used to screen for the presence of this
mutation in the clinical samples. QRDR were restricted with (lOu/pl), 5pi of
restriction buffer (10 mM Tris-HCl, pH7.5, 60 mM NaCl, 7mM MgCk), 1 pi ofBSA
(O.lmg/L), 4pl of sterile MilliQ water and 40 pi of amplified PCR product. Digestion
was carried out for a maximum three hours at 37°C. Fragments were resolved by
agarose gel electrophoresis using 2% agarose (MAST Gel™ BB mast diagnostic
Mast group Ltd. Merseyside, UK) in lxTAE buffer, then stained with ethidium
bromide, and visualized with a UV light.
2.13 Pulse field gel electrophoresis (PFGE)
Restricted genomic DNA fragments were separated on a Contour-clamped
Homogenous Electric Field (CHEF) electrophoresis system (CHEF-II, Bio Rad)
according to the manufacturer's instructions
2.13.1 Preparation of genomic DNA in plugs
Strains were inoculated into 10 ml of nutrient broth (Oxoid) and incubated at 37°C
overnight. The cells were harvested by centrifugation at 3000 rpm for 30 minutes (
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SORVALL R77 pulse) at 4°C. The supernatant was discarded, and the cells were
washed 2X in 10 ml of cell suspension buffer CSB (Tris-HCl, EDTA, NaCl, pH 8.0).
After the final wash, the cells were re-suspended in 5ml of CSB and kept at room
temperature.
Low melting point agarose (2%) (Bio-Rad) was dissolved in TE buffer (10 mM Tris-
HCl, 10 mM Na2 EDTA, pH 7.5) using a microwave oven and placed at 56°C until
required. Equal volumes of CSB and 2% low melting point agarose (500 pi from
each) were pipetted into sterile eppendorf tubes. The tubes were mixed well by
inverting several times and kept molten at 56°C. Plug moulds (Bio-Rad) were wiped
with ethanol and sealed with tape at the bottom. Ninety pi from each culture/agarose
mixture was carefully pipetted into each area of the mould to give a total of 5 plugs
per strain. The moulds were then allowed to set at room temperature for
approximately 20 minutes, after which time the tap was removed from the bottom
and plugs were carefully transferred into sterile bijou bottles by pushing them
through from the moulds with a sterile pipette tip.
2.13.2 Lysis of DNA in agarose plugs
A 3 ml volume of lysis buffer (1% N- lauroylsarcosine, 50 mM Na2 EDTA, pH 9.5)
containing 0.5 mg/ml proteinase K ( Sigma) was added to each bijou bottle and plugs
were incubated at 56°C for 3 days in a waterbath (GallenKamp). After incubation,
the lysis buffer was removed and then, the plugs were washed in 2 ml of TE buffer
for 30 minutes at room temperature. The wash stage was repeated a further 2 times
with fresh TE buffer used each time. The plugs were subsequently stored in TE
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buffer at 4°C until ready for use ( Plugs were stored under these condition for several
months with no DNA degradation if the TE buffer was replaced approximately every
4 weeks).
2.13.3 Digestion of DNA in agarose plugs
DNA plugs were transferred into a sterile petri dish where an appropriate portion
(equivalent to the size of the well formed) was cut using a sterile scalpel blade. Each
plug piece was washed with sterile distilled water for 10 minutes, and then allowed
to equilibrate in IX restriction buffer at 37°C for 30 minutes before the digestion.
The DNA plugs were transferred to a new sterile eppendorf to which the following
components were added in this order: (I) 87pL of MilliQ water, (ii) 9 pi of 10X
enzyme buffer (Promega, Ltd.), (iii) 2 pi of 1 pg/pl BSA (Promega, Ltd.), (iv) 4 pi
of lOu/pl Xbal restriction endonuclease (Promega, Ltd.) and (v) 87 pi of sterile
MilliQ water.
The contents were mixed well by gently tapping the side of the eppendorf several
times. The DNA was subsequently digested overnight at 37°C, after which the
restriction mixture was removed and the plug piece carefully transferred to sterile 20
ml universal containers. A 10 ml volume of sterile MilliQ water was added to each
universal to wash the DNA plugs. The universals were kept for 30 minutes at room
temperature. Plugs were stored at 4°C until the gel was ready to be loaded.
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2.13.4 Preparation of agarose gel
The gel casting tray was wiped with absolute alcohol and assembled according to the
manufacturer's instructions (Bio-Rad). Tris-Borate-EDTA (TBE) buffer was diluted
1:10 to give a final concentration of X 0.5 in a 2 litre volume. A 100 ml volume of
this dilution was aliquoted into a sterile 250 ml Duran bottle (Schott), into which
PFGE-grade agarose (Bio-Rad) was added. The agarose in the TBE buffer was
melted in a microwave oven and then kept at 55°C to cool. The cooled agarose was
carefully poured into the assembled casting tray (leaving approximately 3 ml in the
bottle at 55°C) and allowed to set for at least 45 minutes. The rest of the diluted
buffer was added to the electrophoresis cell (Bio-Rad), and allowed to circulate with
cooling until it reached the required temperature.
2.13.5 Loading of PFGE gel
Once the comb had been carefully removed from the gel, the plugs containing
restricted DNA were inserted into the appropriate wells using a sterile spatula,
ensuring that no air bubbles were introduced. DNA size standards (A ladder range
from 48.5 to 970 Kbp, Bio-Rad) were also loaded into a well approximately halfway
along the gel. The wells were filled with the rest of the molten agarose and the gel
was kept at 4°C until the agarose had set.
2.13.6 Running conditions
The gel was removed from the casting tray and placed in the electrophoresis cell
(CHEF-II, Bio Rad) Contour-clamped Homogenous Electric Field. Gel running
condition were as follows:
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Initial pulse time 5 seconds Voltage 200 volts (6v/cm)
Final pulse time 45 seconds Run temperature 14°C
Run time 22 hours Gel concentration 1%
2.13.7 Gel staining and visualization of PFGE patterns
The gel was carefully removed from the electrophoresis cell and transferred to a
container to which 200 ml of ethidium bromide solution (0.5 mg/L) had been added.
Staining was carried out for 45 minutes, followed by 2x15 minute washes in distilled
water.
PFGE patterns were visualised on a UV transilluminator and photographs were taken
by a diversity database camera.
2.13.8 Analysis of PFGE patterns
The data obtained for PFGE patterns on the gels were analysed by Diversity database
finger printing software (Bio-Rad). In which, the presence/ absence of shared
fragments used to estimate the relatedness of the PFGE patterns was presented in a
binary data matrix. The relatedness were compared by RAPdistance package version
1.04, (http//:www.life.anu.edu.au.molecular/software/rapid.html). The RAPdistance
program calculates the genetic distance by the Nei distance method (Nei, 1972).
Patterns were also analysed manually using the criteria of Tenover (Tenover et al.,
1995).
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2.14 Outer membrane protein (OMPs) preparation
Bacterial strains were inoculated into 100 ml ofBHIB (Oxoid) and incubated at 37°C
overnight with gentle agitation (200 osc/min). The cells were harvested by
centrifugation at 6000 g (Sorvall® RC-5B Refrigerated Super-speed centrifuge) at
4°C. After the supernatant had been discarded, the pellet was washed in 10 ml of 50
mM sodium phosphate, pH 7.0, the cells were centrifuged again at 3000 g , and the
pellet was re-suspended in 3 ml of 50 mM sodium phosphate, pH 7.0.
Cells were subjected to ultrasonication (MSE Soniprep 150, MSE instrument,
Crawley) for 3 x 30 seconds at an amplitude of 8 microns with constant cooling and
with a 1 minute cooling period between each sonication. The cell lysate was cleared
(unbroken cells removed) by centrifugation (MSE Microcentaur centrifuge) at high
speed 13000g for 10 minutes at 4°C. The supernatant containing OMP's was
transferred to a centrifuge tube. Cell membrane was sedimented from the supernatant
fluid by centrifugation at 15600 g for 30 minutes at 4°C. The pellet was re-
suspended in 3 ml of 2% (w/v) N-laurylsarcosine and incubated for 30 minutes at
room temperature. Then sarcosyl-insoluble OMP's were sedimented by
ultracentrifugation (40000 g for 60 minutes at 4°C). The clear OMP's pellet was re-
suspended in 1 ml of sterile MilliQ water and stored at -20°C until required.
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2.14.1 Dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) of OMPs
OMPs for each isolate were mixed with an equal volume of protein sample buffer
(stock= 4 ml distilled water, 1 ml 0.5 M Tris-HCl, pH 6.8, 800 pi glycerol, 1.6 ml
10% (w/v) SDS, 400 pi 2-mercaptoethanol, 200 pi 1% bromophenol blue), heated at
100°C for 5 minutes in a waterbath, and kept on ice until required for gel loading. A
30 pi volume of each sample was loaded into the wells of a ready-made gel (Bio
Rad). Low range molecular weight marker (Bio Rad) was added to a well on one side
of the gel. The gel was inserted into a mini-gel electrophoresis apparatus
(Miniprotean® II, Bio Rad) then electrode buffer (0.025M Tris, 0.19M glycine and
0.1% SDS, pH 8.3) was added and electrophoresis was carried out at 200 V for 45
minutes or until the dye in the sample buffer had reached the end of the gel.
2.14.2 Staining (SDS-PAGE) of OMPs
SDS- PAGE gels were stained in Coomassie Blue (40% v/v methanol, 10%v/v acetic
acid, 0.25% w/v Coomassie blue R-250) with gentle shaking for a minimum of one
hour. The gel was transferred to a destaining solution (40% v/v methanol, 10% v/v
acetic acid in distilled water) and destained with gentle shaking for approximately 4-
5 hours, or until the background became clear. Destaining solution was replaced with
fresh solution several time during this period. As this procedure results in shrinking,




Characterisation of Extended Spectrum (3-
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3.1 Introduction
Since the introduction of third-generation cephalosporins into clinical practice there
has been excessive use of extended-spectrum cephalosporins in hospitals (Du Bois et
al., 1995; Heritage et al., 1999). The effectiveness of these P-lactam antibiotics has
been diminished by Klebsiella spp. that are resistant to their mode of action. This
resistance has spread to strains of E.coli and to other Gram-negative bacteria
(Sanders et al., 1996). Investigations into the mechanism responsible for this
resistance have revealed the presence of extended spectrum P-lactamase (ESBL)
enzymes derived from the ubiquitous TEM-1/2 and SHV-1 family. To date, there are
over 100 derivatives of TEM P-lactamases and more than 35 derivatives of SHV P-
lactamases (Bush et al., 1995; Bradford et al., 1995; Bradford et al., 1996; Bradford,
2001; Jacoby and Medeiros, 1991; Philippon et al., 1989b; Sanders et al., 1996).
These enzymes are usually less efficient at hydrolysis of penicillins than their parent
enzymes, but show hydrolytic activity against cephalosporins. Their detection is
difficult to demonstrate in currently used routine susceptibility tests. Therefore,
ESBL-producing Klebsiella spp. and E.coli may appear falsely susceptible to newer
cephalosporins (Katsanis et al., 1994; Philippon et al., 1989b; Sanders et al., 1993).
There is clearly a requirement to detect the resistance mechanism itself rather than to
rely on in vitro susceptibility testing. The Vitek system (bioMerieux, Ltd.,
Basingstoke, England) has an ESBL detection test as an integral part of the routine
susceptibility test card. There have been several positive studies on the efficacy on the
Vitek system with known ESBL producing strains (Gibb and Crichton, 2000; Sanders
et al., 1996).
Chapter 3 Results
This study was performed to assess the behaviour of ESBLs in clinical strains
detected by this system in comparison with two other commercial ESBL detection
methods.
3.2 Materials and Methods
3.2.1 Bacterial isolates
One hundred and one clinical isolates of Klebsiella pneumoniae (69) and E.coli (32)
were obtained from various clinical samples sent to the clinical bacteriology
laboratories of the Royal Infirmary of Edinburgh (RIE). The 101 isolates had
previously been identified and reported as ESBL-positive by the Vitek system.
Working isolates were stored on nutrient agar slopes at room temperature until
required.
3.3 Results
Presence of ESBL activity was initially detected by the Vitek system. The test is
based on the inhibitory effect of clavulanic acid on the ESBL in the presence of either
cefotaxime or ceftazidime and in the presence of the antibiotic on its own. The test is
interpreted by measuring the difference in bacterial growth with or without inhibitor.
Based on the automated version of the synergy test in the Vitek system, 87 isolates
were ESBL positive. ESBL activity in all those isolates was re-confirmed by the E-
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test ESBLs strips (see 3.3.1). Of the 101 strains originally tested, 15 were negative
for ESBL production when tested with both cefotaxime and ceftazidime E-test strips.
These 15 E-test negative strains, (all E. coli) were re-tested with Vitek (GNS-532
card) and 14 of these strains were subsequently found to be ESBL negative. One
strain still was identified as ESBL positive by Vitek. The re-tested 14 ESBL negative
strains were not subjected to any further studies.
3.3.1 E-test ESBL Strips
3.3.1.1 Cefotaxime
The cefotaxime ESBL strip detected the presence of ESBL activity in 83 (95.4%) of
the tested isolates (16 E.coli and 67 K pneumoniae) (see table 3.1). Of these strains,
19 (22%) demonstrated "phantom phenomena" as described in the manufacturer's
interpretation guide*. Four strains were negative for ESBL activity with the
cefotaxime ESBL strip, 2 strains of E.coli (A332, A336) and 2 strains of K.
pneumoniae (A359, A338).





With ceftazidime E-test strips, ESBL activity was detected in 47 (54%) of the study
isolates, (11 E. coli and 36 K. pneumoniae) (see table 3.1). Of these, 1 E.coli and 2
K. pneumoniae were positive by the demonstration of "phantom phenomena".
Only 40 of ESBL-positive strains gave a positive ESBL reaction with both strips, the
other 47 were only positive with one or other of the strips used. The strains that were
deemed ESBL-positive by the production of phantom phenomena with the cefotaxime
strip were all positive with ceftazidime with the exception of one strain. All ESBL E-
test results are presented in appendix I.
The use of the combination of both cefotaxime and ceftazidime E-test ESBL strips
detected ESBLs in 86 of the 87 test isolates (98.8%) see figure (3.1). This data
illustrates the use of both strips is essential for optimal detection of ESBL activity.
Only one strain of K. pneumoniae that demonstrated positive ESBL activity with the
Vitek system was not detected by E-test ESBL strips despite repeat testing. This




Results of ESBL E-test strips with the 87 test isolates
E-test ESBL positive E. coli K. pneumoniae Total
Cefotaxime 16 67 83






















Figures 3.2 and 3.3 show representative plates with E-test strips indicating ESBL




Plate showing positive ESBL reaction with E-test strips containing
cefotaxime + cefotaxime/clavulanic acid (CT/CTL) and ceftazidime +
ceftazidime/clavulanic acid (TZ/TZL). The zone of inhibition is read on













Plate showing negative ESBL reaction with E-test strips
containing cefotaxime + cefotaxime/clavulanic acid (CT/CTL) and
ceftazidime + ceftazidime/clavulanic acid (TZ/TZL).
Ratio value <8 for both strips.
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3.3.2 Double disc diffusion (DDD)
Testing was performed according to NCCLS guidelines (NCCLS, 1999). A positive
result was indicated by a zone size difference of > 5mm diameter between the
combination disc and the corresponding standard antibiotic disc (see figures 3.4 and
3.5). Results of the DDD method are summarized in table 3.2. The results of the
DDD for individual isolates are presented in appendix II.
Using the DDD method, the combination disc containing cefotaxime detected the
presence of ESBL activity in 74 (85%) (64 K. pneumoniae and 10 E.coli) strains
whilst the cefpodoxime combination disc detected ESBL activity in 64 (73.5%) strains
(54 K. pneumoniae and 10 E.coli). The ceftazidime combination disc had the poorest
sensitivity, detecting the presence of ESBL activity in only 40 (46%) strains (31 K.
pneumoniae and 9 E.coli). The strain of K. pneumoniae that demonstrated no ESBL
activity by E-test was ESBL positive with the DDD method. When the results of all
three cephalosporin combination discs were taken into consideration, 80 (92%) of the
87 ESBL-positive strains were detected (table 3.2).
A comparison of results of the DDD test and those obtained with the E-test ESBL
strips (table 3.3) showed that E-test strips were more sensitive at detecting ESBL
production than the DDD test. The DDD test demonstrated ESBL activity in 80





Figure showing a negative ESBL reaction with the DDD test indicated by a zone
difference of< 5mm diameter between the 3 combination discs and the corresponding
standard
1- Cefotaxime disc.
2- Combination disc of cefotaxime + clavulanic acid.
3- Cefpodoxime disc.
4- Combination disc of cefpodoxime + clavulanic acid.
5- Ceftazidime disc.




Figure showing a positive reaction with the DDD test indicated by a zone difference
of > 5mm diameter between the 3 combination discs and the corresponding standard
antibiotic discs.
1- Combination disc of cefotaxime + clavulanic acid.
2- Cefotaxime disc.
3- Combination disc of ceftazidime + clavulanic acid.
4- Ceftazidime disc.




ESBL reactions with the DDD method for the 87 test isolates








Cefotaxime 10(55) 64 (92.7) 74 (85)
1 Ceftazidime 7(39) 39 (56) 46 (53)
Cefpodoxime 10(55) 54 (78) | 64 (73.5)
All three antibiotics 13 (72) 67 (97) 80(92)
Table 3.3
Comparison of the DDD test and E-test ESBL strips in detecting ESBL
production in the 87 test strains
Combination
disc/strip
Double Disc Diffusion Method.
No. ESBL positive (%)
E-test ESBL strip
No. ESBL positive (%)
Cefotaxime 74 (85) 84 (96.5)
Ceftazidime 40 (46) 47 (54)
Cefpodoxime 64 (73.5) "
| Total (%) ESBL +ve 80 (92) 86 (98.8)
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Antimicrobial Resistance Amongst ESBL-
Producing Klebsiella pneumoniae and E.coli
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4.1 Introduction
Since penicillin was introduced into clinical practice in the 1940s, the evolution of
bacteria clearly indicates that antimicrobial resistance will develop given sufficient
time and use of a particular agent or class of agents. fS-lactam resistance in clinically
important pathogens has increasingly limited their usefulness. To treat infections due
to P-lactamase-producing bacteria that were resistant to penicillin and early
cephalosporin derivatives, new generations of relatively enzyme-stable and broad-
spectrum cephalosporin derivatives were introduced in the late 1970s and early
1980s. However, over the past decade, antibiotic-resistant mutants producing ESBLs
have emerged among Gram-negative bacteria, predominantly E.coli and K.
pneumoniae (Livermore, 1995).
The emergence of ESBL-producing isolates has important clinical and therapeutic
implications. Firstly, in most bacterial isolates, resistance determinants for ESBL
production are carried on plasmids that can be easily spread from organism to
organism (Bush, 1996). Secondly, the spread of resistance toward extended-spectrum
cephalosporins further limits the use of the P-lactam class and may lead to increased
prescribing of more broad-spectrum and expensive drugs such as imipenem. In
addition, these resistant isolates may escape detection with routine susceptibility
testing performed by a clinical microbiology laboratory, which can result in adverse
therapeutic outcomes (Tenover et al., 1999).
More importantly, antibiotic selection for treatment of serious infections due to
ESBL-producing E.coli and K. pneumoniae is a clinical challenge because of the
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complex nature of in vitro susceptibility testing and in vivo correlation (Wong-
Beringer, 2001). The biggest challenge lies in overcoming widespread unawareness
among clinicians regarding these resistant organisms which results from under¬
reporting by microbiology laboratories and lack of an obvious marker to indicate
production of an ESBL (Paterson and Yu, 1999).
Some ESBLs confer high-level of resistance to all oxyimino-P-lactams, but some are
selective for particular p-lactams. This creates a problem for clinical laboratories,
since organisms producing less active ESBLs can fail to reach current NCCLS
break point values for resistance yet can cause significant disease (Katasanis et al.,
1994).
4.2 Results of the antimicrobial susceptibility tests
4.2.1 Disc diffusion (NCCLS)
All 87 isolates were tested for susceptibility to 15 different antibiotics by disc
diffusion following the NCCLS method (NCCLS, 1999). Results of the susceptibility
patterns are summarized in table 4.1. Results for each isolate are presented in
appendix III.
All strains were susceptible to meropenem and resistant to ampicillin. In addition,
98.8% (86) and 97.7% (85) of them were resistant to amoxicillin and cephalothin
respectively. Similarly 95% (83) were resistant to cefuroxime, 86% (75) to
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trimethoprim, 78% (68) to ciprofloxacin, 72% (63) to tazobactam, 71% (62) to
chloramphenicol, 62% (54) to amikacin, 51.7% (45) to nitrofurantoin and





Results in No. of antimicrobial susceptibility testing by the NCCLS disc
diffusion method to various antimicrobials for the 87 ESBL positive strains
Antibiotic Disc
Resistant Intermediate Sensitive
Ampicillin 87 - -
Amoxicillin
86 - 1
Trimethoprim 75 - 12









Ciprofloxacin 68 1 18













All 87 isolates were tested for susceptibility to the same antimicrobial agents as those
used for the NCCLS disc diffusion test. The results are summarized in table 4.2 and
antibiograms for each isolate detailed in appendix IV.
All isolates were susceptible to meropenem and amikacin. 98.8% (86) were resistant
to ampicillin and cephalothin. 93% (81) were resistant to cefuroxime, 89.6% (78) to
ceftazidime, 86.2% (75) to cefotaxime, 82.7% (72) to amoxicillin, 74.7% (65) to
trimethoprim, 65.5% (57) to chloramphenicol, 49.5% (43) to ciprofloxacin, 41.4%
(36) to tobramycin and finally, 40% (35) to both nitrofurantoin and gentamicin. A
few 14.9% (13), of the isolates showed intermediate resistance to amoxicillin
following NCCLS guidelines.
4.2.3 Comparison of susceptibility determined by disc diffusion
(NCCLS) and the Vitek system.
Results of both methods were in complete agreement for meropenem. Amoxicillin,
ampicillin, cephalothin and gentamicin all had one discrepancy, while two
differences were found with the cefuroxime results. There was more variation and
disagreement for the results for amikacin. All strains were reported sensitive by the
Vitek system while the disc diffusion method indicated that 62% were resistant and
27.5% were intermediate. Results for ceftazidime were even more discrepant in
which 39% of the isolates were resistant by the disc diffusion method while the Vitek




Results of susceptibility tests in No. by the Vitek system to various antimicrobial
of the 87 ESBL positive strains.
Antibiotic Disc
Resistant Intermediate Sensitive
Ampicillin 86 - 1
Amoxicillin 85 - 2
Trimethoprim 65 - 22
Cephalothin 86 - 1
Cefuroxime 81 - 6
Cefotaxime 75 - 12
Ceftazidime 78 - 9
Gentamicin 35 - 52
Ciprofloxacin 43 - 44
Tobramycin 36 - 51
Tazobactam 85 - 2
Meropenem - - 87
Chloramphenicol 57 - 20
Nitrofurantoin 35 - 52
Amikacin - - 87
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Forty percent of strains were resistant to nitrofurantoin by the Vitek system, while
57% were reported resistant by disc diffusion. Sixty-five percent of isolates were
reported to be resistant to chloramphenicol with Vitek compared to 71% by the disc
diffusion method. For tazobactam, 79% of the isolates were resistant by Vitek, and
72% by the disc diffusion method. For trimethoprim, 74% were resistant by the Vitek
system, and 86.2% by the disc diffusion method, while for ciprofloxacin, 72%, were
resistance by disc diffusion and 49% by Vitek. For cefotaxime, there was only one
discrepancy between the results obtained by the Vitek system and the disc diffusion
method.
4.2.4 Determination of minimum inhibitory concentration (MIC) by
E-test
MfCs were determined for both third generation cephalosporins; cefotaxime and
ceftazidime by the use of E-test strips. Results of the E-tests are summarized in table
4.3, and results for each isolate detailed in appendix V.
The MIC for ceftazidime to the test strains as determined by E-test strips ranged
from a low of 0.5 mg/1 to a high of >32mg/l. The MIC results were using NCCLS
breakpoint values for cefotaxime and ceftazidime, and the results interpreted as
either sensitive, intermediate or resistant. Forty-seven percent (No.=41) of the test
strains were resistant to ceftazidime with MIC values of 32.0 mg/1 or higher. The




Determination of the MIC of the 87 test isolates by Etest strips
Antibiotic MIC E.coli K. pneumoniae Total
Cefotaxime
> 16 mg/1 1 19 20
16 mg/1 9 38 47
Total resistant to cefotaxime 67
Antibiotic MIC E.coli K. pneumoniae Total
Ceftazidime
> 32 mg/1 1 2 3
32 mg/1 7 31 38
Total resistant to ceftazidime 41
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resistance. With cefotaxime, MICs ranged from 0.25 mg/1 to 16.0 mg/1. Twenty-three
percent (No.=20) of strains were resistant to cefotaxime with MIC values >16.0 mg/1.
Fifty-four percent (47) were of intermediate resistance. Twenty-three percent (No.
=20) were sensitive.
For the majority of strains, E-test results were easy to interpret. However, in a few
isolates, results were not clear-cut and there was a double zone of inhibition.
Furthermore, For some strains, there was a growth of single colonies within the zone
of inhibition, these resistant colonies were subbed for purity and repeated. The same
results were obtained indicating that they were not true mutants.
4.2.5 MICs of the 87 test strains to gentamicin, tobramycin and
ciprofloxacin by serial agar dilution
The MICs for gentamicin, tobramycin and ciprofloxacin were determined by the agar
dilution method. The results are presented in table 4.4.
MICs for gentamicin ranged from 0.25-> 32.0 mg/1. Thirty five (40%) of the isolates
were resistant to gentamicin, 32 (6 E.coli and 26 K. pneumoniae) had MIC values of
> 32 mg/1., and 3 K. pneumoniae isolates had MIC values of 16 mg/1. One K
pneumoniae isolate demonstrated intermediate resistance to gentamicin with an MIC
value of 8 mg/1.
MICs of tobramycin ranged from 0.25-> 32.0 mg/1. Forty (46%) of the isolates were
resistance to tobramycin. Twenty strains (1 E.coli and 19 K. pneumoniae) had MICs
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values of > 32 mg/1., whereas 20 (5 E.coli and 15 K. pneumoniae) had MIC values
of 16 mg/1. Only 4 isolates (1 E.coli and 3 K. pneumoniae) demonstrated an MIC
value of 8mg/l, indicating intermediate resistance.
MICs of ciprofloxacin ranged from 0.25- >32 mg/1. Forty (46%) of the isolates were
resistant to ciprofloxacin. Thirty-eight of these strains (6 E.coli and 32 K.
pneumoniae) had MIC values > 32 mg/1. Two K. pneumoniae had MIC values of
32.0 mg/1. Eleven (12.6%) of K. pneumoniae demonstrated intermediate resistance
with MIC values of>2 mg/1. but <32mg/l.
4.2.6 Comparison of MICs obtained by the agar dilution method and
the Vitek system
For gentamicin, both methods gave similar results, for which 40% of the isolates
were resistant to gentamicin. The tobramycin results were similar, with the exception
of four isolates that were resistant by the agar dilution method but considered as
sensitive by the Vitek system. A similar observation was found in the case of
ciprofloxacin, in which only 3 isolates showing resistance by the Vitek system were
reported as intermediate by the agar dilution method.
4.2.7 Comparison of MIC values for cefotaxime and ceftazidime
obtained by the Vitek system and E-test strips
E-test indicated that 23% of the isolates were resistant to cefotaxime and 54%




MICs of the 87 test strains to gentamicin, tobramycin and ciprofloxacin by
serial agar dilution
Antibiotic MIC E.coli K. pneumoniae Total
Gentamicin
> 32 mg/1 6 26 32
16 mg/1 - 3 3
Total resistant to gentamicin 35
Antibiotic MIC E.coli K. pneumoniae Total
Tobramycin
> 32 mg/1 1 19 20
16 mg/1 5 15 20
Total resistant to tobramycin 40
Antibiotic MIC E.coli K. pneumoniae Total
Ciprofloxacin
> 32 mg/1 6 32 38
32 - 2 2
Total resistant to ciprofloxacin 40
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the 87 isolates were resistant to cefotaxime, eight of these isolates were reported as
intermediate by E-test strips.
There was less agreement with MICs for ceftazidime. Forty eight percent of the test
strains were resistant to ceftazidime by E-test strips, whereas by Vitek 89.6% of the
isolates were reported resistant.
4.2.8 Comparison of susceptibility results as determined by disc¬
diffusion (DD), Vitek system and E-test to both cefotaxime and
ceftazidime for the 87 ESBL positive strains
The results are summarized in table 4.5. With cefotaxime, 20 (23%) of the isolates
were resistant by E-test, 40 (46%) by disc diffusion and 75 (86.2%) by the Vitek
system. With ceftazidime, 41 (47%) of the isolates were resistant by E-test, 34 (39%)
by disc diffusion and 78 (89.6%) by the Vitek system. The numbers of strains
classified as intermediate resistance for cefotaxime were 47 (54%) by E-test, 34
(39%) by disc diffusion. None of the isolates were classified as intermediate by the
Vitek system. This is because we opted not to have an intermediate category for
cefotaxime and ceftazidime (i.e. we used, user defined breakpoints*) and any isolate
which would have been classified as intermediate resistance was termed as resistant.
For ceftazidime, one (1.15%) strain was intermediate by E-test, seven (8%) by disc




Comparison of susceptibility results as determined by Disc-Diffusion (DD),
Vitek system and E-test to both cefotaxime and ceftazidime for the 87 ESBL
positive strains
E-Test
Cefotaxime (87 strains) Ceftazidime (87 strains)
Sensitive Intermediate Resistant Sensitive Intermediate Resistant
20 47 19 45 1 41
Disc-Diffusion
Cefotaxime (87 strains) Ceftazidime (87 strains)
Sensitive Intermediate Resistant Sensitive Intermediate Resistant
13 34 40 46 7 34
Vitek System *
Cefotaxime (87 strains) Ceftazidime (87 strains)
Sensitive Intermediate Resistant Sensitive Intermediate Resistant
12 - 75 9 - 78
* Break point for ceftazidime (8 sensitive and 16-32 mg/1 resistant), and for
cefotaxime (4 sensitive and 8-64 mg/1 resistant).
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ESBL enzymes, derived from blarem-i, bla-xem-2 and blaSHv-i genes, confer resistance
to the (3-lactams and monobactams (DAgata et al., 1998). ESBL production has been
found mainly in K. pneumoniae but has also been described in other
Enterobacteriaceae, including E.coli, Proteus mirabilis, Salmonella spp.,
Enterobacter spp., Citrobacter spp. and Serratia spp. (De Champs et al., 1991; Sirot
et al., 1992; Elammami et al., 1991; Mariotte et al., 1994; Pitit et al., 1990).
Outbreaks of nosocomial infections due to ESBL-producing strains are being
increasingly reported in intensive care units (ICUs) and chronic care facilities (Bingen
et al., 1993; Bauernfeind et al., 1993; Naumovski et al., 1992; Rice et al., 1990). The
reservoir for these strains appear to be the gastrointestinal tract of patients (De
Champs et al., 1989), with patient-to-patient contamination occurring via the hands of
health care providers (Casewell and Philip, 1977).
Hospital colonisation by these ESBL-producing strains usually is a complex
phenomenon involving different mechanisms of dissemination of several epidemic
strains (Gouby et al., 1994; Johnson et al., 1992; Weller et al., 1997), dissemination
of plasmids and resistance genes (Bingen et al., 1993; Kitzis et al., 1988; Naumovski
et al., 1992), or concurrent dissemination of plasmids, genes and strains (De Champs
et al., 1991). Moreover, identical ESBLs have evolved independently in different
places at different times (Hibbert et ah, 1994) and, occasionally, single isolates have




5.2.1 Results of isoelectric focusing (IEF)
Assessment of P-lactamase activity was performed using the nitrocephin spot test.
The time in seconds for nitrocephin to change from yellow to red is proportional to
the volume in pi of P-lactamase preparation added to the isoelectric focusing gel
(Paton, 1994). Most strains demonstrated positive activity within 10 seconds. Three
isolates took up to 30 minutes. Four strains failed to show any P-lactamase activity by
the spot test.
5.2.1.1 Analytical isoelectric focusing
Sonicated extracts of the 87 ESBL producing isolates were examined by analytical
IEF. Crude P-lactamase extracts of the 87 clinical isolates were applied to
polyacrylamide gel containing broad - range ampholines (pH 3.5 - 10.0).
Control P-lactamases of known pi were added to analytical IEF gels in order to
establish the isoelectric point of the unknown enzymes. Six isolates exhibited P-
lactamases bands characteristic of TEM derived enzymes with pi values of 5.4.
Thirty-two isolates exhibited P-lactamase bands at pi 7.6, which is identical to the pi
of SHV2/SHV-1. Eight isolates exhibited P-lactamase bands at pi 7.0, which is
identical to that of SHV-3. Some isolates exhibited more than one enzyme, with
differing pi values. Thirty-five isolates exhibited two enzymes with pi values of 5.2
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and 7.6 identical to that of TEM-1 and SHV1. Two isolates had pis of 8.2 indicating
that they were probably derived from SHV. Four other isolates (AD338, AD346,
AD382 and AD389) exhibited p-lactamase bands with pi values of 5.2 (TEM
derived), 7.6 and 8.2. These are identical to pis of the SHV1 and SHV-5. |3-
lactamases. (See figure 5.1, tables 5.1. and 5.2).
5.2.2 Results of PCR using SHV and TEM primers on the 87 ESBL
positive clinical isolates of E. coli and K. pneumoniae
Plasmid DNA from all the 87 studied isolates was extracted and analysed for the
presence of the two most common ESBL genes blajtu, bla$nv derivatives by PCR.
Primers specific for each of the ESBL (bla-xEm and bla^m) were used. The results are
summarised in table 5.3.
The amplified products obtained with primers specific for the bla-xem were 858 bp (see
figure 5.2), which is the expected product size of the amplified gene with the set of
primers used. The bla-xem ESBL was detected in 42 isolates consisting of 33 K.
pneumoniae and 9 E.coli strains. The 6/<2shv ESBL was detected in 81 out of the 87
tested isolates (see figure 5.3), consisting of 66 K. pneumoniae and 15 E.coli. The
size of the amplified product was 383 bp which is the expected size of amplified
product with the primers used. From the 87 tested isolates, 36 of them were positive
for both ESBL genes (bla-xem and blashv), consisting of 30 K. pneumoniae and 6
E.coli. In total, PCR was successful in detecting either bla-xEM and/or blasm genes in




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
■I ■■
7.6 7.0 5.4 8.2
Analytical IEF of P-lactamases produced by K. pneumoniae and E.coli isolates from
clinical specimens.
Lane 1: TEM-1 control strain.
Lane 2: SHV-1 control strain.
Lane 4,8,11,12,13 and 15: strains with pi value 7.0
Lane 3,6,7,9,18 and 20: strains with pi value 7.6
Lane 5 : strain with pi value of 5.4
Lane 13, 14, 16, 17: strains with pi values of 5.2, 7.6 and 8.2




pi values of (3-Iactamase activity of the 69 isolates of Klebsiella pneumoniae
IEF pi Values Strain tested
7.0 AD333 AD374 AD375
7.6
AD313 AD314 AD317 AD319 AD325 AD328
AD329 AD330 AD331 AD334 AD335 AD336
AD337 AD339 AD340 AD342 AD343 AD344
AD350 AD352 AD353 AD354 AD355 AD366
AD370 AD391 AD392 AD401 AD410 AD411
5.4 and 7.6
AD315 AD316 AD318 AD320 AD321 AD322
AD323 AD324 AD326 AD327 AD341 AD345
AD348 AD351 AD356 AD358 AD362 AD363
AD364 AD365 AD367 AD368 AD377 AD378
AD380 AD384 AD395 AD402 AD404 AD407
AD408 AD409
5.4, 7.6 and 8.2 AD338 AD346 AD382 AD389
Table 5.2
pi values of P-lactamase activity of the 18 isolates of E.coli
IEF pi Values Strains tested
5.4 AD332 AD357 AD385 AD399 AD400 AD403
7.0 AD369 AD371 AD386 AD387 AD388 AD393
7.6 AD336 AD349






Detection E. coli K. pneumoniae Total number of isolates
SHV-only 9 36 45
TEM-only 3 3 6
SHV+TEM 6 30 36




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
- 858
250
Ethidium bromide-stained agarose gel showing PCR products with molecular
size of 858 bp of bla-\EM- Lanes 1 and 17 : shows 1Kb molecular size marker,








PCR showing a blasuv product of molecular size 3 83bp,
Lanes 1 and 6: shows 1Kb molecular size marker. Lanes 5
and 4 are negative and positive control strains respectively
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5.2.3 Results of Dot-Blot (DNA-DNA) Hybridisation
The results of Dot-Blot hybridisation are listed in Appendix (VI). A blaSHV DNA
probe of molecular size 1017bp was used for the identification of blasHV gene, and
DNA probe of molecular size 838bp was used for the identification of blaTEM gene.
The labelled SHV probe hybridised with the DNA of 77 isolates, 63 from K.
pneumoniae and 14 from E.coli. The TEM probe hybridised with DNA of 62 isolates,
51 from K. pneumoniae and 11 from E.coli. See figures 5.4 A and 5.4 B.
5.2.3.1 Hybridisation of PCR products against labelled DNA probe
To confirm that the PCR products contained DNA specific for ESBL enzymes, the
PCR products for SHV and TEM were transferred to Hybond-N+ membrane by
southern blot after agarose gel electrophoresis and probed with the labelled DNA
probes used in the Dot-Blot experiment. This was performed with probes for blasm
SHV and blarEM. The probe hybridised with the expected corresponding PCR product.
5.2.3.2 Comparison of Dot-Blot and PCR for the detection of Z>/«shv
and blutem
A comparison of the results obtained by both methods is presented in table 5.4. The









SHV Only 45 25
TEM Only 6 10
SHV and TEM 36 52
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PCR was more effacious at detecting blashv with 81 positive reactions compared to
77 for dot blot. Dot-blot however appeared to be more efficient at detection of blaTEM
with 62 positive reactions compared to 42 for PCR. blasnv was detected in 65 K.
pneumoniae and 16 E.coli by PCR, while it was detected in 63 K. pneumoniae and 14
E.coli by dot-blot.
PCR detected the blaTEM in 42 isolates, 34 K pneumoniae and 8 E.coli, while dot-blot
detected TEM in 62 isolates, 51 K. pneumoniae and 11 E.coli. One isolate (AD392)
was detected by dot blot but not by PCR. However, it was confirmed as ESBL
positive by the DDD, Etest ESBL strips and the Vitek system in addition to dot blot.
5.2.4 Pulsed field Gel-electrophoresis (PFGE) of 69 K. pneumoniae
isolates
The PFGE data obtained for all restriction fragments on the gels was analysed by
diversity database finger printing software (Bio-Rad). Data obtained was transformed
into a binary data matrix in which each fragment was scored as 1 (present) or 0
(absent). Thus, the data from PFGE experiments in which enzyme Xbal was used
yielded a matrix of 68 K. pneumoniae X 29 characters (one isolate failed to type).
Their relatedness was compared by the Rapiddistance package version 1.04 which
also generated a dendogram for the distinct genotypes. PFGE analysis of these K.
pneumoniae isolates with Xbal revealed 13 distinct genotypes. The results are










Representative DNA-DNA hybridisation using a labelled PCR-product
to detect bla^v in the clinical isolates showing positive and negative
reactions:
No. 36: positive control
No. 35: negative control
Nos. 4,10,17 and 27: show a negative reaction.
Nos.l, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23,
24, 25, 26, 28, 29, 30, 31, 32, 33, 34: show a positive reaction.
• ■> • . • •
• ••< • •
• o • • •
• • • • •










Representative DNA-DNA hybridisation using a labelled PCR-
product to detect bla-rEm in the clinical isolates showing
positive and negative reactions:
No. 36: positive control
No. 35: negative control
Nos. 3,17 and 21: show a negative reaction.
Nos.l, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20,
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Distribution ofESBL-producing K. pneumoniae into PFGE groups
PFGE group Isolate Total No,
group A
AD315 AD316 AD320 AD322 AD326 AD327 AD345
AD346 AD351 AD356 AD362 AD364 AD338 AD348
AD363 AD367 AD377 AD378 AD382 AD384 AD389
AD395 AD402 AD404 AD408
25
group B
AD313 AD314 AD325 AD328 AD329 AD330 AD339
AD343 AD344 AD401 AD410 AD411
12
group C AD340 AD342 AD354 AD355 4
group D
AD318 AD319 AD321 AD324 AD331 AD334 AD335
AD337 AD350 AD353
10
group E AD317 AD323 AD358 AD365 AD370 5
group F AD380 AD391 AD409 3
group G AD375 AD366 AD374 3
group H AD407 1
group I AD368 1
group J AD333 1
group K AD359 1
group L AD352 1




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
PFGE profile of Xbal macrorestriction fragments of ESBL producing K.
pneumoniae.
Lanes 1, 8 and 15: Lambda DNA ladder marker.
Lanes 2 and 14: isolates belonging to PFGE group B
Lanes 3, 4, 9, and 11: isolates belonged to PFGE group A.
Lanes 5 and 12: isolates belonged to PFGE group E





1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
PFGE profile of Xbal macrorestriction fragments of ESBL producing K.
pneumoniae.
Lanes 1, 8 and 15: Lambda DNA ladder marker.
Lanes 2, 3, 7 and 14: PFGE group A.
Lane 9: PFGE group I.
Lane 5: PFGE group E.
Lane 10: PFGE group H.
Lanes 6, 12 and 13: PFGE group G.
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Seven clusters each containing isolates with a similar coefficient were identified
among 62 isolates ofK. pneumoniae . A high level of genetic heterogeneity was found
among the remaining 6 isolates and between each cluster. One isolate (AD392) was
not typed by PFGE.
Ofall the restriction endonuclease enzymes tested, only Xba 1 was found to generate a
PFGE profile that could be interpreted clearly. However, in support of these results,
PFGE groups A, B and D had very similar band patterns when the Spe\ restriction
endonuclease was used. (See figure 5.8).
The isolates examined in this study have been shown to belong to several PFGE
groups (A, B, C, D, E, F and G). However, PFGE group A was by far the most
common, having been found mainly within Ward 15 of the RIE but also in other
wards around the hospital and from a single isolate from a GP. Our results mirror that
of previous studies indicating that the dissemination of strains producing SHV-(3-









DNA profile produced by pulsed-field gel electrophoresis of SpeI
macrorestriction fragments ofESBL producing K. pneumoniae.
Lanes 1, 8 and 15: Lambda DNA ladder marker.
Lanes 2-7: isolates from PFGE group A
Lanes 9-1: isolates from PFGE group B.




shows the distribution of ESBL-producing K. pneumoniae in their PFGE groups
including the clinical sources of the isolates.
PFGE group Sex Source of isolate
Group A (25 isolates)
Male Female Urine Swab Sputum
9 16 12 6 7
PFGE group Sex Source of isolate
Group B (12 isolates)
Male Female Urine Swab Sputum
4 8 10 2 -
PFGE group Sex Source of isolate
Group C (4 isolates)
Male Female Urine Swab Sputum
4 - 4 - -
PFGE group Sex Source of isolate
Group D (10 isolates)
Male Female Urine Swab Sputum




PFGE group Sex Source of isolate
Group E (5 isolates)
Male Female Urine Swab Sputum
3 2 3 - 2
PFGE group Sex Source of isolate
Group F (3 isolates)
Male Female Urine Swab Sputum
2 1 2 - 1
PFGE group Sex Source of isolate
Group G (3 isolates)
Male Female Urine Blood Sputum
2 1 2 1 -
The other PFGE groups showed no genetic relationship with any other strain (H, I, J,
K. L and M). These were collected from various GPs and from a variety of differing
clinical specimens (See, table 2.1 Materials and Methods).
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Twenty-six strains were isolated from single patients admitted to Ward 15 (general
intensive care unit). All these isolates belonged to PFGE groups that showed a genetic
relationship to each other manually using the criteria of Tenover (Tenover et al.,
1995). These were termed PFGE A-G. Eighteen of these 26 strains belonged to
PFGE A. All the 26 isolates collected from Ward 15 produced TEM-1 and SHV-2,
while four also produced SE1V-5 P-lactamase.
5.2.4.1 PFGE analysis for the 18 ESBL-producing E.coli isolates
Eight of the ESBL-producing E.coil isolates demonstrated diverse PFGE patterns
indicating no genetic relationship between any other isolate. These were collected
from different GPs in Edinburgh. Five isolates demonstrated identical PFGE patterns
(PFGE X). These were collected from the same GP source. PCR products from
representative isolates ofESBL-producing E. coli were subjected to automated DNA
sequencing, the extracted P-lactamases from these isolates were also subjected to IEF
analysis. The results demonstrated that, two of the five harboured p-lactamases with
pi values 5.4 (TEM-1) and 7.6 (SHV-2), two with pi value of 7.6 (SHV-2), and one
harboured B-lactamases with pi value of 8.2 (SHV-5). Two isolates belonged to
PFGE group Z and harboured a P-lactamase with a pi value of 5.4 (TEM-33).Three





1 2 3 4 5 6 7 8
Representative PFGE profile of Xbal macrorestriction
fragments ofESBL producing E.coli.
Lanes 1 and 8: Lambda DNA ladder marker.
Lanes 2 and 4: isolates from PFGE group X.
Lanes 3, 5 and 6: represent different PFGE patterns that
belonged to different groups.
Lane 7: non-typeable isolate with PFGE.
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5.2.5 Restriction fragment length polymorphism (RFLP)
An Nhel restriction endonuclease was used to cleave the SHV-specific PCR product
for 66 strains harbouring a B-lactamase with a pi value of 7.6 (see table 5.1 and 5.2)
Successful restriction of all 66 strains indicated that this enzyme was SHV-2 derived
(figure 5.10). The PCR product was then sent for automated sequencing and the
presence of the 6/oshv-2 was confirmed. Nhel was also used to cleave the PCR SHV
products for the three isolates with a pi of 7.0 thus suggesting that these isolates
harboured blaSm-3 ■
Msel and Sau3Al restriction endonucleases were used to restrict the TEM PCR
products to differentiate between TEM-1, 19 and 20. All these enzymes have identical
pi values of 5.4. (Arlet et al., 1995). Results of restriction patterns are shown in
figures 5.11 and 5.12. The use of these enzymes did not distinguish between TEM
derivatives. All TEM enzymes demonstrated a pi value of 5.4. Automated DNA
sequencing was performed on a representative TEM PCR product from four
representative strains from PFGE group A, two from PFGE B-G and X, one from
PFGE group that contained only a single isolate. The results show that the majority
were TEM-1 P-lactamase, however, few isolates (6 E.coli) produced TEM-33 which





1 234567 8 9
Agarose gel showing RFLP analysis of SHV-specific PCR product restricted
with Nhe\ restriction endonuclease. The enzyme cleaved the SHV PCR
product bands resulting in two bands with molecular size 219 bp and 164




Digestion of TEM PCR product with Mesl endonuclease.
12 345 678 9 10
Lanes 1 and 7: DNA marker (100 bp)
Lane 2: TEM-1.




Digestion of TEM PCR product with Sau3A\ endonuclease
1 2 3 4 5
Lane 3: DNA marker (100 bp)
Lane 1: TEM-1 control.




Two different plasmids were found, with sizes of 70 and 141 kb. The results seems to
indicate that the blasm gene was carried on the larger plasmid with molecular size
141 Kb and the smaller plasmid of 70 Kb carried the 6/otem gene. Further plasmid





Results of plasmid isolation of the 68 ESBL-producing K. pneumoniae
PFGE No. of stains P-lactamase Plasmid No. Plasmid size
A 21 TEM-1, SHV-2 2 70 & 141 kb
A 4 TEM-1, SHV-2 & SHV-5 2 70 & 141 kb
B 12 SHV-2 1 141 kb
C 4 TEM-1 & SHV-2 2 70 & 141 kb
D 10 SHV-2 1 141 kb
E 5 TEM-1 & SHV-2 2 70 & 141 kb
F 3 SHV-2 1 141 kb
G 3 SHV-2 1 141 kb
H 1 SHV-2 1 141 kb
I 1 SHV-2 1 141 kb
J 1 SHV-2 1 141 kb
K 1 SHV-2 1 141 kb
L 1 SHV-2 1 141 kb
M 1 SHV-2 1 141 kb
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When ciprofloxacin was first introduced, resistance in K. pneumoniae and other
Enterobacteriaceae, such as E. coli, was virtually unknown. However, in the last 10
years, cases of bacteraemia with ciprofloxacin-resistant E.coli have increased in
number, together with upward trends in the use of quinolones in the community and in
hospital (Pena et al., 1995). The occurrence of ciprofloxacin resistance in K
pneumoniae is now well known and exceeds 5% in many centres in North America,
Europe, and Asia (Blondeau et al., 1999; Jones et al., 1996; Thomson, 1999;
Turnidge, 1995).
At the same time resistance to ciprofloxacin emerged, resistance to P-lactams
antibiotics became prominent. This resistance was as a result ofESBLs which mediate
resistance to newer P-lactams agents possessing an oxyamino group, such as
ceftazidime, ceftriaxone, cefotaxime, and aztreonam. In addition, plasmids that carry
and contain genes encoding ESBLs also harbour genes that encode mechanisms of
resistance to other classes of antimicrobials. In many regions of the world where
antibiotic use is high, ESBLs are present in -25% of all K. pneumoniae from
intensive care units, and patient-to-patient transfer of resistant organisms frequently
occurs (Paterson et al., 2000).
Some years ago, (Hobson et al., 1996), there was a major out break of ESBL in
Klebsiella spp in Aberdeen. Until recently, it was not thought that ESBL infiltration
had been a problem in Edinburgh. However, the introduction of the Vitek system
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with its integrated ESBL detection system demonstrated that K. pneumoniae
harbouring ESBLs were present within the hospital environment. Until this finding,
other studies from the same area had shown no evidence of ESBL-producing K.
pneumoniae (Paton, 1994). Many of these strains showed concomitant resistance to
ciprofloxacin.
This study was performed to determine the relationship between ESBL production
and ciprofloxacin resistance in K pneumoniae isolated from the Royal Infirmary of
Edinburgh and associated GP practices.
6.2 Results
MIC values according to NCCLS criteria (NCCLS, 1999) demonstrated that 32
(46.4%) of the 69 ESBL-producing K. pneumoniae were resistant to ciprofloxacin;
11 (16%) were intermediate and 26 (37.6%) were sensitive. All ciprofloxacin-resistant
K. pneumoniae were reported by the laboratory as resistant to the third generation
cephalosporins cefotaxime and ceftazidime. Thirty (93.8%) were resistant to
tobramycin and 24 (75.2%) were resistant to gentamicin. (Table 6.1).
6.2.1 Isoelectric focusing (IEF)
The p-lactamase complement of the 32 ciprofloxacin-resistant ESBL-positive isolates
was investigated. All isolates harboured a P-lactamase with a pi of 7.6, which was
probably an SHV-derived P-lactamase. Twenty-five of the 32 strains also
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demonstrated a TEM-derivative (3-lactamase with a pi of 5.4. Four of these 25
isolates also harboured another p-lactamase with a pi value of 8.2. These P-
lactamases have subsequently been identified by DNA sequencing as SHV-2 (pi 7.6),
SHV-5 (pi 8.2) and TEM-1 P-lactamase (pi 5.4) (see table 6.1).
6.2.2 Pulsed field gel-electrophoresis (PFGE)
PFGE analysis of the 32 ciprofloxacin-resistant ESBL-producing K. pneumoniae
isolates indicated that they belonged to four different genotype cluster groups, (see
figure 6.1) designated A, B, C and D. Group A consisted of 25 isolates, group B, 3
isolates, group C and D, 2 isolates each, (see table 6.1).
6.2.3 DNA-sequencing
Representative PCR products were taken from each of the PFGE cluster groups; four
from group A, and one from the other groups, and analysed by automated sequencing
for mutations in the gyrA and/or parC gene regions. The sequencing results
confirmed mutations in both genes.
To confirm the mutation in the gyrA region, RFLP was performed and confirmed a
mutation at Ser 83 .
For the parC mutation, all the representative isolates demonstrated a point mutation
at position 80 from AGC (serine), to ATC (isoleucine). Figure 6.2 demonstrates the













A CAZ, CTX, CIP, GM & TC TEM-1 and SHV-2 21
A CAZ, CTX, CIP, GM & TC TEM-1 , SHV-2 and SHV-5 2
A CAZ, CTX, CIP & TC TEM-1 , SHV-2 and SHV-5 2
B CAZ, CTX & CIP SHV-2 1
B CAZ, CTX, CIP & TC SHV-2 2
r
CAZ, CTX, CIP, GM & TC SHV-2 2
D CAZ, CTX, CIP & TC SHV-2 2





Dendogram of the PFGE analysis of the 32 ciprofloxacin resistant strains of K.
pneumoniae
Group A 25 isolates
Group B 3 isolates
— Group C 2 isolates




Agarose gel electrophoresis ofparC PCR products from ciprofloxacin-resistant
K. pneumoniae
346 bp
Lane 1: 100 bp DNA ladder
Lane 2: parC PCR product ofAD409
Lane 3: parC PCR product ofAD327
Lane 4: parC PCR product ofAD409
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In the gyrA region of the type strain E.coli NCTC 10418 and ciprofloxacin-sensitive
ESBL-positive K. pneumoniae, the codons at amino acid position 83 were TCC
(serine) and ACT (threonine) respectively, while at amino acid position 87 both
control strains expressed GAC (aspartic acid). Figure 6.3 shows the DNA sequence of
the gyrA gene of K. pneumoniae as found in GENE bank. Figure 6.4 shows the
sequence for the gyrA PCR products from all 4 strains sequenced from PFGE group
A.
Figure 6.5 Shows the DNA sequence of the gyrA gene of K. pneumoniae strain as
found in GENE bank and Dimre & Das, 1990. Figure 6.6 Shows the automated
sequencing results for the gyrA PCR products from PFGE groups B, C and D.
Figure 6.7 demonstrates ParC QRDR sequence ofK. pneumoniae as listed in GENE
bank. Figure 6.8 Shows a representative automated sequencing result for ParC gene
of the ciprofloxacin resistant K. pneumoniae strains.
Twenty-five of the 32 ciprofloxacin-resistant isolates, were PFGE group A. Four
representative strains of this group were sequenced and showed a mutation from TCC
(serine), to TTC (phenylanlanine) at codon 83 and a change from GAC (aspartic acid)
to TAC (tyrosine) at codon 87. The representative PCR products for the other seven





GyrA QRDR sequence of K. pneumoniae, ciprofloxacin-susceptible, as listed in
GENBANK (AF055258)
66 67 68 69 70 71 72 73 74 75
tea gcc cgt gtc gtt ggt gac gta ate ggt
S A R V V G D V I G
76 77 78 79 80 81 82 83 84 85
aaa tac cac ccg cac ggc gac tcc gcg gta
K Y H P H G D S A V
86 87 88 89 90 91 92 93 94 95
tac gac acc ate gtg cgt atg gcg cag ccg
Y D T I V R M A Q P
96 97 98 99 100 101 102 103 104 105
ttc teg ctg cgt tac atg ctg gtg gac ggc
F S L R Y M L V D G
106 107 108 109 110 111 112 113 114 115
cag ggt aac ttt ggt ttc ate gac ggc gac
Q G N F G S I D G D
116 117 118 119 120 121 122 123 124 125
tec gcc gcg gcg atg cgt tat acc gaa att
S A A A M R Y T E 1
126 127 128 129 130 131 132 133 134 135
cgt ctg gcg aaa ate get cat gag ctg atg
R L A K I A H E L M
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136 137 138 139 140 141 142 143 144 145
gcc gat ctt gaa aaa gag acg gtc gat ttc
A D L E K E T V D F
146 147 148 149 150 151 152 153 154 155
gtc gac aac tat gac ggt acg gag cgt att
V D N Y D G T E R I
156 157 158 159 160 161 162 163 164 165
ccg gsc gtc atg ccg acc aaa att cct aac
P D V M P T K I P N
166 167 168 169 170 171 172
ctg ctg gtg aac ggc gcc tcc
L L V N G A S
Single-letter amino-acid codon:
A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H
histidine, I isoleucine, K lysine, L leucine, M methionine, N aspargine, P proline, Q




GyrA QRDR sequence of ciprofloxacin-resistant (MIC > 32 mg/1) K. pneumoniae
from PFGE group A
66 67 68 69 70 71 72 73 74 75
tea gcc cgt gtc gtt ggt gac gta ate ggt
S A R V V G D V I G
76 77 78 79 80 81 82 83 84 85
aaa tac cac ccg cac ggc gac TTC gcg gta
K Y H P H G D F A V
86 87 88 89 90 91 92 93 94 95
tac TAC acc ate gtg cgt atg gcg cag ccg
Y Y T I V R M A Q P
Two point mutations were observed: at amino acid 83, TCC (serine) to TTC




GyrA QRDR sequence of ciprofloxacin-susceptible K. pneumoniae, as listed in
GENBANK (X16817.KPGYRA) and Dimre & Das,1990
66 67 68 69 70 71 72 73 74 75
tct gcc cgt gtc gtt ggt gac gta ate ggt
S A R V V G D V I G
76 77 78 79 80 81 82 83 84 85
aaa tac cac cct cat ggt gat act gcc gtg
K Y H P H G D T A V
86 87 88 89 90 91 92 93 94 95
tat gac acc att gta cgt atg gcg cag cca
Y D T I V R M A Q P
96 97 98 99 100 101 102 103 104 105
ttc tcc ctg cgt tac atg ctg gta gat ggc
F S L R Y M L V D G
106 107 108 109 110 111 112 113 114 115
cag ggt aac ttc ggt tct ate gac ggc gac
Q G N F G S I D G D
116 117 118 119 120 121 122 123 124 125
tcc gcc gca gca atg cgt tat acg gaa ate




GyrA QRDR sequence of ciprofloxacin-resistant (MIC = 32 mg/I) K.
pneumoniae strains from PFGE groups B, C and D
66 67 68 69 70 71 72 73 74 75
tea gcc cgt gtc gtt ggt gac gta ate ggt
S A R V V G D V I G
76 77 78 79 80 81 82 83 84 85
aaa tac cac ccg cac ggc gac ATT gcg gta
K Y H P H G D I A V
86 87 88 89 90 91 92 93 94 95
tac gac acc ate gtg cgt atg gcg cag ccg
Y D T I V R M A Q P





ParC QRDR sequence of K. pneumoniae ciprofloxacin-susceptible strain, as
listed in GENEBANK (AF303646)
76 77 78 79 80 81 82 83 84 85
ccg cac ggc gac age gcc tgc tat gaa gcg
P H G D S A C Y E A
86 87 88 89 90 91 92 93 94 95
atg gtg ctg atg gcg cag ccg ttc tct tac
M V L M A Q P F S Y
96 97 98 99 100 101 102 103
cgc tat ccg ctg gtg gat ggt cag
R Y P L V D G Q
Single-letter amino-acid codons:
A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H
histidine, I isoleucine, K lysine, L leucine, M methionine, N aspargine, P proline, Q




Representative parC QRDR sequence ofK. pneumoniae strains (MIC > 32 mg/1),
AD 313, AD 314, AD 315, AD 409 and AD 380
76 77 78 79 80 81 82 83 84 85
ccg cac ggc gac ATC gcc tgc tat gaa gcg
P H G D I A C Y E A
86 87 88 89 90 91 92 93 94 95
atg gtg ctg atg gcg cag ccg ttc tct tac
M V L M A Q P F S Y
96 97 98 99 too 101 102 103
cgc tat ccg ctg gtg gat ggt cag
R Y P L V D G Q




6.2.3 Relationship between antibiotic resistance and PFGE groups
Twenty-three of the 25 isolates that belonged to PFGE group A were resistant to
ceftazidime, cefotaxime, gentamicin and tobramycin; however, the remaining two
isolates from this group were resistant to all antimicrobial agents tested with the
exception of gentamicin.
Of the 3 PFGE group B isolates, two were resistant to ceftazidime, cefotaxime,
tobramycin, and sensitive to gentamicin, however, the third isolate was sensitive to
both gentamicin and tobramycin.
Both isolates that belonged to PFGE group C were resistant to all the antibiotics
tested, while isolates from PFGE group D were sensitive to gentamicin only. See table
6.2.
Isolates belonging to PFGE group A all harboured both the SFIY-2 (pi 7.6) and
TEM-1 (pi 5.4) P-lactamase. In addition, four of the 25 strains also harboured SHV-5
(pi 8.2).
The isolates belonging to group B,C and D harboured only a SHV-2 P-lactamase.





Susceptibility results of the PFGE groups ofK. pneumoniae to various
antibiotics
PFGE group CAZ CTX CIP GM TC Total
A R R R R R 23
A R R R S R 2
B R R R S R 2
B R R R s S 1
C R R R R R 2
D R R R s R 1
D R R R s S 1
Total R 32 32 32 25 30 32
CAZ = ceftazidime, CTX = cefotaxime, CIP = ciprofloxacin, GM = gentamicin, TC =




Results of IEFs and PFGE on the 32 ciprofloxacin resistant strains of K.
pneumoniae
PFGE group pi values ESBL Total No.
A 5.4 and 7.6 TEM-1 and SHV-2 21
A 5.4, 7.6 and 8.2 TEM-1 , SHV-2 and SHV-5 4
B 7.6 SHV-2 3
C 7.6 SHV-2 2
D 7.6 SHV-2 2
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6.2.4 Outer membrane protein (OMP) analysis
SDS-PAGE analysis of the OMPs showed that, seven of the clinical isolates expressed
two major OMPs of about approximately 35KDa and 36 KDa. Twenty five of the
isolates belonging to PFGE group A were deficient in OMP 36KDa, and harboured
TEM-1 , SHV-2 and SHV-5 (3-lactamase.
Isolates lacking the 36KDa porin (with a concomitant expression of SHV-5), were
resistant to all antimicrobial agents tested, and this porin loss may be partially
responsible for this.
The 36KDa porin was absent from isolates for which MICs of cefotaxime,
ceftazidime, gentamicin, tobramycin and ciprofloxacin were greater than 32mg/l.
However, the expression of porin, as visualised by SDS-PAGE (figure 6.9), was
clearly seen in isolates that were sensitive to ceftazidime. On the other hand, another
porin of size ~ 41 KDa was absent in isolates belonging to group B,C and D, and
these isolates harboured the SHV-2 ESBL only, however, sufficient expression of
36KDa was found in their OMPs. The common or major porin that appeared to be





Lost of 41 KDa band Lost of36 KDa band
123456 789 10
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis-profile of outer
membrane proteins of K. pneumoniae isolates, with three major outer membrane
proteins with approximate molecular size of41, 36 and 35 KDa.
Lanes 1 & 10: Molecular size marker with molecular sizes given in kilo-Dalton.
Lane 2: K. pneumoniae ESBL positive, ciprofloxacin sensitive used as control.
Lane 3: AD 315 (loss of 41 KDa. band)
Lane 4: AD 320 (loss of 41 KDa. band)
Lane 5: AD 327 (loss of 41 KDa. band)
Lane 6: AD 313 (loss of 36 KDa. band)
Lane 7: AD 339 (loss of 36 KDa. band)
Lane 8: AD 380 (loss of 36 KDa. band)
Lane 9: AD 409 (lost of 36 KDa. band)
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SHV-39: A novel extended-spectrum p-
lactamase (ESBL) found in Klebsiella
pneumoniae strains isolated from Chile
Chapter 7 Results
7.1 Introduction
SHV-l P-lactamase is found most commonly in K. pneumoniae and it is responsible
for up to 20% of the plasmid-mediated ampicillin resistance in this species
(Tzouvelekis and Bonomo, 1999). blasi iv or related genes is integrated in many
strains of K. pneumoniae through their chromosomal DNA (Livermore, 1995).
Although it has been hypothesized that the gene encoding SHV-l may exist as part
of a transposable element, it has never been proven (Jacoby and Sutton, 1991). There
are relatively few derivatives of SHV-l especially when compared with TEM-type p-
lactamases. Furthermore, changes in the bla^m structural gene have been shown to
occur in fewer position compared with blajEM. (See figure 1.10).
The majority of SHV-variants possessing an ESBL phenotype are characterized by
the substitution of a serine for glycine at position 238. A number of variants related
to SHV-5 also have a substitution of lysine for glutamate at position 240.
Interestingly, both the Gly238Ser and Glu240Lys amino acid substitutions mirror
those seen in TEM-types ESBLs (Bradford, 2001).
The serine residue at position 238 is critical for the efficient hydrolysis of
ceftazidime, and the lysine residue is critical for the efficient hydrolysis of




The seven strains used in this study were collected from hospitalised patients in
Santiago, Valparaiso, Concepcion and Puerto Montt in Chile. (See table 7.1 and
figure 7.1).
7.3 Results
7.3.1 Minimum inhibitory concentration (MIC)
Minimum inhibitory concentration (MIC) were determined by serial agar dilution.
The results demonstrated that all seven strains were resistant to both ceftazidime and
cefotaxime with MICs of>256 mg/1 and 16-32 mg/ml respectively.
7.3.2 Pulsed field gel-electrophoresis (PFGE)
Strains were genotyped by PFGE using Xba\ restriction enzyme, although there were
some variation in genotypes, within each hospital there was consistency of banding
pattern (PFGE) indicating a genetic relationship. Ftowever, there was no relationship
between strains isolated from different cities, indicating diversity i.e. different
clones.
7.3.3 Analytical iso-electric focusing (IEF)
Sonicated extracts of the seven ESBL-producing K. pneumoniae were examined by




The source of the isolates
Isolate No. Hospital City
34 G.Grant-Benavente Concepcion
100 Catholic Santiago
129 Gustavo Fricke Valparasio
130 Gustavo Fricke Valparasio
139 Catholic Santiago
1 150 Catholic Santiago





















































Examination of the IEF gels showed a [3-lactamases with pi value of 5.4, present in
all strains. A (3-lactamases of pi 7.6 was present in 5 strains while (3-lactamases of pi
7.0 was present in 3 strains and (3-lactamases with pi > 8.0 was found in 5 strains.
See table 7.2.
7.3.4 Polymerase chain reaction (PCR)
Plasmid DNA from all seven isolates was extracted (see section 2.7) and were
analysed for the presence of blasnv gene by PCR. The size of the amplified product
was 383bp which is the expected size ofamplified product with the primers used.
7.3.5 DNA sequencing
PCR products were sent to the Department of Hematology, Royal Infirmary of
Edinburgh, Scotland for automated sequencing. The automated analysis of the
sequence showed that, all the seven isolates had a Gly238Ser mutation that is
characteristic of the SHV-2 ESBL. However, another mutation at amino acid 267





Isolate No pi values
34 5.4, 7.6
100 5.4, 7.6 and >8.0
130 5.4, 7.6 and >8.0
150 5.4, 7.0
129 5.4, 7.0 and >8.0 j
139 5.4, 7.0 , 7.6 and >8.0




DNA sequencing results that show the new mutation Thr267Ser.





R G A R G I V
GCT AGC AAG CGG GGT GCG CGC GGG ATT GTC
A S K R G A R G I V
GCC CTG CTT GGC CCG AAT AAC AAA GCA GAG
A L L
250
G P N N K A E
GCC CTG CTT GGC CCG AAT AAC AAA GCA GAG
A L L G P N N K A E
CGC ATT GTG GTG ATT TAT CTG CGG GAT ACC
R I V
260
V I Y L R D T
267
CGC ATT GTG GTG ATT TAT CTG CGG GAT TCC






Over the last 15 years, ESBLs have gone from being an interesting scientific
observation to a phenomenon of great medical importance. The introduction of the
oxyimino-P-lactam antibiotics has given rise to the emergence of new P-lactamases.
Some of these new P-lactamases, like the TEM- and SHV- type ESBLs, result from
simple point mutations in existing p-lactamase genes that lead to a changed substrate
profile. Other new p-lactamases, such as the CTX-M type enzymes, have been
'borrowed' from the chromosomally encoded P-lactamases that occur naturally in
other species of Enterobacteriaceae (Bradford, 2001). The development and spread
of ESBLs have most likely been caused by the overuse of expanded-spectrum
cephalosporins in the hospital setting.
Numerous methods have been proposed for detection of ESBLs in clinical isolates.
However, it is important to note that none of the methods that rely on phenotypic
expression of the P-lactamase will detect every ESBL-producing isolate.
Nevertheless, increased awareness of the need to detect ESBL-producing strains
among clinical microbiology laboratory and infection control personnel will help in
the interpretation of these tests.
Current therapy for strains of Enterobacteriaceae that express ESBLs is limited to
such broad-spectrum agents as imipenem. However, there have already been reports
of therapeutic failures of this drug with strains that produce multiple P-lactamases
(Ahmad et al., 1999) There are limited therapeutic options left for some of these
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organisms. Strains expressing extended-spectrum P-lactamases will present a major
challenge for clinical microbiologists and clinicians alike as we head into the 21st
century.
The majority of clinical laboratories do not have the resources to identify ESBL
producing strains by molecular methods, therefore it is important to have an easy to
perform methodology that can be used in the routine laboratory.
This study shows the importance of identification of Enterobacteriaceae to species
level and the usefulness of the Vitek system for routine detection of ESBLs ifwe are
to report accurate and consistent results to clinicians. In a recent survey of detection
of ESBLs in clinical isolates, Tenover et al. (Tenover et al., 1999), found that only
18% of laboratories correctly identified challenge organisms as potential ESBL-
producers using susceptibility to one or more expanded- spectrum B-lactam
antibiotics as the method of detection. Furthermore, a survey in Europe found that
37% of ESBL producing organisms were mistakenly reported as being susceptible to
expanded-spectrum cephalosporins (Livermore and Yuan, 1996). Another recent
report described the retrospective detection of ESBLs in five of 20 strains of K.
pneumoniae isolated from blood cultures. In some of these cases patients were
treated with an inappropriate third-generation cephalosporin. Treatment in these
patients was changed after clinical failure (Crowley, 2001). If an ESBL detection test
was available at the original time of susceptibility testing then appropriate results




There is currently a great need for reliable and efficient tests to detect ESBLs in
clinical isolates of Enterobacteriaceae. Conventional susceptibility testing methods,
on their own, fail to present reliable susceptibility results for p-lactam antibiotics
when testing those species that harbour ESBLs.
8.2.1 Vitek system
Currently, most UK clinical laboratories do not use a standard method for the
detection of ESBLs and many clinical laboratories do not routinely identify
Enterobacteriaceae to genus and species level. The Vitek system addresses these
issues. It will only validate a susceptibility result once the organism has been
identified to species level. If the system detects the presence of an ESBL resistance
mechanism in strains of Klebsiella spp. and E. coli, the system then utilises its
'expert' software and applies it to the final susceptibility results, p-lactams
susceptible to ESBL activity are then flagged as resistant whether or not the in vitro
test indicates susceptibility.
This study has shown that the Vitek system, in our hands, whilst easy to perform and
without any subjective interpretative of results, reported false positive detection of
ESBL activity with fourteen strains of E. coli. On re-testing these strains with Vitek
(GNS-532 card) they were correctly reported as ESBL negative. All these strains
were initially tested with the same batch number of Vitek (GNS-526 card). When re-
tested, the GNS-532 card was used; this card has superseded the GNS-526 with
accompanying software upgrades. Although internal quality control (QC) is
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performed on these cards, an ESBL-producing E.coli is not used as part of the QC
battery. It was initially thought that the 14 false-positive ESBL E. coli might have
been as a result of a faulty batch of GNS-526 cards. However, recent work in this
laboratory, with ten recently isolated 'Vitek' ESBL-positive E. coli showed two of
these ten strains to be ESBL-negative by E-test. On re-testing with the same batch of
Vitek GNS-532, these two strains were subsequently reported as ESBL negative.
Although the percentage false-positive E. coli ESBL strains fell from approximately
50% to 20% with the new card it was still a concern that these strains were
misreported as ESBL-producers with subsequent 'expert' rules for antibiotic
susceptibility to (3-lactam antibiotics applied. There appears to be no obvious reason
for these results. It is unlikely to be technical error as the Vitek is a highly
standardised system. These strains have been forwarded to bioMerieux for further
studies. Tzelepi et al. have reported that the Vitek ESBL detection test failed to
detect the majority of ESBL-producing strains of Enterobacteriaceae (Tzelepi et al.,
2000). In a study of Klebsiella spp. and E.coli expressing well-characterised fi-
lactamases, Sanders et al. showed that the Vitek ESBL test was 99% sensitive and
specific for the detection of ESBLs (Sanders et al., 1996). However a recent study in
Brazil showed the Vitek system to have only 90.2% sensitivity (Hsiung et al., 2002).
Up-dated computer algorithms in the new Vitek2 system have been shown to
categorise the phenotype of susceptibility patterns with various [3-lactam antibiotics
(Sanders et al., 2000).
It should be noted, that in our hands, some E. coli were reported as falsely ESBL-
positive. For ESBL positive K. pneumoniae in this study the Vitek test was accurate
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but it should be noted that this study only included Vitek ESBL-positive strains and
was therefore not an evaluation of the Vitek ESBL test itself.
8.2.2 Double disc diffusion
The DDD test requires careful spacing of discs for accurate results and careful
interpretation of zone sizes. It is therefore technically demanding. In previous
studies, the DDD test was able to detect 82% and 88% of ESBL-positive strains
respectively (Gibb and Crichton, 2000; Thomson and Sanders, 1992). The limitations
of this test have been described elsewhere (Bush, 1996; M'Zail et al., 2000;
Thomson and Sanders, 1992). A recent study reported that cefpodoxime achieved a
100% sensitivity rate in detecting ESBLs in tested isolates; the sensitivity of
cefotaxime was 92% and that of ceftazidime was 82% (Appleton and Hall, 2000). In
contrast, this study showed that cefotaxime was the most efficient cephalosporin for
the detection of ESBLs with a sensitivity rate of 85%, with rates of 73.5% for
cefpodoxime and 46% for ceftazidime. This may reflect the type of ESBLs in our
isolates, but it emphasises the importance of testing more than one cephalosporin.
8.2.3 E-Test ESBL
The commercially available ESBL E-test strip is a quantitative technique and is
widely regarded as the 'gold standard' for detection of ESBL production in routine
clinical laboratories (M'Zail et al., 2000). This test was shown to be more sensitive
than the double disc diffusion test in detecting ESBL's in clinical isolates (Cormican
et al., 1996). In our hands it detected 98.8% of the test isolates but only if both
cefotaxime and ceftazidime strips were used in conjunction. In a study by
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Vercauteren et al. (Vercauteren et al., 1997), only using the ceftazidime E-test ESBL
detected 81 % of ESBL-producing strains isolated in their laboratory, compared to
97% detected by the double disk test. This technique is expensive and most clinical
laboratories would use it only for confirmation rather than as a routine test.
In conclusion, none of the detection tests that are based on phenotype of the 13-
lactamase produced are 100% sensitive or specific for the accurate detection of
ESBL's among clinical isolates of Gram-negative bacteria. The need for improved
detection ofESBLs in clinical isolates is well recognised (Paterson and Yu, 1999).
The Vitek ESBL test was cost effective as an ESBL screen in so much as the ESBL
test is an integral part of the susceptibility card and performed simultaneously with
the susceptibility tests. In addition, the Vitek test is interpreted by the system, which
removes any errors of subjectivity. No additional outlay of resources is required. We
would recommend strains ofE.coli be confirmed as ESBL positive by an additional
method such as E-test.
8.3 Antimicrobial susceptibility profile
8.3.2 Susceptibility and identification by the Vitek system
Identification of Gram-negative bacteria was performed using the GNI card. This
card contains 29 different biochemical reaction wells, and one negative control well.
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Incubation times varied from two to 15 hours, depending on the growth rate of the
organism (Paton, 2000).
The GNI card now has been superceded by the GNI+, which claims identification of
more species and a faster identification time (between two to 12 hours) for both
Gram-negative and Gram-positive bacteria (Bourbeau and Heiter, 1998).
The Vitek system successfully identified all the test isolates as K. pneumoniae.
Susceptibility tests were performed on GNS cards, which also have an integrated
ESBL detection test. If the instrument flags up an organism as positive for ESBL
production the expert software system automatically flags up all cephalosporins as
resistant, regardless of the actual test result to the antibiotic. It has been stated
elsewhere that if organisms are known to harbour ESBLs then all cephalosporins
should be reported as resistant (Livermore et al., 2001). Expert systems such as this
are invaluable as an aid for detection of resistance mechanisms. The results from the
Vitek show the susceptibility data before it was interpreted by the expert software
system, in each case the expert software would have recognised the presence of an
ESBL and advised that the susceptibility results for cephalosporins be reported as
resistant regardless of the instrument result. The Vitek is now due to be superceded
by the Vitek 2 that has an improved Advance Expert system (AES). This system has
recently been evaluated by Livermore et al (Livermore et al., 2002).
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8.3.2 Susceptibility studies by the disc diffusion method
The disc diffusion method is by far the most popular technique used throughout the
world and is largely suitable for testing most rapidly growing bacteria. It provides
relative data concerning the susceptibility of particular microorganisms against the
antibiotic tested.
Disturbingly, the disc diffusion method repeatedly failed to confirm resistance to
third generation cephalosporins in ESBL-positive strains. This is not a new finding
and has been reported elsewhere (Jacoby and Han, 1996). Interestingly, in our study
we found that false susceptibility was most prevalent with ceftazidime which is in
contrast to the study by Jacoby and Han (1996) where higher false-susceptibility
rates were seen with cefotaxime. This may however, possibly reflect the different
populations of organisms tested rather than the antibiotic concerned.
In a study by Babini and Livermore (Babini and Livermore, 2000), it was found that
up to 40% ofESBL-producers had been reported as susceptible to cefotaxime and /or
ceftazidime. It is disturbing that even armed with the scientific knowledge and
methodologies to detect ESBL producers, many laboratories simply do not use this
information to good effect and still rely on the disc diffusion method, which has
clearly be shown to be fraught with frailty for use with these antibiotics/organism
combinations. It is of great concern that patients may receive inappropriate treatment
with the obvious repercussions involved.
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Aminoglycoside resistance was found to be concomitant with ESBL production in
many of the test strains with resistance rates of between 39% and 62% dependant on
the aminoglycoside concerned.
8.3.3 MICs determined by agar dilution
The determination of the MIC is the 'gold standard' standard quantitative technique
for testing the antimicrobial susceptibility of bacteria (Brown and Brown, 1991). The
MIC is determined by serial dilutions of the appropriate antibiotic in either agar or in
broth. The most common use of dilution methods is in the evaluation of new
antimicrobial agents and in the establishment of criteria for interpretation of disc
diffusion methods. However, the dilution methods are not useful for organisms that
grow slowly or with organisms where diffusion tests have doubtful reliability (Brown
and Brown, 1991).
In this study the MICs of tobramycin, gentamicin and ciprofloxacin for the test
organisms were determined by the traditional agar dilution method. Resistance rates
for ciprofloxacin, gentamicin and tobramycin were 46%, 40%, and 46% respectively.
However, it should be noted that these prevalence rates of resistance are in a highly
biased study population and on their own are of little value. Several other studies also
report resistance to aminoglycosides as being common among ESBL-producers
(Babini and Livermore, 2000; Palucha et al., 1999).
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Interestingly, resistance rates for ciprofloxacin in this study were greater than those
previously reported (Babini and Livermore, 2000).
8.3.4 MICs determined by E-test strips
MICs to the test strains for cefotaxime and ceftazidime were determined by E-test
strips. This test uses plastic strips containing a preformed gradient of antibiotic. This
is placed on the agar medium after the plate has been inoculated, the antibiotic
diffuses from the plastic strip into the agar medium. In this study for the most part,
the endpoints were clear except in a few cases where interpretation of the end point
was difficult as a result of the presence of double zones of inhibition. This is known
problem with Etest strips and the manufacturer has issued guidelines for the
interpretation of the test.
With E-test strips for cefotaxime, 77% of the isolates were resistant/intermediate to
cefotaxime. MICs of ceftazidime indicated that only 47% of strains were resistant to
this drug.
Treatment failures due to undetected ESBL producing K. pneumoniae have already
been reported (Karas et al., 1996). No clear connection can be made between B-
lactamase production and the in vitro resistance level of the host (Magdalena et al.,
1997). Other factors must therefore be taken into consideration , e.g. permeability
changes or the influence of the specific host environment (Magdalena et al., 1997).
The MICs of cefotaxime were significantly higher than those of ceftazidime for all
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isolates producing ESBL. Similar results were reported in a study by Palucha et al. in
1999 (Palucha et al., 1999).
In general, the stability of the antimicrobial gradient produced by E-test is only
marginally effected by inoculum, pre-inoculation and pre-diffusion, which generally
have a marked effect on the disc diffusion test (Brown and Brown, 1991). In
addition, E-test may prove a more reliable alternative for conventional diffusion or
dilution test for fastidious or slow growing organisms.
8.4 Molecular detection of blasnv and A/«tem genes
In this study, the ESBL genes were detected by dot-blot hybridisation and by the
amplification ofDNA sequence coding blaj^u and blaSm ESBLs by PCR.
The results obtained from dot-blot for blasuv were comparable with those obtained
by PCR analysis and the results generally agreed. The two techniques showed
marked differences for the detection of the blaj^u gene. bla^M gene was detected
by PCR in 42 stains, while it was detected in 62 strains by dot-blot hybridisation. The
high incidence of positive W^tem gene results by dot-blot could be as a result of
cross-hybridisation with the 6/«shv gene as they have been shown to share more than
68% homology (Heritage et al., 1999), but this is unlikely as the controls were




PCR has been used extensively in the detection and analysis of resistance genes in
bacterial isolates (Brown et al., 1996; Vila et al., 1995), and in the detection of
specific micro-organisms directly in clinical and environmental specimens (Brakstad
et al., 1992; Persing, 1993; Shirai et al., 1991). It is a very useful technique for the
early detection and specific diagnosis of infectious disease. Our data shows that
PCR was successful in detecting the presence of blasm and/or blajEu genes in the
test isolates.
8.5 The p-lactamases of ESBL-producing K. pneumoniae
and E.coli
The IEF results suggested that four P-lactamases with pi values of 5.4, 7.0, 7.6 and
8.2 were identified. The determination of the isoelectric point on its own is useful for
the indication of SHV-derived enzymes but is clearly insufficient for the TEM
derived P-lactamases where at least 14 enzymes share the same pi of 5.2 and more
than 10 share pi 5.4. Further characterisation requires genetic analysis by sequencing
or oligotyping.
Some ESBL-SHV enzymes with pi of 7.6 or 8.3 contain a glycine to serine amino
acid substitution at position 238 as a result of a mutation, which creates a new
endonuclease restriction site, Nhel (Niiesch et al., 1996). PCR-RFLP with NheI
endonuclease can therefore be used to distinguish blasm-2 and blasm-2 from blasm-i
(Chanawong et al., 2000). The amino acid sequence of blasm-2 differs from that of
blasm-2 by a change at position 205, where leucine in blasm-2 is substitution by
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arginine in b/asHv-3 (Garbargchenon et al., 1990; Peduzzi et al., 1989). This mutation
can be detected by DNA-sequencing or by Bcefl restriction endonuclease, however,
currently there are no suppliers of this enzyme (Chanawong et al., 2000).
Nevertheless, in organisms that encode multiple SHV-type (3-lactamases genes, the
combination of IEF and RFLP analysis of SHV-specific PCR products can aid in the
identification of multiple SHV-type (3-lactamases encoded by one isolate (Hanson et
al., 1999). Isoelectric point determination could differentiate these two (3-lactamases,
SHV-3 has a pi of 7.0 and SHV-2 has a pi 7.6 (Chanawong et al., 2000). Using this
information we can therefore deduce that regarding our findings in this study, we
have isolates harbouring either SHV-2 or SHV-3 ESBLs.
In conclusion, both PCR-RFLP and IEF are useful aids for more accurate molecular
characterisation of ((-lactamases and provide a sensitive technique when used in
tandem for the identification of SHV-ESBL family genes other than employing direct
molecular sequencing. The situation is different with the TEM-ESBL family for
which the combination of PCR-RFLP and IEF was not able to identify the TEM-
derived enzymes in this study, which subsequently required full DNA sequencing.
DNA-sequencing results indicated that enzymes with a pi value of 5.4 were TEM-1
in K. pneumoniae isolates and were TEM-33 (IRT) in our E.coli isolates.
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8.6 Molecular and epidemiological studies of ESBL-
producing K. pneumoniae and E.coli
PFGE is often considered as the "gold standard" of molecular typing techniques
(Olive and Bean, 1999). However, molecular typing methods, as applied to the genus
Klebsiella, are still in their infancy. Preliminary work has been published on plasmid
profiles (Hartstein et al., 1993; Podschun and Ullmann, 1998), ribotyping, multilocus
enzyme analysis, and applications of pulse-field gel electrophoresis (Bingen et al.,
1994). The procedures vary from laboratory to laboratory but lack of standardisation
makes it difficult to compare them.
In recent years, K. pneumoniae isolates harbouring ESBLs have produced significant
outbreaks in hospitals world-wide (Eisen et al., 1995; M'Zali et al., 1996; Rice et al.,
1990; Rice et al., 1996; Sirot et al., 1988). Our data, according to the results ofPFGE
analysis of genomic DNA showed strains isolated throughout 14 wards within the
RIE (see table 2.1).
The results of epidemiological studies confirm that the ESBLs-producing K.
pneumoniae from Ward 15 are as a result of the dissemination of a resistance
plasmid (see table 5.7) or mutations in existing plasmid-mediated (3-lactamases
probably as a result of selective pressure produced by the overuse of third generation
cephalosporins. This mutation may also explain why some strains had one SHV-gene
variant whereas others had a different variant. Most SHV-differ from one another by
only one amino acid (M'Zali et al., 1996), so a single point mutation might modify
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the enzyme type. The SHV-5 ESBL present in group A PFGE has probably evolved
from an SHV-2 (3-lactamase.
The other major PFGE groups B and D consisted of 12 and 10 isolates respectively,
producing SHV-2 and TEM-1 or just SHV-2 alone. PFGE group C consisted of 4
isolates producing SHV-2, PFGE group F consisted of 3 isolates, 2 produced TEM-1
and SHV-2 and one produced SHV-2 only. PFGE group E consisted of 5 isolates,
one strain produced SHV-2 while the others produced both TEM-1 and SHV-2.
PFGE group G consisted of 3 isolates, 2 produced SHV-3 and one SHV-2. The other
six individual PFGE groups (H, I, J, K, L, and M) consisted of a single isolate each
and were unrelated to the other PFGE groups. Table 2.1 and Table 5.7 shows the
demographics of these isolates.
Interestingly isolate AD404 and isolate AD410 had PFGE patterns placing them in
PFGE groups A and B respectively. These strains were collected from samples sent
to the laboratory by GPs. This would indicate that the dissemination of these
particular strains is not limited to the hospital only but occur in the community as
well. It is not known whether these patients had been hospitalized prior to isolation
of these strains.
In general, the majority ofK pneumoniae isolates (95%) harboured an SHV-derived
|3-lactamase, this was SHV-2 which is in accordance with the situation reported in
other studies (Jutersek et al., 2002). From this work, we can suggest that PFGE when
combined with IEF analysis is an effective tool for investigating the epidemiology of
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ESBL-producing K. pneumoniae, and negates the requirement for expensive and
time consuming molecular sequencing.
The E.coli strains harbouring ESBLs were all collected from GPs, and all of them
were isolated from urine samples of patients with UTI infection with the exception of
one strain that was isolated from a sputum sample. It is well known that E.coli is the
main cause ofUTI.
Interestingly 5 isolates that belonged to PFGE group X were collected from the same
GP. Although these strains were shown not to all harbour the same (3-lactamase
enzymes (see table 5.3) it indicates the spread of a promiscuous strain of E. coli
among these patients and further epidemiological investigations are required on the
spread of this particular strain.
8.7 Epidemiological findings
Previous epidemiological studies of ESBL-producing strains indicated a combination
of epidemic modes of dissemination including strains, self-transferable plasmids and
gene transposition (Deere et al., 1998; De Champs el al., 1991; Kitzis et al., 1988;
Petit et al., 1990; Sirot et al., 1988).
The presence of this ESBL-harbouring K. pneumoniae in these wards was probably
initially as a result of heavy use of third generation cephalosporins within the ITU
setting and horizontal dissemination has occurred allowing the spread of this strain to
other patients in different wards. Klebsiella spp. are protected from drying by their
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capsule and can survive better than other Enterobacteriaceae on skin and medical
equipment facilitating cross-infections (Casewell and Desai, 1983).
Interestingly, an isolate of each PFGE group (A-G) was found from Ward 15. This
might also indicate that cross-infection by medical stuff including nurses,
physiotherapy stuff or medical students (the RIE is a teaching hospital) may have
played a role in the dissemination of these resistant isolates between the different
wards within the hospital.
This study clearly indicates the need for on-going careful epidemiological
investigations and shows that certainly in this case cross infection within the RIE has
become a major problem, not only within the hospital itself but particularly within
the ITU. Only with the enforcement of strict infection control measures and strict
antibiotic guidelines can we hope to control the appearance and spread of these
organisms within the hospital but in the community as well.
8.8 Quinolone resistance and ESBL-producing K.
pneumoniae
Initial studies on the development of quinolone resistance demonstrated two basic
strategies that bacteria could adopt to circumvent the action of quinolones. Alteration
in DNA gyrase (the target of the quinolones) and mutation leading to reduced access
of quinolone to DNA gyrase (either efflux or alteration in the outer membrane of
Gram-negative bacteria) (Wiedemann and Heisig, 1994). Alteration in the structure
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of DNA gyrase has been the most commonly identified resistance mechanism in
clinical isolates (Ball, 1994; Maxwell, 1997; Wiedemann and Heisig, 1994).
This study clearly shows ciprofloxacin resistance in K. pneumoniae is closely
associated with ESBL production. This association is of grave concern in as much as
ESBL producing K. pneumoniae are often resistant to other classes of antimicrobials.
Therefore, ciprofloxacin resistance in these strains severely limits already restricted
treatment options. It might have been interesting to have investigated ciprofloxacin
resistance in ESBL-producing K. pneumoniae but this was not performed in this
study.
This molecular epidemiological study of ciprofloxacin-resistant ESBL producing K
pneumoniae showed genotypically identical isolates within one group consisting of
25 strains. The patterns obtained by Rapiddist were similar to those analysed
manually using the criteria of Tenover and Arbeit (Tenover et al., 1995). All the
ESBL-positive, ciprofloxacin resistant isolates showed four DNA bands common to
all isolates.
8.8.1 The role ofgyrA and parC in quinolone resistance
Alteration of the gyrA. subunit of DNA gyrase has a central role in conferring high-
level quinolone resistance in Gram-negative bacteria (Deguchi et al., 1997a).
Ciprofloxacin resistance in K. pneumoniae is predominantly due to a chromosomal
mutation in the gyrA gene (Thomson, 1999). RFLP, using a Hinfl restriction
endonuclease assay, demonstrated a mutation at serine 83 in the QRDR of the gyrA
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region. This mutation is known to confer quinolone resistance and results in the loss
of the HinfL G/ANTC restriction site. RFLP using HinfL can also be useful to
distinguish between those K pneumoniae that possess serine at position 83 but not K.
pneumoniae possessing threonine at position 83. DNA sequencing also showed a
point mutation at codon 83 located in the QRDR region. Amino acid position 83 was
changed from ACT to ATT (threonine to isoleucine) in seven of the isolates. The
other 25 isolates belonging to PFGE group A. In parC, one single base change
leading to a single amino acid change was identified in all tested isolates. This
alteration was present on codon 80, the same alteration in parC has been observed in
previous studies (Deguchi et al., 1997b). Nevertheless, in this study, no strains had
alteration in parC without the concomitant presence of alteration in gyrA. These
finding are consistent with other studies indicating that in K pneumoniae, DNA
gyrase is a primary target of quinolones, and only a single amino acid change at
position 83 or two amino acid changes at position 83 and 87 in GyrA are sufficient to
generate high-level resistance to ciprofloxacin. In addition, the accumulation of
alteration in GyrA and simultaneous presence of alteration in ParC play a
complementary role in developing high-level quinolone resistance. (See table 8.1).
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8.8.2 The role of OMPs in quinolone resistance
Porins are OMPs that allow the non-specific diffusion of small molecules into the
bacterial cell. Most of the studies on OMPs have been carried out with E.coli, in
which two major porins (OMP C and OMP F) have been characterised (Ardanuy et
al., 1998). In K. pneumoniae, two main porins have been characterised; OMP K35
(the homology of OMP F) and OMP K36 (the homology of OMP C) (Alberti et al.,
1995). Recently, loss of the OMP K36 porin has been associated with both cefoxitin
resistance and increase in cephalosporin and quinolone MICs (Bradford et al., 1997).
There are several reports on the association of loss of porins and increased resistance
to antimicrobial agents, particularly with E.coli and Salmonella typhimurium
(Martinez et al., 1996). For other Gram-negative bacteria, the association of loss of
OMP with various size ranges has been reported (Ardanuy et al., 1998; Deguchi et
al., 1997b; Martinez et al., 1996), and resistance to antimicrobial agents has been
considered evidence of the role of these OMPs as porins (Ardanuy et al., 1998;
Martinez et al., 1996). The OMP results in this study demonstrated that some of the
isolates had lost one porin that might be 41 KDa. A similar conclusion was found in
a study by Deguchi et al. in 1997 (Deguchi et al., 1997b).
Other isolates that belong to PFGE group A showed loss of a porin that might be
porin K(36 KDa), similar findings have been reported in other studies (Ardanuy et
al., 1998; Martinez et al., 1996). However, in many cases, the exact nature of the
protein has not been established, and the assumption that the involved proteins were
porins were largely based on their molecular masses (Martinez et al., 1996).
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Furthermore, the lack of a good definition of K. pneumoniae porins has resulted in
their having an inferred, rather than demonstrated, role in antimicrobial resistance in
this species (Pangon et al., 1989).
In this study, the diminished activity of ciprofloxacin appears to be related to
mutation in gyrase encoding amino acid 83 and the pleiotropic effect of the loss of
porin, either 41 or 36 KDa from their OMPs. There are also other resistance
mechanisms in this species to be considered. The first study of plasmid-mediated
ciprofloxacin resistance has recently been reported (Martinez et al., 1998). Other
potential explanations for the association between resistance to 3rd generation
cephalosporins and quinolones include active efflux (Paterson et al., 2000).
In general, results from this study confirm previous observations (Martinez et al.,
1996; 1999), indicating that resistance to extended-spectrum cephalosporins
increases in K. pneumoniae strains that produce SHV-type ESBL that lack the two
major porins of their species.
As a general conclusion, treatment of infection caused by K. pneumoniae producing
ESBLs is difficult not only because of their resistance to expanded-spectrum
cephalosporins, but also because of their often concomitant resistance to other
antimicrobial agents encoded by the same or different plasmid. Ciprofloxacin
resistance and ESBL production in members of Enterobacteriaceae are
geographically widespread (Paterson et al., 2000). Continued world-wide
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surveillance of K. pneumoniae isolates is necessary to provide information on the
dissemination of these important pathogens.
8.9 The discovery of SHV-39 in K. pneumoniae strains
isolated from Chilean hospitals
To date, the majority of SHV-type derivatives possess the ESBL phenotype.
However, one variant, SHV-10, is reported to have an inhibitor-resistant phenotype.
This enzyme appears to be derived from SHV-5 and contains one additional amino
acid substitution of glycine for serine 130 (Prinarakis et al., 1997). It is interesting
that the inhibitor-resistant phenotype conferred by the Serl40Gly mutation seems to
override the strong ESBL phenotype usually seen in enzymes containing the
Gly238Ser and the Glu240Lys mutations seen in other SHV-5 type enzymes
(Bradford, 2001). The majority of SHV-type ESBLs are found in strains of K
pneumoniae.
K. pneumoniae is a widespread nosocomial pathogen within Chilean hospitals. It has
largely been treated with ceftriaxone and ceftazidime and resistance has increased
markedly. The fifth member of the SHV family (SHV-5) was first observed in Chile
(Gutmann et al., 1989). This was the first variant not to have been first observed in
Europe. SHV-5 again was first described from K. pneumoniae and has a pi of 8.2. As
with SHV-4, the amino acid found at position 240 in SHV-5 is lysine. It is possible
to speculate from which ancestral gene the SHV-5 determinant evolved as it is most
likely to be evolved by a point mutation from SHV-2.
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K. pneumoniae strains used in this study were isolated from hospitalised patients
from the Catholic University hospital in Santiago, the Gustavo Fricke hospital in
Valparaiso, which lies 100 miles to the east, the G.Grant-Benavente hospital in
Concepcion which lies 300 miles to the south, and a hospital in Puerto Montt which
lies 800 miles to the south, (see figure 7.1). Our results demonstrated that although
there were some variations in genotype, within each hospital there was consistency
of PFGE banding patterns. Flowever, there was no similarity between strains isolated
from different cities showing they were different clones. Examination of the (3-
lactamases showed that TEM-1 was always present; however, the cephalosporin
resistance was associated with an SHV-derived [3-lactamase with a pi value greater
than 7.0. PCR amplification and sequencing revealed a hitherto undescribed enzyme
with not just a Gly238Ser mutation, characteristic of SHV-2, but also a Thr267Ser
mutation. This ESBL conferred MICs of ceftazidime of >256 mg/1 and MICs
between 16-32mg/l for cefotaxime. This (3-lactamase has not previously been
reported. The amino acid sequence has been deposited with
(www.lahev.org/studies/webt.htm) and the enzyme has been designated SHV-39.
This enzymes seems to be widely disseminated in Chile both geographically and




Appendix I Results of E-Test ESBL strips
Strains CT/CTL Comments | TZ/TZL Comments
AD 313 256 +Ve ESBL j 2.67 -Ve ESBL
AD 314 680 +VeESBL J 24 +Ve ESBL
AD 315 Phantom +VeESBL 84 +Ve ESBL
AD 316 680 +VeESBL 128 +Ve ESBL
AD 317 Phantom +VeESBL 21 +VeESBL
AD 318 340 +VeESBL 2 -Ve ESBL
AD 319 106 +VeESBL 2 -Ve ESBL
AD 320 Phantom +VeESBL 2.64 -Ve ESBL
AD 321 61 +VeESBL 340 +Ve ESBL
AD 322 Phantom +VeESBL 128 +Ve ESBL
AD 323 ,5 +VeESBL 2.64 -Ve ESBL
AD 324 340 +VeESBL 2.67 -Ve ESBL
AD 325 340 +VeESBL 2 -Ve ESBL
AD 326 Phantom +VeESBL 168 +VeESBL
AD 327 Phantom +VeESBL 375 +Ve ESBL
AD 328 32 +VeESBL 2 -Ve ESBL
AD 329 340 +VeESBL 2.67 -Ve ESBL
AD 330 127 +VeESBL 2 -Ve ESBL
AD 331 32 +Ve ESBL 2 -Ve ESBL
AD 332 2 -Ve ESBL 2.64 -Ve ESBL
AD 333 680 +VeESBL 2 -Ve ESBL
AD 334 16 +VeESBL 1.97 -Ve ESBL
AD 335 12 +VeESBL 5.3 -Ve ESBL
AD 336 0.27 -Ve ESBL 21 +VeESBL
AD 337 24 +VeESBL i -Ve ESBL
AD 338 Phantom +VeESBL Phantom +VeESBL
AD 339 21.3 +VeESBL 1.5 -Ve ESBL
AD 340 10.40 +VeESBL '.5 -Ve ESBL
AD 341 86.95 +VeESBL 0.5 -Ve ESBL
AD 342 32 +VeESBL 1.5 -Ve ESBL
AD 343 85.1 +VeESBL 1.5 -Ve ESBL
AD 344 42.3 +VeESBL 2 -Ve ESBL
AD 345 Phantom +VeESBL 32 +Ve ESBL
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AD 346 Phantom +Ve ESBL 32 +Ve ESBL
AD 348 Phantom +VeESBL Phantom +VeESBL
AD 349 Phantom +VeESBL 256 +VeESBL
AD 350 187.5 +Ve ESBL 4 -Ve ESBL
AD 351 Phantom +VeESBL 168.5 +VeESBL
AD 352 680 +Ve ESBL 4 -Ve ESBL
AD 353 170 +VeESBL 3.9 -Ve ESBL
AD 354 15.60 +Ve ESBL 2 -Ve ESBL
AD 355 62.5 +Ve ESBL 3.9 -Ve ESBL
AD 356 1000 +VeESBL 128 +VeESBL
AD 357 34 +Ve ESBL 168.5 +VeESBL
AD 358 Phantom +VeESBL 256 +VeESBL
AD 359 2.6 -Ve ESBL 2 -Ve ESBL
AD 360 500 +Ve ESBL 15.8 +VeESBL
AD 362 phantom +VeESBL 128 +VeESBL
AD 363 340 +Ve ESBL 84.5 +VeESBL
AD 364 16 +VeESBL 32 +VeESBL
AD 365 1000 +VeESBL 84 +VeESBL
AD 366 340 +VeESBL 8 +Ve ESBL
AD 367 340 +VeESBL 128 +VeESBL
AD 368 21 +VeESBL 2.6 -Ve ESBL
AD 369 15 +VeESBL 7.8 -Ve ESBL
AD 370 10.2 +Ve ESBL 2.6 -Ve ESBL
AD 371 128 +VeESBL 21.5 +VeESBL
AD 374 Phantom +VeESBL 84 +VeESBL
AD 375 250 +VeESBL 4 -Ve ESBL
AD 377 695 +VeESBL 128 +Ve ESBL
AD 378 250 +VeESBL 64 +Ve ESBL
AD 380 500 +VeESBL 168 +VeESBL
AD 382 1000 +VeESBL 340 +VeESBL
AD 384 phantom +VeESBL 256 +VeESBL
AD 385 16 +VeESBL 8 +VeESBL
AD 386 16 +VeESBL 6 -Ve ESBL
AD 387 170 +VeESBL 6 -Ve ESBL
AD 388 0.25 -Ve ESBL 8 +VeESBL
AD 389 25 +Ve ESBL 64 +VeESBL
AD 391 phantom +VeESBL 84 +VeESBL
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AD 392 695 +VeESBL 2 -Ve ESBL
AD 393 128 +Ve ESBL 84 +VeESBL
AD 395 695 +VeESBL 500 +VeESBL
AD 399 16 +VeESBL 1.97 -Ve ESBL
AD 400 21 +VeESBL 84.5 +VeESBL
AD 401 42 +VeESBL 2.7 -Ve ESBL
AD 402 phantom +VeESBL 340 +VeESBL
AD 403 15.6 +VeESBL Phantom +VeESBL
AD 404 Phantom +VeESBL 84 +VeESBL
AD 405 64 +VeESBL 64 +Ve ESBL
AD 407 64 +VeESBL 42.5 +VeESBL
AD 408 250 +VeESBL 128 +Ve ESBL
AD 409 500 +VeESBL 500 +VeESBL
AD 410 84.5 +VeESBL 5.3 -Ve ESBL
AD 411 128 +Ve ESBL 4 -Ve ESBL
AD 412 84.5 +VeESBL 2.6 -Ve ESBL
AD 413 170 +VeESBL 32 +VeESBL
TZ = Ceftazidime TZL = Ceftazidime + Clavulanic acid.
CT = Cefotaxime CTL = Cefotaxime + Clavulanic acid.
Interpretation :
MIC for CT/CTL or/and
MIC for CT/CTL or/and
TZ/TZL <8 = -Ve ESBL.
TZ/TZL >8 = +Ve ESBL.
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AD 313 + " CTX
AD 314 + - + CTX& CPD
AD 315 + + + CTX, CAZ & CPD
AD 316 + + + CTX, CAZ & CPD
AD 317 + + CTX, CAZ & CPD
AD 318 - + CPD
AD 319 + + CTX & CPD
AD 320 + + + CTX, CAZ & CPD
AD 321 + - + CTX & CPD
AD 322 + + + CTX, CAZ & CPD
AD 323 + " CTX
AD 324 + - + CTX & CPD
AD 325 + CPD
AD 326 + + + CTX, CAZ & CPD
AD 327 + + + CTX, CAZ & CPD
AD 328 + " + CTX & CPD
AD 329 + - _ CTX
AD 330 + - + CTX & CPD
AD 331 + - - CTX
AD 332 + - - CTX
AD 333 + " - CTX
AD 334 + - + CTX & CPD
AD 335 + - + CTX & CPD
AD 336 - " NONE
AD 337 + ■ CTX & CPD
AD 338 + + + CTX, CAZ & CPD
AD 339 + - + CTX & CPD
AD 340 + - + CTX & CPD
AD 341 + - - CTX
AD 342 + - - CTX
AD 343 + - - CTX
AD 344 + - - CTX
AD 345 + + + CTX, CAZ & CPD
AD 346 + + + CTX, CAZ & CPD
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AD 348 + + + CTX, CAZ & CPD
AD 349 + + + CTX, CAZ & CPD
AD 350 + - - CTX
AD 351 + + + CTX, CAZ & CPD
AD 352 + - + CTX & CPD
AD 353 + - CTX
AD 354 + - CTX
AD 355 + - + CTX & CPD
AD 356 + + + CTX, CAZ & CPD
AD 357 + + + CTX, CAZ & CPD
; AD 358 + + + CTX, CAZ & CPD
AD 359 - - - NONE
AD 360 + + + CTX, CAZ & CPD
AD 362 + + + CTX, CAZ & CPD
AD 363 + + CTX, CAZ & CPD
AD 364 + + + CTX, CAZ & CPD
AD 365 + + + CTX, CAZ & CPD
AD 366 + - - CTX
AD 367 + + + CTX, CAZ & CPD
AD 368 - CTX
AD 369 - NONE
AD 370 " " - NONE
AD 371 + - + CTX & CPD
AD 374 + + + CTX, CAZ & CPD
AD 375 + + CTX & CPD
AD 377 + + CTX, CAZ & CPD
AD 378 + + + CTX, CAZ & CPD
AD 380 + + + CTX, CAZ & CPD
AD 382 + + + CTX, CAZ & CPD
AD 384 + + + CTX, CAZ & CPD
AD 385 - - - NONE
AD 386 - - - NONE
AD 387 + + + CTX, CAZ & CPD
AD 388 - " + CPD
AD 389 + - + CTX & CPD
AD 391 + + + CTX, CAZ & CPD
AD 392 + - + CTX & CPD
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AD 393 + + + CTX, CAZ & CPD
AD 395 + + + CTX, CAZ & CPD
AD 399 - " " NONE
AD 400 - + + CAZ & CPD
AD 401 - - + CPD
AD 402 + + + CTX, CAZ & CPD
AD 403 + CAZ & CPD
AD 404 + + + CTX, CAZ & CPD
AD 405 + + + CTX, CAZ & CPD
AD 407 + + CTX & CPD
AD 408 + + + CTX, CAZ & CPD
AD 409 + + CTX, CAZ & CPD
AD 410 + - + CTX & CPD
AD 411 + - + CTX & CPD
AD 412 + ~ " CTX

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix V -Determination of MIC by agar dilution
Isolate
Ciprofloxacin Gentamicin Tobramycin
MIC Comment MIC Comment MIC Comment
AD 313 32 R 1 S 16 R
AD 314 32 R 1 s 1 S
AD 315 32 R 16 R 16 R
AD 316 32 R 16 R 16 R
AD 317 0.125 S 1 S 1 S
AD 318 0.5 S 16 R 16 R
AD 319 1 s 1 S 2 S
AD 320 32 R 16 R 16 R
AD 321 0.5 i s 16 1 R 16 R
AD 322 32 R 16 R 16 R
AD 323 0.125 s 16 R 16 R
AD 324 0.5 S 16 R 8 I
AD 325 2 I 1 S 1 S
AD 326 32 R 16 R | 16 R
AD 327 32 R 1 S 16 R
AD 328 2 I 1 s 1 S
AD 329 2 I 1 s 1 S
AD 330 2 I 1 s 1 s
AD 331 32 R 1 s 1 s
AD 332 0.125 S 1 s 1 s
AD 333 0.5 S 1 s 1 s
AD 334 0.5 s 16 1 R 16 R
AD 335 0.5 s 1 s 2 s
AD 336 0.25 s 1 s 2 s
AD 337 2 I 1 s 1 s
AD 338 32 R 16 R 16 R
AD 339 2 I 1 s 2 s
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AD 340 2 I 1 S 2 S
AD 341 0.125 s 1 S 1 S
AD 342 0.5 s 1 s 1 s
AD 343 0.5 S 1 s 1 s
AD 344 0.5 s 1 s 1 s
AD 345 32 R 1 s 16 R
AD 346 32 R 16 R 16 R
AD 348 32 R 1 s 16 R
AD 349 32 R 2 s 16 R
AD 350 0.5 S 1 s 1 S
AD 351 32 R 16 R 16 R
AD 352 0.5 s 1 s 1 s
AD 353 2 I 1 s 1 S
AD 354 0.125 S 1 s 1 S
AD 355 0.125 s 1 s 1 s
AD 356 32 R 16 R 16 R
AD 357 0.125 S 4 s 16 R
AD 358
1
0.125 s 1 s 16 R
AD 359 0.25 s 8 I 2 S
AD 360
I
32 R 16 R 8 I
AD 362 32 R ,6 R 16 R
AD 363 32 R 16 R 16 R
AD 364 32 R 16 R 16 R
AD 365 0.25 S 4 s 8 I
AD 366 0.5 S 1 s 1 S j
AD 367 32 R 16 R 16 R
AD 368 1 s 1 S 1 S
AD 369 0.125 s 1 s 1 s
AD 370 0.125 s 1 s 1 s
AD 371 0.5 s 1 s 1 s
AD 374 0.5 s 1 s 1 s
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AD 375 0.125 S 1 S 1 S
AD 377 32 R 16 R 16 R
AD 378 32 R 16 R 16 R
AD 380 32 R 16 R 16 R
AD 382 32 R 16 R 16 R
AD 384 32 R 16 R 16 R
AD 385 32 R 16 R 16 R
AD 386 0.125 S 1 S 1 S
AD 387 32 R 16 R 4 S
AD 388 0.125 S 1 S 1 s
AD 389 32 R 16 R 16 R
AD 391 32 R 1 S 8 I
AD 392 4 R 1 s 1 S
AD 393 32 R 16 R 4 s
AD 395 32 R 16 R 16 R
AD 399 1 S 1 S 2 s
AD 400 32 R | 1 s 16 R
AD 401 32 R II 1
1
s 16 R
AD 402 32 R 16 R 16 R
AD 403 0.125 S 1 s 1 S
AD 404 32 R 16 R 16 R
AD 405 0.125 S 16 R 16 R
AD 407 2 I 1 S 1 S
AD 408 32 R 16 R 16 R
AD 409 32 R 16 R 16 R
AD 410 2 I 1 S 1 S
AD 411 2 I 1 S 1 S
AD 412 32 R 1 s 16 R
AD 413 32 R 16 R 4 S
R = resistant, S = sensitive and I = intermediate
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Appendix VI PCR and Dot-Blot results
No Isolate PCR Dot-blot
SHV TEM SHV TEM
1. AD 313 + - + +
2. AD 314 + - + -
3. AD 315 + + + +
4. AD 316 + + + +
5. AD 317 + - + +
6. AD 318 + - + +
7. AD 319 + - + +
8. AD 320 + + + +
9. AD 321 + - + -
10. AD 322 + + + +
11. AD 323 + - + +
12. AD 324 + - - +
13. AD 325 + - - +
14. AD 326 + + + +
15. AD 327 + + + +
16. AD 328 + - - +
17. AD 329 + - + -
18. AD 330 + - - +
19. AD 331 + - - +
20. AD 332 + + - +
21. AD 333 + - + +
22. AD 334 + - + -
23. AD 335 + - + +
24. AD 336 + - + -
25. AD 337 + - + -
26. AD 338 + + + +
27. AD 339 + - + +
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28. AD 340 + - + +
29. AD 341 - + + +
30. AD 342 + - + +
31. AD 343 + - + +
32. AD 344 + - + -
33. AD 345 + + + +
34. AD 346 + + + +
35. AD 348 + + + -
36. AD 349 + + + +
37. AD 350 + - + -
00 • AD 351 + + + +
39. AD 352 + - +
-
40. AD 353 + - + +
41. AD 354 + - + +
42. AD 355 - + + -
43. AD 356 + + + +
44. AD 357 + + + +
45. AD 358 - + + +
46. AD 359 - + + +
47. AD 360 + - +
-
48. AD 362 + + + +
49. AD 363 + + + +
50. AD 364 + + + +
51. AD 365 + + + -
52. AD 366 + - + -
53. AD 367 + + + +
54. AD 368 + - + -
55. AD 369 + - - +
56. AD 370 + - + +
57. AD 371 + - + -
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58. AD 374 + - + -
59. AD 375 + - + +
60. AD 377 + + + +
61. AD 378 + + + +
62. AD 380 + + + -
63. AD 382 + + + +
64. AD 384 + + + +
65. AD 385 - + + +
66. AD 386 + - - +
67. AD 387 + - + -
68. AD 388 + - + -
69. AD 389 + + + -
70. AD 391 + + + +
71. AD 392 + - - -
72. AD 393 + - + -
73. AD 395 + + + +
74. AD 399 - + + +
75. AD 400 + + + +
76. AD 401 + - + +
77. AD 402 + + + +
78. AD 403 + + + +
79. AD 404 + + + +
00o AD 405 + + + +
81. AD 407 + + + +
82. AD 408 + + + +
83. AD 409 + + + +
84. AD 410 + - + -
85. AD 411 + - + +
86. AD 412 + + - +
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Abstract
Dne hundred and one unique patient isolates of Klebsteia pneumoniae (69) and Escherichia coli (32), flagged as
extended spectrum p-lactamase (ESBL) positive by the Vitek system (GNS-526 card), were collected. These strains
nore isolated from a variety of clinical specimens submitted to the clinical bacteriology laboratories of the Royal
-Infirmary of Edinburgh (RIE). Of the 101 strains tested. 15 E. coli were found to be ESBL-negative by Etest ESBL
strips. On re-testing the 15 E. coiiwith Vitek GNS-532 card which had superseded the GNS-526 card. 14 of these
were found to be ESBL negative despite originally flagging as ESBL positive. The remaining 87 ESBL producing
strains were also subjected to the double disc diffusion (DDD) technique lor the detection of ESBLs. Of these, one
was falsely negative by Etest ESBL test strips (using both cefotaxime and ceftazidime strips) and 7 were false
negatives by the double disc diffusion method. The Etest false negative ESBL producing strain of K. pneumoniaewas
positive by DDD. Technically, the Vitek method was the least demanding method to perform as it is an integral part of
=the routine susceptibility test card. Ete6t strips were reliable but the most expensive of all techniques used. The DDD
lest, while relatively inexpensive was technically subjective and, in our hands, 7 of the ESBL positive strains that were
confirmed by the other 2 techniques, were not detected. Despite the false positive ESBL producing E. coli, the Vitek
susceptibility card with its integral ESBL test offers the clinical laboratory a valuable and affordable option to screen
for ESBL producing Klebsiella spp. and £ coli as part of the routine laboratory methodology.
Introduction
Since the introduction of third generation cephalosporins into clinical practice there has been excessive use
of extended-spectrum cephalosporins in hospitals . The effectiveness of these p-lactam antibiotics has been
diminished by Klebsiella spp. that are resistant to their mode of action. Thi6 resistance has spread to strains of E.ooH
and to other Gram negative bacteria as well . Investigations mto the mechanism responsible for this resistance have
revealed the presence of extended spectrum p-lactamase (ESBL) enzymes derived from the ubiquitous TEM-1/2
and SHV-1 family.To date, there are over 80 derivatives of TEM p- lactamases and more than 26 derivatives of SHV
p-lactamases . These enzymes are usually less efficient at hydrolysis than their parent enzymes and subsequently
their detection is difficult to demonstrate in currently used routine susceptibility tests. Therefore. ESBL producing
Klebsiella spp. and E.colimay appear falsely susceptible to newer cephalosporins There is clearly a requirement
to detect the resistance mechanism itself rather than to rely on in vitro susceptibility testing. The Vitek system
(bk>M4rieux, Ltd., Basingstoke, England) has an ESBL detection test as an integral part of the routine susceptibility




One hundred and one clinical isolates of Klebsiella pneumoniae (69) and E.coli (32) were obtained from various
clinical samples sent to the clinical bacteriology laboratories of the Ftoyal Infirmary of Edinburgh (RIE). The 101
isolates had previously been identified and reported as ESBL positive by the Vitek system. Isolates were stored on
nutrient agar slopes at room temperature until required.
ESBL detection methods
Vitek system
The Vitek is an automated system for identification or/and susceptibility testing. Vitek susceptibility test results
are expressed as MIC values, and interpreted as susceptible, intermediate or resistant by referral to an NCCLS
breakpoint". This system is able to detect ESBL production by an automated version of the 6ynergy test, which
is based on detection of the inhibitory effect of clavulanic acid on ESBL in the presence of either cefotaxime or
ceftazidime. The test is interpreted by measuring the difference in bacterial growth with or without inhibitor. All isolates
were originally tested on GNS-526 cards. Only Etest negative strains were re-tested with GNS-532 cards.
E-Teet ESBL strips
Etest ESBL strips (AB Biodisk, Solna, Sweden) are double-ended strips with antibiotic and antibiotic/inhibitor
gradients. These strips yield the minimum inhibitory concentration a6 well as the MIC ratio, which determines the
presence of an ESBL. The strips used in this study were ceftazidime + clavulanic acid (TZ/TZL) and cefotaxime +
clavulanic acid (CT/CTL) where the recommended ratio value indicates the presence of an ESBL. Interpretation of
the result was as recommended by the manufacturer.
Double Disc-Diffusion method
This method was used to test the 87 strains that were ESBL positive by Etest and/br Vitek GNS-532 card. The
DDD method was 6 discs, 3 containing ceftazidime (30pg). cefotaxime (30pg), or cefpodoxime (10pg), and 3 with
a combination of the same antibiotics with the addition of clavulanate with concentrations of 10pg, 10>tg and 1pg
respectively (Oxoid Ltd., Baoingotoko, England). A broth culture of the test organism w»* adjusted to a 0.5 McFarland
standard and inoculated onto Mueller-Hinton agar (Oxoid). The combination discs and the corresponding standard
cephalosporins disc were placed the recommended distance from each other on the plate. The plates were incubated
at 37*0 tor 18 hours in air before the zone sizes were recorded. A positive result was indicated by a zone size
difference of 2 5mm diameter between the combination disc and the corresponding standard antibiotic disc.
For all ESBL detection methods, known ESBL producing E.coli (TEM SA1636 and SHV SA1652) were used as
positive controls. E. coli NCTC 10418 was used as a negative control.
Results
Of the 101 strains tested, 15 were negative for ESBL production by both cefotaxime and ceftazidime Etest strips.
These 15 Etest negative strains, (all £ coli) were re-tested with Vitek (GNS-532 card) and 14 of these strains were
subsequently found to be ESBL negative. One strain still flagged ESBL positive by Vitek. The re-tested 14 ESBL
negative, strains were not subjected to any further studies.
The cefotaxime ESBL strip detected the presence of ESBL activity in 84 (96.5%) of the tested isolates. Of these, 19
(22%) demonstrated phantom phenomena ESBL positive as described in the manufacturer's interpretation guide.
Four strains (2 E. coH and 2 K. pneumoniae) were negative for ESBL activity with cefotaxime ESBL strips.
With ceftazidime Etest strips, ESBL activity was detected in 47 (54%) of the study isolates. Of these, 3 (3.5%) were
positive by demonstration of phantom phenomena. The use of the combination of both cefotaxime and ceftazidime
E-test ESBL strips detected ESBLs in 66 of the test isolates (98.6%). From this data it appears that the use of
both 6tripe is essential for optimal detection of ESBL activity. Only one 6train of K. pneumoniae that demonstrated
positive ESBL activity with the Vitek system was not detected by Etest ESBL strips. This strain remained positive
when re-tested with Vitek.
Using the ODD method, the combination disc containing cefotaxime detected the presence of ESBL activity in 74
(85%) (64 K. pneumoniae and 10 E.coli) strains whilst the cefpodoxime combination disc detected ESBL activity in
64 (73.5%) strains (54 K. pneumoniae and 10 E.coli). The ceftazidime combination disc was the least efficacious,
detecting the presence of ESBL activity in only 40 (46%) strains (31 Klebsiella pneumoniae and 9 E.coli). The strain
of Klebsiella pneumoniae that demonstrated no ESBL activity by Best was ESBL positive with the DDD method.
When the results of att 3 cephalosporins combination discs were taken into consideration, 80 (92%) of the 87 ESBL
positive strains were detected (Table).
Discussion
To date there is currently a great need for reliable and efficient tests to detect ESBLs in clinical isolates of
Enterobacteriaceae. Conventional susceptibility testing methods, on their own. fail to present reliable susceptibility
results for p-lactam antibiotics when testing those species that harbour ESBLs.
Currently, most UK clinical laboratories do not use a standard method for the detection of ESBLs and many clinical
laboratories do not routinely identify enterobacteriaceae to genus and species level. The Vitek system addresses this
issue. It will only validate a susceptibility result once the organism has been identified to species level. If the system
detects the presence of an ESBL resistance mechanism in strains of Klebsiella spp. and E. coli, the system then
utilises its expert' software and applies it to the final susceptibility results, p-lactams susceptible to ESBL activity are
then flagged as resistant whether or not the in vitro test indicates susceptibility.
This study has shown that the Vitek system, in our hands, whilst easy to perform and without any subjective
interpretative of results, reported false positive detection of ESBL activity with fourteen strains of E. coli. On re-testing
these strains with Vitek (GNS-532 card) they were correctly reported as ESBL negative. All these strains were initially
tested with the same batch number of Vitek (GNS-526 card). When re-tested, the GNS-532 card was used, this
card has superseded the GNS-526 with accompanying software upgrades. Although internal quality control (QC) is
performed on these cards an ESBL producing E.coli is not used as part of the QC battery. It was initially thought that
the 14 false positive ESBL E. coli might have been as a result of a faulty batch of GNS-526 cards. However, recent
work in this laboratory, with ten recently isolated 'Vitek' ESBL positive E. coli 6howed two of these ten strains to be
ESBL negative by Etest. On retesting with the same batch of Vitek GNS-532, these two strains were subsequently
reported as ESBL negative. Although the percentage false positive E. coli ESBL strains fell from approximately
50% to 20% with the new card it was still a concern that these strains were misreported as ESBL producers with
subsequent 'expert' rules for antibiotic susceptibility to ^-lactam antibiotics applied. There appears to be no obvious
reason for these results. It is unlikely to be technical error as the Vitek is a highly standardised system. These strains
have been forwarded to bioM6rieux for further studies.
The DDD test requires careful spacing of discs for accurate results and careful interpretation of zone sizes. It i6
therefore technically demanding. In previous studies, the DDD test was able to detect 82% and 88% of ESBL positive
strains respectively . The limitations of this test have been described elsewhere . A recent study reported
that cepodoxime achieved a 100% sensitivity rate in detecting ESBLs in tested isolates, cefotaxime was 92% and
ceftazidime 62% . in contrast, this study showed that cefotaxime was the most efficacious cephalosporin for the
detection of ESBLs with a sensitivity rate of 85%, 73.5% for cepodoxime and 46% for ceftazidime.
The commercially available ESBL Etest strip is a quantitative technique and is widely regarded as the 'gold standard'
for detection of ESBL production in clinical laboratories -. In our hands it detected 98.8% of the test isolates but
only if both cefotaxime and ceftazidime strips were used in conjunction. This technique is expensive and most
clinical laboratories would U6e it only for confirmation rather than as a routine test. All 87 strains in this study were
confirmed ESBL positive by molecular investigations (data not shown). Most clinical laboratories do not have the
resources to identify ESBL producing strains by molecular methods, therefore it is important to have an easy to
perform methodology that can be used in the routine laboratory. It should be noted, that in our hands, some £ coli
were reported as fafeely positive ESBL production and we would confirm the Vitek ESBL results by Etest for these
strains.
This study shows the importance of identification of Enterobacteriaceae to species level and the usefulness of the
Vitek system for routine detection of ESBLs if we are to report accurate and consistent results to clinicians. This
was clearly demonstrated in a recent report that described the retrospective detection of ESBLs in five of 20 strains
of K pneumoniae isolated from blood cultures. In 6ome of these cases patients were treated with an Inappropriate
third-generation cephalosporin. Treatment in these patients was changed after clinical failure . If an ESBL detection
test was available at the original time of susceptibility testing then appropriate results would have reported to the
clinician.
In conclusion, the Vitek test was cost effective in so much as the ESBL test Is an integral part of the susceptibility card
and performed simultaneously with the susoeptibility tests. In addition, the test is interpreted by the system, which
removes any errors of subjectivity. No further outlay of resources is required.
Results of Etest ESBL strips and the Double Disc Diffusion method for detecting the presence of ESBLs in 87 strains
of £ coli and K. pneumoniae
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SHV-39: a new extended -spectrum B-lactamase found throughout Chile
H. Bello, M. Dominquez, A. A. Dashti, G. Gonzales-Rocha and S.G.B Amyes.
Deparetmento de Microbiology, University of Concepcion, Concepcion, Chile and
Medical Microbiology, Medical School, University of Edinburgh, Edinburgh,
Scotland, UK.
Klebsiella pneumoniae is a widespread nosocomial pathogen within Chilean hospitals.
It has largely been treated with ceftriaxone and ceftazidime and resistance has
increased markedly.
K. pneumoniae strains were isolated from hospitalised patients from Catholic
University hospital in Santiago, the Gustavo Fricke hospital in Valparaiso (100 miles
to the east) and the G. Grant-Benavente hospital in Concepcion (300 miles to the
south). The minimum inhibitory concentration of antibiotics was determined by agar
dilution and all strains were genotyped by pulsed-field gel electrophoreses (PFGE).
The number of P-lactamase was determined by Iso-electric focusing. Although there
were some variations in genotype, within each hospital there was consistency of
banding pattern (PFGE). However, there was no similarity between strains isolated in
the different cities showing they were different clones. Examination of the P-
Lactamase showed that TEM-1 was always present; however, the cephalosporin
resistance was associated with an SHV-derived P-lactamase with pi greater than 7.0.
PCR amplification and sequencing revealed a hitherto undescribed enzyme with not
just a GIy238Ser mutation, characteristic of SHV-2, but also a Thr267Ser mutation.
This extended-spectrum P-lactamase (ESBL) conferred MICs of ceftazidime up to
greater than 256 mg/L and of cefotaxime between 16 and 32 mg/L.
These results show that there is a new ESBL, now called SHV-39 that is widely
disseminated in Chile both geographically and between different strains of K.
pneumoniae.
